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LIST OF ABBREVIATIONS 
 
µg microgram 
µL microliter 
µm micrometer 
Ab antibody 
ACN acetonitrile 
ANOVA analysis of variance 
APP acute phase protein 
APR acute phase response 
AUC area under the plasma concentration-time curve 
BCL protein B-cell leukemia/lymphoma 
BRD bovine respiratory disease 
BW body weight 
C5a complement factor 5a 
CBA cytometric bead array 
CD cluster of differentiation 
CFU colony forming unit 
Cl total body clearance 
cm centimeter 
Cmax maximum plasma concentration 
COX cyclooxygenase 
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CV coefficient of variation 
d days 
DAMP danger-associated molecular pattern 
DEX dexamethasone 
dp particle size 
DTT DL-Dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
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ELISA enzyme-linked immuno sorbent assay 
EMA European Medicines Agency 
EtOH ethanol  
F bioavailability 
FBS fetal bovine serum 
g gravity 
G gauge 
GAM gamithromycin 
GPI glycosylphosphatidylinositol 
h hour 
h-ESI heated electrospray ionisation 
Hp haptoglobin 
HPLC high-performance liquid chromatography 
Hsp heat shock protein 
i.d. internal diameter 
IFN interferon 
IKK IκB kinase 
IL interleukin 
IM intramuscular 
IND indomethacin 
IP intraperitoneal 
IRAK IL-1 receptor-associated kinase 
IRF IFN regulatory factor 
IS internal standard 
IU international units 
IV intravenous 
JNK c-jun N-terminal kinase 
kabs absorption rate constant 
kDa kilodalton 
kel; λz elimination rate constant 
KETO ketoprofen 
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kg kilogram 
LBP lipopolysaccharide binding protein 
LC-MS/MS liquid chromatography-tandem mass spectrometry 
LOD limit of detection 
LOQ limit of quantification 
LOX lipoxygenase 
LPS lipopolysaccharide 
LT leukotriene 
Mal MyD88 adaptor like protein 
MALT mucosa-associated lymphoid tissue 
MD myeloid differentiation protein 
mCD14 membrane-bound CD14 
MeOH methanol 
MFI median fluorescence intensity 
mg milligram 
MIC minimum inhibitory concentration 
min minute 
mL milliliter 
mm millimeter 
MRM multiple reaction monitoring 
MyD88 myeloid differentiation primary response protein 88 
m/z mass-to-charge ratio 
N/A not applicable 
ND not detected 
NEM N-ethylmaleimide 
NF-κB nuclear factor-κB 
ng nanogram 
NI no increase 
(N)SAID (non)steroidal anti-inflammatory drug 
p.a. post administration 
p.i. post infection 
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PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
PD pharmacodynamic 
PE phycoerythrin 
PG prostaglandin 
PI propidium iodide 
pig-MAP pig major acute phase protein 
PIM pulmonary intravascular macrophage 
PK pharmacokinetic 
PL phospholipase 
PO per os 
RIP receptor-interacting protein 
ROA route of administration 
RSD relative standard deviation 
RT rectal body temperature 
s second 
SAA serum amyloid A 
SC subcutaneous 
SD standard deviation 
sCD14 soluble CD14 
SRD swine respiratory disease 
SRM  selected reaction monitoring 
sulfo-SMCC sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
t1/2abs half-life of absorption 
t1/2el half-life of elimination 
TAK transforming growth factor β-activated kinase 
TIR toll/interleukin-1 receptor 
TIRAP TIR domain containing adaptor protein 
TLR toll-like receptor 
tmax time of maximum plasma concentration 
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TNF tumor necrosis factor  
TOA time of administration 
Tollip Toll-interacting protein 
TRAF TNF receptor-associated factor  
TRAM TRIF-related adaptor molecule 
TRIF TIR-domain-containing adapter-inducing interferon-β 
TSA trypticase soy agar 
TX thromboxane 
ubc ubiquitin-conjugating enzyme complex 
UPLC ultra-performance liquid chromatography 
Vd volume of distribution 
Vss volume of distribution at steady state 
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GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from 
Wyns, H., Plessers, E., De Backer, P., Meyer E., Croubels, S. (2014) In vivo porcine 
lipopolysaccharide inflammation models to study immunomodulation of drugs. Veterinary 
Immunology and Immunopathology (under revision).  
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1. The acute phase response 
 
In mammals, the acute phase response (APR) is a well-coordinated sequence of 
processes, initiated at the site of inflammation upon infection or trauma, and is 
characterized by the production and release of a variety of inflammatory mediators, 
cellular interactions, vascular and metabolic changes, all eventually attempting to restore 
homeostasis (Baumann and Gauldie, 1994; Gruys et al., 2005).  
While bacteria have developed mechanisms to improve their adhesion and 
subsequent colonization in host cells, the latter have developed mechanisms to recognise 
bacterial cell surface components ultimately leading to phagocytosis and elimination of 
micro-organisms (Heumann and Roger, 2002). In this respect, innate immunity is the first, 
non-specific line of defence against invading micro-organisms based on pattern-recognition 
systems, including bacterial lipopolysaccharide (LPS) (Heumann and Roger, 2002; Brown et 
al., 2011). Both monocytes and neutrophils are important cells in the innate immune 
response. While neutrophils efficiently initiate degranulation, phagocytosis and killing of 
invading micro-organisms without new synthesis of proteins, monocytes are a major 
source of inflammatory mediators. Furthermore, macrophages considerably contribute to 
the adaptive immune response as antigen-presenting cells (Baumann and Gauldie, 1994; 
Cavaillon and Adib-Conquy, 2005; Sanz-Santos et al., 2011). In general, the blood monocyte 
or tissue macrophage is the leukocyte which triggers the APR cascade, by initially releasing 
early or alarm cytokines, such as tumor necrosis factor α (TNF-α) and interleukin (IL)-1, 
which subsequently provoke the release of a secondary wave of cytokines, including IL-6. 
As a result, chemotactic molecules lead to the recruitment and migration of immune cells, 
such as neutrophils and mononuclear cells, to the target tissue. TNF-α, IL-1 and IL-6 are 
also considered to be involved in the regulation of the febrile response, mediating fever 
through the upregulation of cyclooxygenase (COX), mainly COX-2, and the subsequent 
induction of prostaglandin (PG) E2, which is finally responsible for the increase of the body 
temperature. Meanwhile, IL-1 and IL-6 further stimulate the adrenal pituitary axis and the 
subsequent production of adrenocorticotropic hormone providing a negative feedback and 
inhibiting further cytokine gene expression. Following cytokine stimulation, hepatic protein 
synthesis is modified resulting in a dramatic increase or decrease in the concentration of 
several plasma proteins, the so called positive and negative acute phase proteins (APPs), 
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respectively (Heinrich et al., 1990; Baumann and Gauldie, 1994; Petersen et al., 2004; 
Gruys et al., 2005). Major porcine APPs are C-reactive protein (CRP), serum amyloid A (SAA) 
and haptoglobin (Hp) (Heinrich et al., 1990; Baumann and Gauldie, 1994; Petersen et al., 
2004; Gruys et al., 2005). 
The vascular tone is altered subsequent to the release of low-molecular-weight 
mediators from the inflamed tissue, including reactive oxygen species, nitrous oxide and 
several metabolites of the arachidonic acid cascade. The latter includes thromboxane A2 
(TXA2), (PGs) and leukotrienes (LTs) which are responsible for tissue vasoconstriction and 
vasodilatation as well as bronchoconstriction and bronchodilatation. Dilatation and leakage 
of the blood vessels, particularly at the post-capillary venules, result in extravasation of 
erythrocytes and apparent redness (Baumann and Gauldie, 1994). 
 
2. Lipopolysaccharide 
 
LPS (Figure 1) is a structural part of the outer membrane of Gram-negative bacteria. 
The LPS component is crucial for outer membrane integrity and bacterial viability, since it 
plays a key role in nutrient transport and the access of toxic compounds, including 
antibiotics. When bacteria multiply or die and lyse, LPS is released from the surface. 
Released LPS has been identified as a very potent bacterial toxin and to distinguish LPS 
from the actively secreted exotoxins, it was defined endotoxin (Rietschel et al., 1993 and 
1994). However, strictly, LPS refers to the purified glycolipid, whereas endotoxins may also 
contain small amounts of cell wall proteins, lipids, lipoproteins and polysaccharides in 
addition to LPS (Fink and Heard, 1990). Bacterial LPS is one of the most effective 
stimulators of the immune system in mammals (Dinarello, 1997; Tobias et al., 1999, Seydel 
et al., 2003). In contrast to bacterial exotoxins being toxic by killing host cells, endotoxins 
evoke an active response of host cells (Rietschel et al., 1994). Conversely, if LPS remains 
membranar, activation of the innate immune system is weak (Miyake, 2004; Jerala, 2007).  
 
2.1. Molecular structure of lipopolysaccharide 
 
LPS is an amphiphilic molecule, consisting of a hydrophilic heteropolysaccharide and 
a covalently bound lipid component, lipid A. In the case of Enterobacteriaceae, the 
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heteropolysaccharide can be subdivided into the O-polysaccharide (O-antigen or O-specific 
chain) and the core oligosaccharide (R-core). This core region on the other hand, can be 
further subdivided into the O-chain proximal outer core and the lipid A inner core region as 
illustrated in Figure 1 (Wright and Kanegasaki, 1971; Rietschel et al., 1994).  
 
 
Figure 1. Schematic diagram of the LPS structure (Tobias et al., 1999) 
 
The O-specific chain is a polymer of repeating oligosaccharide units, composed of 
either identical or different monosaccharide residues. The structure of these repeating 
units (nature, ring form, anomeric configuration, substitution, sequence and type of linkage 
of the monosaccharide residues) is characteristic for a given LPS molecule and its parental 
bacterial strain within a serotype. The R-core oligosaccharide is a saccharide portion, 
composed of up to 15 monosaccharide residues (Holst, 2007). The lipid A component is a 
fatty acid acylated and phosphorylated disaccharide (Tobias et al., 1999). The structures of 
lipid A and of the R-core oligosaccharide appear to be constant for a given genus. Even in 
different genera, the lipid A/R-core does not vary significantly (Wright and Kanegasaki, 
1971). In contrast, the O-polysaccharide shows a high degree of variability amongst 
bacteria and determines the LPS antigenic specificity (Miyake, 2004). Variability in the R-
core and O-polysaccharide can significantly affect the response as well as the type of the 
signaling pathway (Jerala, 2007).  
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The lipid A component has been proven to constitute the endotoxic and 
immunomodulatory principle of LPS (Wright and Kanegasaki, 1971; Rietschel et al., 1994). 
Recently, also the covalently linked core region has been suggested to possess 
immunogenic properties (Holst, 2007).  
 
2.2. Extracellular lipopolysaccharide recognition  
 
The extracellular recognition of LPS requires the sequential cooperation of three 
extracellular LPS-binding proteins, lipopolysaccharide binding protein (LBP), cluster of 
differentiation 14 (CD 14) and the glycoprotein myeloid differentiation (MD)-2, which 
chaperone LPS from the bacterial membrane to the transmembranar toll-like receptor 
(TLR) 4 (Jerala, 2007).  
 
2.2.1. Lipopolysaccharide binding protein 
 
Lipopolysaccharide binding protein (LBP) is a glycoprotein of approximately 60 kDa 
which is normally circulating in plasma (Martin et al., 1992). Here it recognizes and forms a 
high-affinity complex with the LPS lipid A component presented as either fragments, free 
molecules, or even still bound to the outer membrane of intact bacteria (Pålsson-
McDermott and O’Neill, 2004). Due to its amphiphilic nature, LPS isolates typically form 
aggregates in a solution. One of the main functions of LBP is the disaggregation of LPS for 
subsequent presentation to cells (Tobias et al., 1999). Thus, LBP rapidly catalyzes the 
transfer of LPS to either membrane-bound CD14 (mCD14) or soluble CD14 (sCD14) 
(Triantafilou and Triantafilou, 2002). However, it should be remarked that LBP has a 
concentration-dependent dual role: at low concentrations it stimulates LPS signalling by 
extracting LPS from the bacterial membranes and transferring LPS monomers to CD14, 
while at high concentrations, it inhibits LPS signaling by shuttling the LPS to serum 
lipoproteins and by forming aggregates with LPS. As systemic LBP levels increase 
dramatically after induction of an acute phase reaction, LBP serves as an inhibitor of the 
excessive response to LPS (Gutsmann et al., 2001; Jerala, 2007). 
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2.2.2. CD14 
 
The CD14 molecule exists in two forms. While mCD14 is attached to the surface of 
myeloid cells via a glycosylphosphatidylinositol (GPI) tail, sCD14 occurs in plasma where it 
helps to convey LPS signaling in cells lacking the membrane-bound CD14 form, including 
endothelial and epithelial cells (Pålsson-McDermott and O’Neill, 2004). Although CD14 has 
been identified as an LPS receptor, it is a GPI-anchored protein lacking transmembrane and 
intracellular domains. Therefore, the role of CD14 in LPS signaling appears to be binding of 
LPS and subsequent presentation and transfer of LPS to MD-2 (Triantafilou and 
Triantafilou, 2002; Pålsson-McDermott and O’Neill, 2004; Peri et al., 2010).  
2.2.3. TLR4-MD-2 complex 
 
TLRs are a family of cell-surface and endosomally expressed receptors, recognizing a 
variety of pathogen-associated molecular patterns (PAMPs), including lipids, proteins, 
lipoproteins and nucleic acids, as well as endogenous mediators released upon tissue 
damage (danger-associated molecular patterns or DAMPs) (Ulevitch, 2004; Lorne et al., 
2010; Wittebole et al., 2010; Brown et al., 2011). TLRs are expressed on innate immune 
cells, including monocytes, macrophages, neutrophils, dendritic cells and mucosal epithelial 
cells (Beinke and Ley, 2004). More specifically, TLR4 has been established as the receptor 
for LPS (Pålsson-McDermott and O’Neill, 2004).  
The discovery of TLR4 unravelled the missing link between LPS recognition by LBP 
and then CD14 on the one hand, and the intracellular signaling pathway, leading to the 
production of pro-inflammatory cytokines on the other hand (Wittebole et al., 2010). TLRs 
consist of extracellular leucine-rich repeats, a transmembrane region and an intracellular 
Toll/Interleukin-1 receptor (TIR) domain. For effective LPS recognition, TLR4 additionally 
requires MD-2, which forms a complex with its extracellular domain (Triantafilou and 
Triantafilou, 2002; Jerala, 2007). The secreted glycoprotein MD-2 acts as an extracellular 
adaptor protein in the activation of TLR4 by firstly binding LPS and secondly associating 
with TLR4 via the extracellular leucine-rich repeats inducing TLR4 aggregation (Pålsson-
McDermott and O’Neill, 2004). Dimerization of the TLR4-MD-2-LPS-complex leads to the 
recruitment of adaptor proteins to the intracellular domain of TLR4, initiating the 
intracellular signaling cascade (Peri et al., 2010). 
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2.3. Intracellular lipopolysaccharide signaling  
 
2.3.1. Nuclear factor-κB activation 
 
Nuclear factor-κB (NF-κB) represents a family of transcription factors regulating the 
expression of diverse genes involved in immune and inflammatory responses.  In 
unstimulated cells, NF-κB is kept inactive in the cytoplasm, where its nuclear import is 
blocked (Verstrepen et al., 2008). 
Apart from LPS, NF-κB transcription factors can be activated in response to various 
stimuli including cytokines, infectious agents, injury and other stressful conditions requiring 
rapid reprogramming of gene expression. Following a coordinated cooperation of 
membrane-bound or cytosolic adaptor proteins and kinases, NF-κB is finally released and 
translocates to the nucleus to bind the promoters of responsive genes. These include pro-
inflammatory cytokines, such as TNF-α, IL-1 and IL-6, type I interferons (IFNs), COX-2, 
chemokines and adhesion molecules, which collectively regulate the recruitment of 
immune cells to infection sites. In addition, TNF-α and IL-1 stimulation of their respective 
receptors also strongly activates NF-κB, which plays an important role in amplifying and 
extending the innate immune response (Beinke and Ley, 2004; Brown et al., 2011). 
Theoretically, activation of TLR4 with subsequent cytokine production is beneficial 
for the host, but dysregulation of this process can lead to life-threatening syndromes such 
as sepsis and septic shock (Peri et al., 2010).  
Figure 2 provides an overview of the LPS signaling pathways (Verstrepen et al., 
2008). 
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Figure 2. Lipopolysaccharide (LPS) signaling pathways to NF-κB activation. (A) Extracellular 
LPS recognition. (B) MyD88-dependent intracellular LPS signaling. (C) MyD88-independent 
intracellular signaling (adapted from Verstrepen et al., 2008). 
 
2.3.2. MyD88-dependent and -independent pathways 
 
The TLR4-mediated response to LPS can be divided into an early myeloid 
differentiation factor 88 (MyD88)-dependent response and a delayed MyD88-independent 
response (Pålsson-McDermott and O’Neill, 2004). Activation of both signaling pathways 
occurs sequentially since TLR4 initially induces MyD88-dependent signaling at the plasma 
membrane and after endocytosis of the receptor complex, the MyD88-independent 
signaling is activated in the endosomes. TLR4 is the only TLR, signaling through both 
MyD88-dependent and -independent pathways (Jerala, 2007).  
The TIR domain containing adaptor protein MyD88 is recruited to the TLR4 complex 
via interaction with the TIR domain containing adaptor protein (TIRAP), also known as 
MyD88 adaptor like protein (Mal). As a result, IL-1 receptor-associated kinase 1 (IRAK-1), 
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the adaptor protein Toll-interacting protein (Tollip), TNF receptor-associated factor 6 
(TRAF6), as well as the IRAK-1 related kinase IRAK-4 all are recruited to the activated 
receptor complex in order to form complex I. In addition, protein B-cell 
leukemia/lymphoma 10 (BCL10) interacts with IRAK-1. Activation of IRAK-4 by 
intramolecular autophosphorylation leads to the subsequent phosphorylation and 
activation of IRAK-1. Subsequently, hyperphosphorylation of IRAK-1 results in the 
dissociation from MyD88 and Tollip, whereupon the IRAK-1-TRAF6 complex interacts with a 
transforming growth factor β-activated kinase 1 (TAK1)-TAK1-binding protein (TAB1)-TAB2 
(or TAB3) membrane-bound complex, forming complex II. Upon LPS stimulation, BCL10-
interacting protein mucosa-associated lymphoid tissue 1 (MALT1) interacts with BCL10 as 
well as TRAF6, and pellino-2 interacts with BCL10 in both the membrane-bound and 
cytosolic TAK1 complex. While IRAK-1 remains at the membrane and becomes poly-
ubiquitinated, the TRAF6-TAK1-TAB1-TAB2/3 complex translocates to the cytoplasm, 
where TRAF6 interacts with the E2 ubiquitin-conjugating enzyme complex Ubc13/Uev1A, 
forming complex III. Consequently, poly-ubiquitination of TRAF6 results in the final 
activation of the IKK complex and c-jun N-terminal kinase (JNK). IKKβ is responsible for the 
phosphorylation, poly-ubiquitination and proteolytical degradation of IκBα. Finally, NF-κB is 
released and translocates to the nucleus to bind the promoters of responsive genes 
(Verstrepen et al., 2008). 
The MyD88-independent signaling pathway, on the other hand, concerns the 
recruitement of the TIR domain containing adaptor-inducing IFN-β (TRIF) and the TRIF-
related adaptor molecule (TRAM). TRIF associates with TRAF6 and receptor-interacting 
protein 1 (RIP1) to induce NF-κB activation. Moreover, activation of the IKK-related kinases 
TANK-binding kinase 1 (TBK1) and IKKε by TRIF results in dimerization and phosphorylation 
of the transcription factor IFN regulatory factor 3 (IRF3), which binds and activates type I 
IFN promoters in the nucleus (Verstrepen et al. 2008). 
 
2.4. Inflammasome activation and IL-1β secretion 
 
The production and secretion of biologically active IL-1β involves the combined 
effect of at least 2 activation cascades: first, the gene transcription and cytosolic synthesis 
of an inactive 31-kDa precursor, pro-IL-1β, are induced upon exposure to typically 
 
17 
extracellular (pro-inflammatory) stimuli (vitaPAMPs) pattern recognition receptors (PRRs), 
including TLR4, and down-stream NF-κB signaling; secondly, this pro-IL-1β is proteolytically 
cleaved into mature 17-kDa IL-1β by cysteine-aspartic proteases (caspases), which are 
activated by the inflammasome (Underhill and Goodridge, 2012; Bi et al., 2014).   
The inflammasome is a large multimolecular intracellular protein complex which is 
typically composed of 3 components: a receptor protein part, the apoptosis associated 
speck-like protein (ASC) and caspase 1. The receptor part of inflammasomes is categorized 
by the domain structure of the protein. Similar to TLRs, cytoplasmic nucleotide-binding 
domain and leucin-rich repeat containing receptors (NLRs) are a family of PRRs, which can 
contain a pyrin domain (NLRP) (Horvath et al., 2011; Lamkanfi and Dixit, 2014). The 
canonical inflammasome protein NLRP3 engages ASC and activates caspase 1 to finally 
promote cleavage and secretion of IL-1β, as well as (pyroptotic) cell death.  
To date, inflammasome activation by LPS is not yet fully elucidated and this subject 
is out of the scope of this thesis. Nevertheless, it has been observed in murine 
macrophages that LPS from only one E. coli serotype, more specifically O111:B4, was able 
to elicit caspase 1 activation and secretion of active IL-1β albeit only in combination with 
another toxin as secondary stimulus (Kayagaki et al., 2013). Recently, Gram-negative 
bacteria, including E. coli, also elicit non-canonical inflammasome activation, in which 
caspase 11 was required in addition to NLRP3, ASC and caspase 1 to induce pyroptosis 
(Kayagaki et al., 2013). This E. coli-induced caspase 11 activation plays an important role in 
murine endotoxic shock and sepsis, as cytoplasmic LPS is directly recognized by caspase 11 
and induces the oligomerization and activation of this proteolytic enzyme (Shi et al., 2014).  
Of relevance for this PhD thesis, porcine inflammasome activation, however, 
remains largely unknown till date. It has been suggested that this signaling is expected not 
to differ considerably from other mammalian species i.e. man or mice (Kim et al., 2014). 
Corroborating this suggestion, very recently one group described that the porcine 
reproductive and respiratory syndrome virus (PRRSV) infection significantly induced IL-1β 
production and processing in primary porcine alveolar macrophages in an on TLR/MyD88 
signaling- and NLRP3 inflammasome activation-dependent manner, respectively (Bi et al., 
2014). 
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3. Lipopolysaccharide inflammation in pigs 
 
3.1. Lipopolysaccharide and septic shock 
 
LPS challenge has been commonly used as a model for Gram-negative bacterial 
inflammation and sepsis (Schrauwen et al. 1988; Schmidhammer et al., 2006). LPS is 
hypothesized to play a major role in sepsis, since the antibiotic-induced disintegration of 
bacteria may lead to massive and biologically active LPS release followed by a severe acute 
hemodynamic deterioration (Røkke et al., 1988; Lepper et al., 2002; Poli-de-Figueiredo et 
al., 2008). Sepsis is defined as a complex dysregulation of inflammation, ultimately 
affecting multiple organ systems and leading to irreversible damage (Buras et al., 2005). 
Sepsis is often, but not always, associated with the presence of a severe bacterial, fungal or 
viral infection and remains a major cause of morbidity and mortality (Fink and Heard, 1990; 
Dickneite and Leithäuser, 1999; Poli-de-Figueiredo et al., 2008). Accordingly, septic shock is 
a circulatory decompensation following sepsis and is often the result of vascular invasion 
by bacteria (Fink and Heard, 1990).  
Porcine Gram-negative bacterial shock is characterized by an initial hyperdynamic 
phase with an increased cardiac output, a decreased total peripheral vascular resistance 
and a normal to high arterial blood pressure. Subsequently, when bacteria invade the 
vascular system, the hyperdynamic phase can be followed by a hypodynamic phase with a 
decreased cardiac output, increased total peripheral vascular resistance and a low arterial 
blood pressure (Schrauwen and Houvenaghel, 1985; Holger et al., 2010). Furthermore, 
similar hemodynamic and clinical changes were observed following intravenous (IV) 
administration of living E. coli bacteria and a high or low dose of LPS in pigs, suggesting the 
activation of identical pathophysiological mechanisms. More specifically, porcine E. coli 
sepsis and endotoxemia are hemodynamically characterized by a profound pulmonary 
hypertension, systemic arterial hypotension, a decrease in cardiac output and a reflex 
increase in heart rate (Schrauwen et al. 1988; Olson et al., 1985; Klosterhalfen et al., 1992; 
Schmidhammer et al., 2006).  
However, the suitability of the LPS model to study sepsis is controversial (Fink and 
Heard, 1990; Poli-de-Figueiredo et al., 2008). Experimental endotoxemia as well as 
bacteremia mainly represent a systemic challenge lacking a preceding infectious focus and 
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the characteristic sepsis-induced immune reaction (Poli-de-Figueiredo et al., 2008). 
Moreover, killed E. coli bacteria are more lethal than LPS, suggesting that other 
components of the Gram-negative bacterial cell wall likely also contribute to the systemic 
inflammatory response (Fink and Heard, 1990; Poli-de-Figueiredo et al., 2008). 
In conclusion, LPS injection is generally accepted as a model to study the 
hypodynamic phase of Gram-negative bacterial shock, rather than sepsis (Fink and Heard, 
1990). 
 
3.2. In vivo porcine lipopolysaccharide inflammation models  
 
3.2.1. LPS challenge 
 
Table 1 provides a chronological overview of porcine E. coli LPS inflammation 
models used to study the APR-induced cytokines and, if available, APPs. The techniques 
used for determination of these mediators were also included. In addition to the selected 
E. coli serotype and LPS dose, the duration and route of administration (ROA) are additional 
important variables between these studies.  
 20 
Table 1. In vivo E. coli LPS inflammation models in pigs  
LPS Animals Time to maximal cytokine levels (h p.a.) Acute phase proteins (APP) Technique for cytokine / 
APP analysis 
Reference 
Serotype Dose (µg/kg BW) N° Age (d) BW (kg) TNF-α IL-1β IL-6 CRP SAA Hp 
Intravenous LPS administration 
O111:B4 0.5 over 0.5h 10* - 28-32 1 - 3 - - - 
Radioimmunoassay 
Bioassay 
Klosterhalfen et al., 1992 
O111:B4 200 3* 60-90 - 1 - - - - - Bioassay Nakajima et al., 1995 
O111:B4 75 32 ±28 - 1 Increase 2.5 Increase - Decrease ELISA/ELISA Frank et al., 2003 
O111:B4 
 
4µg/kg/h (0.5h) 
1 µg/kg/h (5.5h) 
4 84-98 20-26 1 - 2-3 - - - ELISA Goscinski et al., 2004 
O111:B4 
 
25 20 27-30 - 1 - 2-2.5 - - - ELISA Carroll et al., 2005 
O111:B4 
 
0.06 5 7-10 2.4±0.17 1 1 - - - - ELISA John et al., 2008 
O111:B4 
 
25 26 35-42 - 1 3 
2.5 
3.5 
Increase Increase Increase ELISA/ELISA Williams et al., 2009 
O111:B4 
 
0.625-5 µg/kg/h (0.75h) 
5 µg/kg/h (1.25h) 
0.625 µg/kg/h (3h) 
7 - 12-16 2.5 
Increase 
to 3.5 
Increase 
to 3.5 
- - - ELISA Levenbrown et al., 2013 
O26:B6 
 
2.5-15 µg/kg/h (0.5h) 
2.5 µg/kg/h (4.5h) 
9 - 30 (1) 2 - 4 - - - In-house fluorometric assay 
Nielsen et al., 2007 
O26:B6 
 
4 (8h) 4* - 25-35 2 ND 4 - - - ELISA 
Ruud et al., 2007 
O26:B6 
 
2.5-15 µg/kg/h (0.5h) 
2.5 µg/kg/h (5.5h) 
12* 96±4 40±3 1 - 4 Increase - - In-house fluorometric assay 
Spectrophotometry 
Ebdrup et al., 2008 
O55:B5 2 or 20 24 - 35 or 85 1-2 - 1-2 - - - ELISA; Bioassay Myers et al., 1999 
O55:B5 2 6* 90-120 25-35 1 NI 3 - - - ELISA; Bioassay Myers et al., 2003 
O55:B5 2 8  70-75 1 - 3 - - - ELISA Peters et al., 2012 
Intraperitoneal LPS administration 
K-235 0.5, 5 or 50 15* - 15-25 1.5 - - - - - ELISA Warren et al., 1997 
K-235 0.5, 5 48* - 11.6 ± 0.19 2 - 4 - - - ELISA; Bioassay Webel et al., 1997 
K-235 5 48* 42 11±1.05 2 NI - Increase Increase NI ELISA Llamas Moya et al., 2006 
O111:B4 100 45 12, 28, 30 - 1 - - - - - ELISA Kanitz et al., 2002 
O111:B4 100 72 12 or 56  1 ND - - - - ELISA Tuchscherer et al., 2004 
O55:B5 100 6* ±26 10.2 ± 0.9 2 - - - - Increase ELISA / 
Colorimetric, enzymatic assay 
Wright et al., 2000 
Intramuscular LPS administration 
O111:B4 25 or 50 24* - 21.3±0.48 - - - NI Increase NI ELISA; Peroxidase activity test (Hp) Frank et al., 2005 
O55:B5 25 20 126 85-100 1 - - - - Increase ELISA / 
Immunoturbidimetric method 
Leininger et al., 2000 
Intramammar LPS administration 
O111:B4 2  5* - 235 3 - 3 - - - ELISA Wang et al. 2006 
BW: body weight; d: days; h p.a.: hours post administration; ND: not detectable; NI: no increase; -: not investigated; *studies including negative control pigs
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 The majority of the studies (over 50 %) used E. coli serotype O111:B4, whereas E. 
coli serotypes O55:B5, O26:B6 and K-235 are used in > 20, > 10 and > 10 % of these studies, 
respectively. LPS challenge can be performed either as a single IV, intraperitoneal (IP) or 
intramuscular (IM) bolus administration, or as a continuous IV infusion. One study, 
however, provided LPS intramammarily. While a single LPS bolus administration provides a 
better perception of the sequence of events following LPS challenge, a continuous LPS 
infusion would imitate more accurately a clinical endotoxemia/septicemia, since endotoxin 
remains in circulation for a longer period (Fink and Heard, 1990; Olson et al., 1995; John et 
al., 2008). As previously mentioned, endotoxin is continuously produced and released by 
surviving bacteria in Gram-negative bacterial sepsis (Schrauwen et al., 1988). In 65 % of the 
reported studies, LPS was IV administered. Moreover, 2/3 of these studies used a bolus 
injection and in 1/3 of the studies an infusion was applied. Conversely, IP and IM 
administration are far less frequently applied, i.e. only in ± 25 and ± 10 % of the studies, 
respectively. 
Considerable species differences are reported with respect to endotoxin sensitivity. 
Unlike poultry and rodents, pigs and cattle are very sensitive to LPS administration (Olson 
et al., 1995; Schmidhammer et al., 2006; Poli-de-Figueiredo et al., 2008). While in pigs and 
cattle LPS doses of 25 and 2.5 µg/kg body weight (BW), respectively, can be considered as 
high; in broiler chickens and rodents doses as high as 2500 and 20000 µg/kg BW have been 
applied, respectively (Gerros et al., 1993; De Boever et al., 2010; Purswani et al., 2002; 
Zhang et al., 2008; Plessers et al., manuscript submitted). Doses of 500 and 2500 µg/kg BW 
have been proven to be lethal in pigs (Schrauwen et al., 1984, 1986; Schrauwen and 
Houvenaghel, 1985). In pigs, 80 % of the reported studies used an LPS dose ≤ 25 µg/kg BW 
(Table 1). In marked contrast, the IV administration of 0.004 µg/kg BW LPS to humans 
already causes fever and a hyperdynamic cardiovascular response (Martich et al., 1993).  
In neonatal calves, Gerros et al. (1993) established that neither the dose nor the 
route of LPS administration affects the sequence of mediator release. To date, the 
influence of LPS serotype, dose and ROA have not been investigated thoroughly in pigs.  
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3.2.2. Clinical symptoms in endotoxemic pigs 
 
As fast as within 15 min after LPS challenge, the first clinical signs occur in pigs. 
Symptoms such as intermittent coughing, salivation, chewing movements, retching and 
vomiting are recurrently observed. Subsequently, pigs become depressed for several hours, 
as manifested by general sickness, lethargy, somnolence and sternal or lateral decubitus. 
Respiratory difficulties develop varying from panting to severe dyspnea. Occasionally, 
shivering, generalized rubor, cyanosis and even necrotic lesions have been described 
(Schrauwen and Houvenaghel, 1985; Schrauwen et al., 1988; Johnson and von Borell, 1994; 
Leininger et al., 2000; Kanitz et al., 2002; Myers et al., 2003; Peters et al., 2012).  
Reduced feed intake and anorexia are also indisputably associated with the 
administration of LPS (Warren et al., 1997; Wright et al., 2000; Myers et al., 2003). 
Additionally, a dose-dependent reduction in feed consumption and activity after an LPS 
bolus administration in pigs was described (Johnson and von Borell, 1994; Frank et al., 
2005). Following intratracheal LPS administration, only moderate clinical signs were 
observed (Villarino et al., 2013). 
 
3.2.3. Pro-inflammatory cytokines 
 
Over the years, enzyme-linked immuno sorbent assay (ELISA) remains the most 
popular immuno-assay for the determination of porcine TNF-α, IL-1 and IL-6 in serum or 
plasma. In initial reports, researchers mostly relied on bioassays for measurement of TNF-α 
and IL-6 using specific murine cell lines. While the presence of IL-6 was commonly 
established by IL-6 dependent proliferation assays, TNF-α activity was quantified by 
measurement of its cytotoxicity to cells in culture (Table 1). Currently, ELISA is still 
considered the gold standard for analysis of systemic cytokines as well as APPs, yet 
multiplex, flow cytometric assays for the simultaneous measurement of multiple porcine 
inflammatory parameters are gaining popularity (Johannisson et al., 2006; Lawson et al., 
2010).  
It should be remarked that the use of different techniques may yield different 
results, i.e. a bioassay measuring biologically active TNF-α will generate different results 
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compared to an ELISA measuring immunoreactive (free and receptor-bound) TNF-α (Myers 
et al., 1999). 
A wide variation in the time points of sampling can be observed within the porcine 
LPS inflammation studies. With the exception of Warren et al. (1997) and Levenbrown et 
al. (2013), who surprisingly determined a maximal plasma concentration of TNF-α only at 
1.5 and 2.5 h post LPS administration (p.a.), respectively, the peak concentration of TNF-α 
is unarguably established at 1 h in pigs after IV, IP and IM LPS administration. A number of 
papers describing a peak concentration of TNF-α at 2 h p.a. simply did not include a 
sampling point at 1h p.a. (Webel et al., 1997; Wright et al., 2000; Llamas Moya et al., 2006; 
Ruud et al., 2007). Notwithstanding John et al. (2008), who observed a 9-fold increase in 
TNF-α levels p.a. following an IV LPS dose as low as 0.06 µg/kg BW, it was repeatedly 
reported that LPS doses < 1 µg/kg failed to provoke a systemic TNF-α response indicating a 
dose-dependent effect on TNF-α levels. Additionally, the ROA is also partially responsible 
for inconsistent results (Warren et al., 1997; Webel et al., 1997; Myers et al., 1999). 
As for IL-6, maximal concentrations were measured between 2.5 and 4 h p.a. Only 
Myers et al. (1999), described a maximal IL-6 concentration already between 1 and 2 h p.a. 
Noteworthy, in set-ups utilizing frequent blood sampling, maximal levels of IL-6 were 
repetitively established at 2.5 h p.a. (Frank et al., 2003; Carroll et al., 2005; Williams et al., 
2009). Although IL-6 is a potent inducer of the APR, it has notable anti-inflammatory 
properties as well. Accordingly, it has been increasingly suggested to classify IL-6 as an anti-
inflammatory cytokine (Opal and DePalo, 2000; Philippart and Cavaillon, 2007). 
Although IL-1 is recognized to be of major importance in the inflammatory process, 
this cytokine is rather scarcely included in the characterisation of the APR of porcine LPS 
inflammation models. IL-1 consists of two related proteins, IL-1α and IL-1β (Murtaugh et 
al., 1996), of which only the latter is investigated in pigs (Table 1). Conversely to TNF-α and 
IL-6, these data presented on porcine IL-1β are not straightforward. More specifically, IL-1β 
has repeatedly been reported either not detectable or not increasing in plasma p.a. of LPS 
in pigs (Myers et al., 2003; Tuchscherer et al., 2004; Llamas Moya et al., 2006; Ruud et al., 
2007). In this respect, it has been suggested that IL-1β production is less sensitive to the 
effects of LPS compared to TNF-α and IL-6 (Myers et al., 2003). Nevertheless, John et al. 
(2008) determined a 5-fold increase in the concentration of IL-1β at 1 h p.a. of an LPS dose 
as low as  0.06 µg/kg BW. Frank et al. (2003) observed a significant increase of this pro-
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inflammatory cytokine between 1 and 2 h p.a. In another study, maximal IL-1β levels were 
only seen at 3 h p.a. (Williams et al., 2009). Interestingly, the studies describing a 
noticeable increase or maximal concentration of IL-1β p.a., all applied E. coli serotype 
O111:B4 (Table 1).  
 
3.2.4. Eicosanoids 
 
3.2.4.1. PGE2 and the febrile response 
 
It is generally accepted that PGE2 is responsible for the increase of the body 
temperature in mammals. PGE2 exerts its pyrogenic action by binding to receptors on 
thermoregulatory neurons in the hypothalamus (Baumann and Gauldie, 1994; Netea et al., 
2000; Blatteis et al., 2005). However, the role of PGE2 in the induction of the febrile 
response has been considered both crucial and controversial (Coceani et al., 1986; Blatteis 
et al., 2005). These PGE2 inconsistencies have been reviewed in detail by Blatteis et al. 
(2005). Briefly, the IV administration of both pyrogenic cytokines and PGE2 to pigs 
undeniably induces fever.  
Treatment with a COX-inhibitor, on the other hand, completely prevents this LPS-
induced fever and sickness in pigs, confirming an important role for PGE2 in the induction 
of fever (Johnson and von Borell, 1994; Vellucci and Parrott, 1994; Parrott et al., 1995; 
Peters et al., 2012) (Figure 5). The synthesis of PGE2 is catalysed by the COX-2 enzyme 
following its transcription and translation. The systemic appearance of PGE2 is therefore 
expected to occur later (Blatteis et al., 2005).  
However, in pigs, maximal plasma concentrations of PGE2 are already observed 
within 1 or 2 h p.a. of LPS (Wright et al., 2000; Peters et al., 2012). The porcine febrile 
response commonly peaks at approximately 4 h p.a. of LPS, with a body temperature rising 
above 40 °C (Johnson and von Borell, 1994; Warren et al., 1997; Leininger et al., 2000; 
Wright et al., 2000; Mustonen et al., 2012a). The duration of the febrile response has been 
determined dose-dependent in LPS-challenged pigs (Johnson and von Borell, 1994). 
 
 
 
 
25 
3.2.4.2. TXA2 and pulmonary hypertension 
 
In marked contrast to other animal species, a dramatic increase in pulmonary 
arterial pressure is noticed in pigs in response to an endotoxin challenge (Olson et al., 
1985; Schrauwen et al. 1988; Klosterhalfen et al., 1992; Schmidhammer et al., 2006). 
Remarkably, differentiated macrophages are observed within porcine lung capillary vessels 
(Winkler and Cheville, 1985). It is hypothesized that those pulmonary intravascular 
macrophages (PIMs) respond to LPS with a rapid and massive release of TXA2, resulting in a 
severe pulmonary hypertension and possibly right heart dysfunction (Klosterhalfen et al., 
1992; Dickneite and Leithäuser, 1999; Schmidhammer et al., 2006). The concentration of 
TXB2, a stable metabolite of TXA2, rapidly increases following LPS challenge in pigs, 
attaining peak plasma concentrations as early as 30 to 45 min p.a. (Klosterhalfen et al., 
1992; Mustonen et al., 2012a). However, Friton et al. (2006) established a maximal 
concentration of TXB2 only at 2 h p.a., while Peters et al. (2012) detected no increase at all 
in pigs. High concentrations of TXB2 are suggested to be associated with more severe 
clinical symptoms (Mustonen et al., 2012a). 
 As for the cytokines, commercial ELISA kits are popular for the determination of 
eicosanoids (Friton et al., 2006; Cao et al., 2006; Mustonen et al., 2012a; Peters et al., 
2012). Although these methods are sensitive, they are less specific. The development of 
highly specific analytical methods for the detection and quantification of multiple 
arachidonic acid metabolites by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) is therefore of growing interest (Araujo et al., 2013). 
 
3.2.5. Acute phase proteins 
 
To study APPs in pigs, inflammation was often aseptically induced by a single 
subcutaneous injection of turpentine (Lampreave et al., 1994; González-Ramón et al., 1995; 
Eckersall et al., 1996). The maximal plasma concentrations of these APPs are typically 
reached within 24 to 48 h after the initiation of the APR (Lampreave et al., 1994; Petersen 
et al., 2004). Additionally, the APP profile has been comprehensively characterized after 
experimental infections with Actinobacillus (A.) pleuropneumoniae and Streptococcus suis 
(Heegaard et al., 1998; Sorensen et al., 2006).  
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In contrast, data on APPs in LPS inflammation models are rather scarce, especially in 
pigs (Table 1). Williams et al. (2009) determined an increase in SAA, CRP as well as Hp after 
an IV LPS bolus injection of 25 µg/kg BW. Apart from a significant increase in SAA, Frank et 
al. (2005) surprisingly observed no increase in CRP nor in Hp after an IM LPS challenge of 25 
or 50 µg/kg BW. The authors considered the possibilities that both CRP and Hp were 
already elevated prior to LPS challenge, or that the blood sampling points (i.e. 0 and 48 h 
p.a.) were likely inappropriate to detect changes in both the APPs. On the other hand, 
Leininger et al. (2000) and Wright et al. (2000) demonstrated increased levels of Hp after 
an IM LPS bolus of 25 µg/kg BW and an IP LPS bolus of 100 µg/kg BW, respectively. Llamas 
Moya et al. (2006) detected an increase in both SAA and CRP after an IP LPS injection of 
only 5 µg/kg BW, yet levels of Hp were not elevated. Finally, Ebdrup et al. (2008) 
established a rise in CRP levels after LPS infusion. Although pig-MAP has been recurrently 
suggested as an excellent biomarker for the indication of porcine stress conditions and 
pathologies (Alava et al., 1997; Piñeiro et al., 2007; Heegaard et al., 2011), to date only our 
group has reported the increase of this interesting APP in an IV LPS inflammation model. 
Apart from a few exceptions, concentrations of APPs were, as for cytokines and 
eicosanoids, determined using commercial ELISA kits (Table 1), which yielded diverse and 
sometimes contradictory results between studies. As CRP is a major APP in humans and 
numerous animal species, different species-specific CRP ELISA kits are commercially 
available. To illustrate the need for careful interpretation, it should be remarked that 
Slagman et al. (2011) considered the results of one CRP ELISA highly controversial.  
In contrast to most human clinical laboratories, where automated 
immunonephelometric and immunoturbidimetric assays are routinely used to quantify 
concentrations of CRP, in clinical veterinary medicine, determination of CRP has not been 
routinely used (Tugirimana et al., 2011; Algarra et al., 2013). Recently, sensitive 
turbidimetric and nephelometric methods, relying on the calcium-mediated, but species-
independent binding of CRP to phosphocholine have been described, which offer further 
interesting perspectives for application in veterinary medicine (Tugirimana et al., 2011; 
Drieghe et al., 2014). 
In conclusion, it can be stated that research on APPs is not as well-established as 
cytokine research in porcine inflammation. A current lack of appropriate and reliable 
detection methods of these APPs in general and CRP in specific is definitely a major hurdle. 
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3.2.6. Endotoxin tolerance 
 
Endotoxin tolerance is defined as a reduced responsiveness to an LPS challenge 
following a first encounter. This phenomenon is regarded as a pathophysiological 
adaptation to protect the host from extensive tissue damage and the manifestation of 
septic shock following uncontrolled inflammation. In this respect, cells or organisms 
exposed to LPS concentrations become temporally unable to respond to further LPS 
challenges (Cavaillon and Adib-Conquy, 2005; Biswas et al., 2009). 
TNF-α has been reported to be the best marker for endotoxin tolerance (Cavaillon 
and Adib-Conquy, 2005). Indeed, TNF-α levels increase both rapidly and dramatically 
following a first LPS administration. After repetitive LPS administrations, TNF-α still peaked 
at 1 h p.a., yet decreasing peak plasma levels were observed in pigs (Klosterhalfen et al., 
1992; Nakajima et al., 1995). Likewise, the release of TXB2 and the marked elevation of the 
pulmonary arterial pressure was greatly reduced (Klosterhalfen et al., 1992). Additionally, 
also CRP levels in porcine saliva are suggested to be tolerance subjective (Escribano et al., 
2014). 
 
4. Immunomodulation in pigs 
 
Immunomodulation is defined as a reorganization of the inflammatory response by 
modifying or regulating functions of the host’s immune system. Immunomodulation differs 
from immunosuppression and anti-inflammation, as it involves both suppression and 
stimulation of the immune response (Blecha, 1988; Kanoh and Rubin, 2010).  
The immunomodulatory properties of drugs have been studied after either in vitro 
or in vivo LPS challenge in different animal species. Notwithstanding in vivo LPS 
inflammation models are extensively applied in porcine research, reports on the possible 
immunomodulatory properties of drugs in such models in pigs are relatively scarce. The 
most studied classes of drugs are (N)SAIDs, while the study of antimicrobial drugs, as well 
as in vitro research is very limited in pigs. Conversely, in humans and rodents, such studies 
are commonly performed and well-established.  
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BW: body weight; ROA: route of administration; TOA: time of administration relative to LPS administration; IV: intravenous; IM: intramuscular; PO: oral administration; IP: intraperitoneal;  
NSAIDs: non-steroidal anti-inflammatory drugs; SAIDs: steroidal anti-inflammatory drugs; - : not investigated;  
 
 
 
 
Table 2. Immunomodulatory effects of drugs in in vivo LPS inflammation models in pigs 
Class of drugs Drug 
DRUG DOSE 
ROA TOA (h) 
EFFECTS 
REFERENCE Bolus 
mg/kg BW 
Infusion 
mg.kg
-1
.h
-1
 
Body 
temperature 
Pulmonary 
response 
Total clinical 
score 
TNF-α IL-6 
NSAIDs Acetylsalicylic acid 100 or 35  PO -2; 2 Decrease - - - - Salichs et al., 2012 
Flunixin meglumine 2 1 IV -0.5 - Effect - - - Olson et al., 1985 
 Flunixin meglumine 2.2  IM -24; -0.5 - - Decrease No influence No influence 
 
Peters et al., 2012 
 Flurbiprofen 1  IV -0.5 - Effect - - - Schrauwen et al., 1984 
 Indomethacin 5 3 IV -0.5 - Effect - - - Olson et al.,1985 
 Indomethacin 5  IP 0 - - Decrease - - Johnson and von Borell, 1994 
 Ketoprofen 2 or 4  PO 1 Decrease - Decrease - - Mustonen et al., 2012a 
 Ketoprofen 1.5  PO -2; 2 Decrease - - - - Salichs et al., 2012 
 Meloxicam 0.4  IM -1 - - Decrease - - Friton et al., 2006 
 Paracetamol 30  PO -2; 2 Decrease - - - - Salichs et al., 2012 
SAIDs Dexamethasone 5 1 IV -18; -1 - Effect - - - Olson et al., 1985 
 Dexamethasone 5  IV -1.33 Decrease - - - - Parrott et al., 1997 
 Dexamethasone 0.5  IV -18; 0; 12 - - - Decrease Decrease Myers et al., 2003 
 Prednisolone 10  IV -0.42 - Effect - - - Schrauwen and Houvenaghel, 
1984 
 Prednisolone 10  IV 0.25; 1.25; 4.5 No influence No influence No influence - - Schrauwen  and 
Houvenaghel,1985 
Antimicrobial 
drugs 
Ceftazidime 41.7  IV -0.08 - No influence - No influence Decrease Goscinski et al., 2004 
 Tobramycin  17.5 (0.33h) IV -0.17 - No influence - No influence No influence Goscinski et al., 2004 
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Table 2 provides a comprehensive overview of the immunomodulatory properties 
of drugs on the inflammatory parameters earlier described in in vivo porcine LPS 
inflammation models. Additionally, in this paragraph, a brief impression of similar research 
in human and rodents is offered. 
 
4.1. Nonsteroidal anti-inflammatory drugs 
 
4.1.1. Mechanism of action 
 
Prostaglandins (PGs), TXs and LTs are all synthesized from cell membrane 
phospholipids and collectively referred to as eicosanoids (Adams, 2001). Arachidonic acid, 
which is incorporated into membrane phospholipids, is the main source of eicosanoids. In 
response to phospholipase (PL) A2, arachidonic acid is released from the cell membrane 
after which it is subject to a rapid oxidative catabolism by two separate enzymatic 
pathways, a COX and a lipoxygenase (LOX) pathway (Adams, 2001) (Figure 5).  
Nonsteroidal anti-inflammatory drugs (NSAIDs) possess anti-inflammatory, 
antipyretic and analgesic properties which are believed to be the result of blocking the PG 
production by binding to and blocking COX (Vane, 1971; Curry et al., 2005). COX exists in 
two major isoforms, COX-1 and COX-2. COX-1 is a constitutively expressed, housekeeping 
enzyme, responsible for the production of PGs and TXs involved in the maintenance of 
physiological processes, including protection of the gastrointestinal mucosa and platelet 
aggregation. COX-2, on the other hand, is not constitutively present, but is induced when 
cells are exposed to bacterial LPS or cytokines and is mainly responsible for the PGs 
involved in inflammation and pain (Vane, 1971; Hersh et al., 2000; Adams, 2001). Blocking 
COX-1 would be associated with more side effects and consequently NSAIDs preferentially 
blocking COX-2 are clinically desirable (Curry et al., 2005). In this respect, the COX-2:COX-1 
ratio represents the amount of drug necessary to inhibit the respective COX isoforms 
(Curry et al., 2005). However, recently, also COX-1 was suggested to be involved in 
inflammatory processes (Teeling et al., 2010). The E. coli LPS-induced fever model has been 
accepted for the evaluation of the antipyretic effect of nonsteroidal anti-inflammatory 
drugs (NSAIDs; EMA, 2001). 
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In contrast to COX, LOX is not as ubiquitous and is predominantly found in the lungs, 
leukocytes and platelets. LTA4 is a potent mediator of (local) inflammation, whereas LTB4 is 
a potent chemoattractant. NSAIDs are not capable of inhibiting LTs synthesis. Paradoxically, 
the use of a COX-inhibitor might result in an overpresentation of arachidonic acid to the 
LOX pathway and following increase in LTs production (Adams, 2011; Curry, 2005) (Figure 
5).  
 
4.1.2. Immunomodulatory effects of nonsteroidal anti-inflammatory drugs 
 
4.1.2.1. Effects on clinical symptoms and febrile response 
 
In LPS-challenged mice, indomethacin and ibuprofen significantly influenced 
behavioural changes, including burrowing, while paracetamol did not. Additionally, 
indomethacin completely blocked PGE2 production and both indomethacin and 
paracetamol reduced changes in body temperature (Teeling et al., 2010). 
In LPS-challenged pigs, treatment with indomethacin completely inhibited the 
anorexia as well as the reduction in activity. Remarkably, when provided alone (without 
LPS administration), indomethacin increased feed intake at 1 to 2 h (Johnson and von 
Borell, 1994). Treatment of pigs with meloxicam or flunixin meglumine before LPS 
challenge significantly decreased the clinical symptoms, including lethargy, skin flushing, 
vomiting, coughing and labored breathing (Friton et al., 2006; Peters et al., 2012). Different 
oral doses of ketoprofen p.a. of LPS showed similar effects (Mustonen et al., 2012a). 
Flurbiprofen pretreatment significantly prolonged the survival time in endotoxemic pigs 
and completely abolished the production of arachidonic acid metabolites (Schrauwen et 
al., 1984). 
An oral bolus of ketoprofen (Figure 3) administered after LPS administration 
prominently decreased the rise in rectal body temperature. Ketoprofen drinking water 
medication started before LPS administration, on the other hand, completely blocked the 
rise in rectal body temperature (Mustonen et al., 2012a; Salichs et al., 2012). Furthermore, 
Salichs et al. (2012) reported the superiority of ketoprofen to acetylsalicylic acid and 
paracetamol in antipyretic activity after oral administration to LPS-challenged pigs. 
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Treatment with meloxicam before LPS challenge reduced the rectal body temperature 
(Friton et al., 2006). Treatment of pigs with flunixin meglumine before LPS challenge 
prevented the increase in PGE2 production, and effected the body temperature (Peters et 
al., 2012). In contrast, in pigs experimentally infected with A. pleuropneumoniae, flunixin 
meglumine administration after the challenge showed no antipyretic effect, whereas 
ketoprofen was again proven to be an effective antipyretic drug (Swinkels et al., 1994). 
 
 
Figure 3. Chemical structure of ketoprofen 
 
4.1.2.2. Effects on pro-inflammatory cytokines and acute phase proteins  
 
In LPS-challenged mice, indomethacin had no inhibiting effect on the serum levels 
of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 p.a. Surprisingly, even increased levels 
of TNF-α were observed (Teeling et al., 2010). In this context, it has been reported that 
NSAIDs stimulate, rather than inhibit, the production of TNF-α and thereby even increase 
mortality in murine endotoxic shock models (Pettipher and Wimberly, 1994; Ghezzi et al., 
1998). 
In pigs, treatment with flunixin meglumine had no influence on the production of 
TNF-α and IL-6 p.a. of LPS (Peters et al., 2012), whereas meloxicam had no effect on the 
levels of CRP and haptoglobin (Friton et al., 2006).  
 
4.1.2.3. Effects on pulmonary response 
 
In LPS-challenged pigs, ketoprofen, meloxicam and flurbiprofen significantly 
reduced the concentrations of TXB2 (Schrauwen et al., 1984; Friton et al., 2006; Mustonen 
et al., 2012a). Flurbiprofen significantly inhibited the early increase in pulmonary arterial 
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pressure and pulmonary vascular resistence (Schrauwen et al., 1984). Likewise, flunixin 
meglumine and indomethacin blocked the initial increase in pulmonary arterial pressure 
and pulmonary vascular resistance, as well as the decrease in cardiac output in LPS-
challenged pigs. However, both drugs did not modify the subsequent increase in 
pulmonary vascular resistance and decrease in cardiac output (Olson et al., 1985).  
 
4.2. Steroidal anti-inflammatory drugs 
 
4.2.1. Mechanism of action 
 
SAIDs or glucocorticoids, are potent anti-inflammatory, yet immunosuppressive 
drugs, having a profound suppressive effect on the endogenous glucocorticoid regulation. 
This class of drugs exerts its main anti-inflammatory effects by the inhibition of PLA2 after 
first enhancing the production of lipocortin. Glucocorticoids are used in veterinary 
medicine to treat inflammatory, immunological and allergic disorders (Ferguson et al., 
2009). However, glucocorticoids, and some NSAIDs, are known to exert additional anti-
inflammatory effects by modulation of COX-independent signal transduction, involving 
inhibition of transcription factors such as NF-κB (Tegeder et al., 2001). In this respect, 
glucocorticoids have been reported to inhibit LPS-induced TNF-α, IL-1β and IL-6 levels both 
in vitro and in vivo in different animal species (Morikawa et al., 1996, Bessler et al., 1999; 
Teeling et al., 2010; Myers et al., 2003). 
Since LPS-induced fever is mainly PG-dependent, both NSAIDs and glucocorticoids 
are expected to have antipyretic properties (Figure 5). PGE2 is a major inflammatory 
mediator, involved in the development of fever (Ivanov and Romanovsky, 2004). The de 
novo formation of PGE2 comprises a three-step cascade reaction catalyzed by PLA2, 
liberating arachidonic acid from the membrane; COX, converting arachidonic acid to PGH2; 
and PGE synthase, finally isomerizing PGH2 to PGE2. Subsequently, PGE2 is rapidly converted 
to its major inactive metabolite 13,14-dihydro-15-keto PGE2, and can be subject to further 
metabolism to 13,14-dihydro-15-keto PGA2 and finally bicyclic PGE2 (Fitzpatrick et al., 1980; 
Granström et al., 1980; Ivanov and Romanovsky, 2004). 
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Figure 4. Chemical structure of dexamethasone 
 
4.2.2. Immunomodulatory effects of steroidal anti-inflammatory drugs 
 
4.2.2.1. Effects on clinical symptoms and febrile response 
 
While no effect of dexamethasone was reported on the behavioural changes in LPS-
challenged mice, PGE2 production was significantly reduced and changes in body 
temperature were completely blocked (Teeling et al., 2010).  
In pigs, it was demonstrated that a single dose of prednisolone before LPS 
administration remarkably increased the survival rate, whereas repeated doses of 
prednisolone during and after LPS administration had no effect (Schrauwen and 
Houvenaghel, 1984; 1985). A bolus administration of a high IV dose of dexamethasone 
prevented LPS-induced fever in pigs. When provided alone (without LPS administration), 
dexamethasone significantly lowered the body temperature (Parrot et al., 1997). 
 
4.2.2.2. Effects on pro-inflammatory cytokines and acute phase proteins  
 
Dexamethasone suppressed and completely abolished the synthesis of TNF-α, IL-1β 
and IL-6 in human monocytes primed with LPS and in LPS-challenged mice, respectively 
(Morikawa et al., 1996; Teeling et al., 2010).  
In pigs, repeated IV treatments with dexamethasone before and after LPS challenge 
significantly decreased TNF-α and IL-6 plasma levels by more than 50 and 90 %, 
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respectively. Surprisingly, neither LPS nor dexamethasone administration had any effect on 
IL-1β levels, which were constitutively present in pigs (Myers et al., 2003). 
 
4.2.2.3. Effects on pulmonary response 
 
Dexamethasone showed similar effects compared to NSAIDs, it is therefore strongly 
indicated that the first phase (0 – 2 h) of the porcine pulmonary response after LPS 
administration is COX-dependent. In contrast, the second phase was only attenuated by 
dexamethasone, suggesting the involvement of COX-independent mechanisms, such as 
lipoxygenase products (Olson et al., 1985).  
 
 
Figure 5. Inhibition of the lipoxygenase- and cyclooxygenase (COX)-catalyzed conversion of 
arachidonic acid by (non)-steroidal anti-inflammatory drugs ((N)SAIDs)  
(Based on Adams, 2001). 
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4.3. Antimicrobial drugs 
 
4.3.1. Mechanism of action 
 
Besides their antimicrobial activities, which will not be discussed in this thesis, 
antibiotics also possess possibly clinically important immunomodulatory properties. The 
effects of (macrolide) antibiotics on inflammation and cytokine release in vitro, and to a 
lesser extent also in vivo, have been summarized in detail (Tauber and Nau, 2008). In this 
respect, mainly 14- and 15-membered, but only few 16-membered macrolides are 
suggested to exert immunomodulatory properties, varying from the release of cytokines 
and mediators, neutrophil function, migration, infiltration and accumulation to mucus 
(hyper)secretion, biofilm formation and bacterial quorum sensing (Čulić et al. 2001; 
Parnham, 2005; Kanoh and Rubin, 2010).  
 
4.3.2. Immunomodulatory effects of antimicrobial drugs 
 
4.3.2.1. Effects on clinical symptoms and febrile response 
 
The macrolide antibiotics roxithromycin, clarithromycin, erythromycin, 
azithromycin, tilmicosin and tylosin are all reported to decrease the in vitro eicosanoid 
production in LPS-stimulated murine macrophages and/or peripheral blood mononuclear 
cells in a concentration-dependent manner (Ianaro et al., 2000; Cao et al., 2006). 
Both ciprofloxacin and florfenicol (pre)treatment significantly increased survival 
rates of LPS-challenged mice by preventing endotoxin-mediated shock and death. In this 
respect, a crucial role of TNF-α in LPS-induced septic shock has been suggested (Purswani 
et al., 2002; Zhang et al., 2008).  
To date, no reports on the influence of antibiotics on the clinical symptoms and 
body temperature are available in porcine LPS inflammation models.  
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4.3.2.2. Effects on pro-inflammatory cytokines and acute phase proteins 
 
In LPS-stimulated human monocytes, fosfomycin inhibited the production of TNF-α 
and IL-1β, while the production of IL-6 was noticeably enhanced (Morikawa et al., 1996). 
Quinolones, including ciprofloxacin, pefloxacin and ofloxacin have been reported to inhibit 
the production of TNF-α, IL-1β and IL-6 in a concentration-dependent manner (Bailly et al., 
1990). Morikawa et al. (1996) demonstrated a clear concentration-dependent suppression 
of the production of TNF-α and IL-1β by clarithromycin, while the suppressive effect on the 
production of IL-6 was very weak.  
In LPS-stimulated murine mononuclear cells, the inhibition of TNF-α, IL-1β and IL-6 
production by diverse macrolide antibiotics, including roxithromycin, clarithromycin, 
erythromycin, azithromycin, tilmicosin and tylosin was reported (Ianaro et al., 2000; Cao et 
al., 2006). Telithromycin significantly inhibited the production of TNF-α by both LPS-
induced murine macrophages and mice (Sugiyama et al., 2007; Leiva et al., 2008). In LPS-
stimulated murine dendritic cells, on the other hand, clarithromycin significantly inhibited 
the production of IL-6, while there was completely no effect on the production of TNF-α 
observed. Additionally, azythromycin had no effect on the production of TNF-α and IL-6 
(Sugiyama et al., 2007). In this respect, also 16-membered macrolide antibiotics, including 
tylosin and tilmicosin, are proven to decrease the production of TNF-α, IL-1β, IL-6 and PGE2 
in humans and rodents. 
Treatment with florfenicol, a broad-spectrum antibiotic and analogue to 
chloramphenicol family, significantly decreased levels of TNF-α and IL-6 in cell supernatant 
of LPS-induced murine macrophages. Accordingly, in LPS-challenged mice, similar results 
were observed. The effect of florfenicol on IL-1β release was negligible both in vitro and in 
vivo (Zhang et al., 2008). Ciprofloxacin significantly decreased production of TNF-α in LPS-
challenged mice, while only a little or no effect was observed for IL-1β and IL-6 (Purswani 
et al. 2002). 
Finally, in pigs treated with the β-lactam antibiotic ceftazidime, significantly 
decreased levels of IL-6 were detected at 6 h after the onset of LPS infusion. However, 
neither ceftazidime nor the aminoglycoside antibiotic tobramycin influenced the levels of 
IL-1β (Goscinski et al., 2004). 
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4.3.2.3. Effects on pulmonary response 
 
Neither ceftazidime nor tobramycin affected the pulmonary response in LPS-
challenged pigs (Goscinski et al., 2004).  
To date, no other in vivo reports on the influence of antibiotics on the pulmonary 
response are available in porcine LPS inflammation models.  
 
In conclusion, LPS inflammation models have been widely applied and 
demonstrated to be a valuable tool for immune challenge in porcine research. Pigs are very 
sensitive to the administration of LPS, yet even small doses (≤ 25 µg/kg BW) provoke a 
profound inflammatory response without causing mortality. After LPS challenge, peak 
concentrations of TNF-α and IL-6 are expected to occur around 1 h and 2.5 h p.a., 
respectively. Reports on porcine IL-1β are rather scarce and contradictorily. While maximal 
concentrations of PGE2 are already reached within around 1 h p.a., the febrile response 
peaks no earlier than at 4 h p.a. in pigs. The APP, including CRP, SAA, Hp and pig-MAP 
generally increase after LPS challenge, yet a lack of appropriate and reliable detection 
methods can partially explain the discrepancies between different studies. 
LPS inflammation models can be used to study possible immunomodulatory 
capacities of drugs. Single or multiple doses of drugs can be administered before and/or 
after LPS administration. Ketoprofen was shown to be an effective antipyretic and anti-
inflammatory drug when administered both before and after LPS challenge. Numerous 
macrolide antibiotics, mainly 14 and 15-membered, including erythromycin, clarithromycin 
and azithromycin; and to a lesser extent also 16-membered, including tylosin and 
tilmicosin, are proven to decrease the production of TNF-α, IL-1β, IL-6 and PGE2 in humans 
and rodents. Murine research has indeed confirmed the suitability of LPS inflammation 
models to investigate the influence of different (N)SAIDs and even antimicrobial drugs on 
the clinical changes, production of pro-inflammatory cytokines, APP and the course of the 
febrile response. 
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Unfortunately, to date, in vitro and in vivo reports on the influence of antimicrobial 
drugs on the APR are largely lacking in pigs, although their well-established use in 
infectious diseases. Also the effects of a combination therapy of antimicrobial drugs and 
(N)SAIDs on the APR are poorly studied in pigs. Moreover, the suitability of IL-1β to study 
immunomodulation of drugs in in vivo porcine LPS inflammation models is highly 
controversial. 
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SCIENTIFIC AIMS 
 
Modulation of the host immune response is of growing interest in human and 
veterinary medicine. To study immunomodulation in different animal species, 
lipopolysaccharide (LPS) - as a major part of the Gram-negative bacterial outer membrane - 
has been recurrently applied. While the LPS-induced fever model has been accepted for 
the evaluation of the antipyretic effect of nonsteroidal anti-inflammatory drugs (NSAIDs), it 
also offers opportunities for the evaluation of these and other classes of drugs, such as 
antimicrobials, on pro-inflammatory mediators from the acute phase response (APR). 
Recently, the combined use of the antibiotic doxycycline and the NSAID ketoprofen 
has been proven beneficial in the treatment of swine respiratory disease (SRD). 
Gamithromycin (GAM) is a 2nd generation macrolide antibiotic which is currently only 
registered for the treatment and prevention of bovine RD. Similar to cattle, SRD associated 
with Gram-negative bacteria including Actinobacillus pleuropneumoniae, Pasteurella 
multocida and Haemophilus parasuis is responsible for considerable economic losses and 
reduced animal welfare.  
 
Therefore, the General Aim of this thesis was to investigate the immunomodulation 
by GAM, KETO and their combination in appropriate in vitro and in vivo porcine LPS 
inflammation models. It is hypothesized that GAM exerts immunomodulatory activities and 
that its combination with KETO would be beneficial compared to the exclusive 
administration of each drug with respect to the pigs’ clinical condition. Dexamethasone 
(DEX), a glucocorticoid and well-known cytokine inhibitor, was included as a positive 
control in this research. 
 
The specific aims of this thesis were: 
1) To determine the pharmacokinetic properties of GAM and DEX in pigs.  
2) To evaluate the pharmacodynamic effects of GAM, KETO, DEX and their two-drug 
combinations in appropriate in vitro and in vivo porcine LPS inflammation models. 
3) To develop and validate a cytometric bead array (CBA) screening tool for the 
simultaneous measurement of porcine pro-inflammatory cytokines in serum and 
plasma. 
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EXPERIMENTAL STUDIES  
 
42 
  
 
43 
CHAPTER 1. 
Pharmacokinetics of gamithromycin and dexamethasone 
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1.1. Pharmacokinetics of gamithromycin after intravenous and subcutaneous 
administration in pigs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from 
Wyns, H., Meyer, E., Plessers, E., Watteyn, A., De Baere, S., De Backer, P., Croubels, 
S. (2014) Pharmacokinetics of gamithromycin after intravenous and subcutaneous 
administration in pigs. Research in Veterinary Science 96, 160-163. 
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Abstract 
 
Gamithromycin (GAM) is a 15-membered semi-synthetic macrolide antibiotic of the 
azalide subclass which has been recently developed for the treatment and prevention of 
bovine respiratory disease (BRD). In this study, the pharmacokinetic properties and 
absolute bioavailability of GAM were investigated after an intravenous (IV) or 
subcutaneous (SC) bolus injection of 6 mg/kg body weight in six male pigs according to a 
single dose parallel design. The plasma concentrations of gamithromycin were determined 
using a validated high-performance liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method, and the pharmacokinetics were analysed by noncompartmental analysis. 
Following IV administration, the mean area under the plasma concentration-time 
curve extrapolated to infinity (AUCinf) was 3.67 ± 0.75 µg.h/mL. The mean elimination half-
life (t1/2λz) and plasma clearance (Cl) were 16.03 h and 1.69 ± 0.33 L/h.kg, respectively. The 
volume of distribution at steady state (Vss) was 31.03 L/kg. 
Following SC administration, the mean AUCinf was 4.31 ± 1.14 µg.h/mL. A mean 
maximal plasma concentration (Cmax) of 0.41 ± 0.090 µg/mL was reached at 0.63 ± 0.21 h. 
The mean t1/2λz and Cl were 18.76 h and 1.47 ± 0.40 L/h.kg, respectively.  
In conclusion, GAM administered subcutaneously to pigs demonstrated a rapid and 
complete absorption, with a high absolute bioavailability of 117.6 ± 39.4 %. None of the 
pharmacokinetic properties significantly differed between both administration routes. 
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1. Introduction 
 
Macrolide antibiotics are a group of antimicrobials characterized by a similar 
chemical structure and mechanism of action, but a different spectrum of activity (Jain & 
Danziger, 2004). The drugs are classified as macrocyclic lactone rings containing 12 to 20 
carbon atoms with diverse combinations of deoxy sugars attached to this ring by glycosidic 
linkages. Erythromycin was the first macrolide isolated from Streptomyces erythreus. 
Numerous other macrolides have been isolated or synthesized from this parent molecule. 
The antibacterial action comprises the inhibition of protein synthesis by binding to the 50S 
ribosomal subunit of prokaryotic organisms and consequently inhibiting the translocation. 
Macrolides in general do not bind to mammalian ribosomes, which makes them a relatively 
safe group of drugs for veterinary use. Furthermore, erythromycin has been confirmed to 
stimulate gastrointestinal motility (Papich & Riviere, 2009).  
Macrolide antibiotics are mainly active against Gram-positive bacteria. In addition 
to the anti-infectious properties, these drugs have been reported to influence a variety of 
inflammatory processes, including the release of cytokines and mediators, the migration of 
neutrophils and the oxidative burst in phagocytes. A significant decrease of the production 
of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 was reported after in vitro 
lipopolysaccharide (LPS) stimulation and treatment with tilmicosin and tylosin. Moreover, 
macrolides are also characterised by an extensive accumulation into leukocytes and lung 
tissues, achieving much higher tissue concentrations compared to those observed in 
plasma (Nightingale, 1997; Ianaro et al., 2000; Cao et al., 2006; Tauber and Nau, 2008; 
Buret, 2010).  
Via introduction of a nitrogen atom into the macrolactone ring, a novel class of 
macrolide antibiotics, the so-called azalides, was generated. Azythromycin was the first 
azalide which has been associated with remarkable pharmacokinetics, such as a high tissue 
distribution, metabolic stability and a high tolerability compared to other macrolide 
antibiotics (Mutak, 2007). 
 
Gamithromycin (GAM; Figure 1) is a 15-membered semi-synthetic macrolide 
antibiotic of the azalide subclass with a uniquely positioned alkylated nitrogen at the 7a-
position of the lactone ring. GAM has been recently developed for the treatment and 
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prevention of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, 
Pasteurella (P.)  multocida and Histophilus somni (Huang et al., 2010). Bacteria, including 
Actinobacillus (A.) pleuropneumoniae, P. multocida, Haemophilus (H.) parasuis and 
Mycoplasma (M.) hyopneumoniae are major pathogens involved in swine respiratory 
disease (SRD). In growing pigs, respiratory infections are responsible for severe economic 
losses and reduced animal welfare. Other second generation macrolide antibiotics, such as 
tulathromycin (Draxxin®) and tildipirosin (Zuprevo®) have been approved for treatment of 
SRD in pigs (EMA, 2008a, 2011; Rose et al., 2013). 
 
 
Figure 1. Chemical structure of gamithromycin (GAM) 
 
The pharmacokinetic (PK) properties of GAM have been determined in cattle, foals 
and broiler chickens (Huang et al., 2010; Berghaus et al., 2011; Watteyn et al., 2013). The 
aim of this study was to determine the PK properties of GAM in pigs, whereafter the 
characteristics of the antibiotic can be used in future research to investigate its 
immunomodulatory properties in a porcine lipopolysaccharide (LPS) inflammation model 
(Wyns et al., 2013). 
 
 
 
 
 
48 
2. Materials and methods 
 
2.1. Experimental design 
 
Twelve clinically healthy male pigs with a mean body weight (BW) of 24.81 ± 1.65 kg 
were randomly divided in two groups. The animals had free access to feed and drinking 
water. The study was conducted according to a single dose parallel design. The pigs 
received a bolus injection of 6 mg/kg BW GAM (Zactran®, Merial), either intravenously (IV) 
in the ear vein (n = 6) or subcutaneously (SC) in the flank region (n = 6). Blood was collected 
from the jugular vein into ethylenediaminetetraacetic acid (EDTA)-coated tubes (Vacutest 
Kima) before administration (time 0 h); at 0.25, 0.50, 0.75, 1, 2, 4, 6, 8, 10, 12 h post 
administration (p.a.) and once daily from day 2 to day 14 p.a. (24 h intervals). Blood 
samples were centrifuged at 2800 x g for 10 min at 4 °C and plasma was stored at ≤ -15 °C 
until analysis. 
The animal experiment was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine of Ghent University (EC2011/159).  
 
2.2. Veterinary drug, chemicals and solutions 
 
Prior to the administration, the veterinary drug formulation Zactran® of 150 mg/mL 
(15.0 % w/v) was diluted with aqua ad injectabilia (Kela Pharma) to a concentration of 50 
mg/mL (5.0 % w/v) in order to avoid possible adverse effects caused by parenteral 
administration. 
High-performance liquid chromatography (HPLC) grade water, methanol (MeOH), 
acetonitrile (ACN) and analytical grade formic acid were purchased from VWR. Ultra-
performance liquid chromatography (UPLC) grade water was purchased from Biosolve. 
HybridSPE®-Phospholipid cartridges (30 mg/mL) were obtained from Sigma-Aldrich.  
Analytical standards of GAM and deuterated GAM (d5-GAM) were kindly donated by 
Merial Ltd and stored at 2 – 8 °C. Stock solutions of GAM and d5-GAM (1 mg/mL) were 
prepared in HPLC MeOH and stored at ≤ -15 °C for at least one month. Working solutions of 
0.010, 0.025, 0.050, 0.10, 0.25, 0.50, 1.0, 2.5, 5.0, 10.0, 25.0, 50.0 and 100 µg/mL of GAM 
were prepared in HPLC water. For the internal standard (IS, d5-GAM), a working solution of 
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1.0 µg/mL was prepared in HPLC water. The working solutions were stored at 2 – 8 °C for at 
least one month.  
 
2.3. Analysis of gamithromycin 
 
Quantification of GAM in porcine plasma was performed using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method. Prior to LC-MS/MS 
analysis plasma samples were subjected to a sample preparation by protein precipitation 
and subsequent phospholipid removal. More specifically, 25 µL of the IS working solution 
was added to 250 µL of porcine plasma. After a vortex mixing (15 s), 750 µL of 1 % formic 
acid in ACN was added, followed by a vortex mixing (15 s) and centrifugation step (10 min, 
7800 x g). The supernatant was transferred to a HybridSPE®-Phospholipid cartridge. The 
sample was collected into a glass tube and vacuum was applied to remove the remaining 
liquid drops from the column. Next, 50 µL of the filtrate was transferred to an autosampler 
vial and 1/2 (v/v) diluted with UPLC water. After vortex mixing, a 2.5 µL aliquot was 
injected onto the LC-MS/MS instrument.  
The LC system consisted of a quaternary, low-pressure mixing pump with vacuum 
degassing, type Surveyor MSpump Plus and an autosampler with temperature-controlled 
tray and column oven, type Autosampler Plus, from ThermoFisher Scientific. The 
temperatures of the column oven and autosampler tray were set at 50 °C and 5 °C, 
respectively. Chromatographic separation was achieved on a Hypersil Gold (50 mm x 2.1 
mm internal diameter (i.d.), particle size (dp): 1.9 µm) column in combination with a pre-
column of the same type (10 mm x 2.1 mm i.d., dp: 3 µm), both from ThermoFisher 
Scientific. 
The LC column effluent was interfaced to a TSQ Quantum Ultra triple quadrupole 
mass spectrometer, equipped with a heated electrospray ionisation probe operating in the 
positive ionisation mode (all from ThermoFisher Scientific). 
MS Acquisition was performed in the selected reaction monitoring (SRM) mode. For 
GAM, the two most intense product ions were monitored (i.e. m/z 777.45 > 619.35 for 
quantification and m/z 777.45 > 157.80 for identification, respectively). For the IS, only one 
SRM transition was monitored (m/z 782.45 > 624.35).  
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The method was validated and the following parameters were successfully 
evaluated: linearity 2.5 - 10.000 ng/mL, within- and between-run accuracy and precision 
(concentration level 25, 250 and 2500 ng/mL), limit of quantification (LOQ, 5 ng/mL, n = 6) 
and limit of detection (LOD, 0.01 ng/mL, n = 6), specificity and carry-over.  
 
2.4. Pharmacokinetic and statistical analysis 
 
The PK properties were determined by means of WinNonlin®, version 6.2.0 
software program (Pharsight Corporation) using a noncompartmental model. Values below 
the LOQ of 5 ng/mL were not included in the analysis. The mean area under the plasma 
concentration-time curve was calculated using the linear trapezoidal method from time 0 
to the last time point with a quantifiable concentration (AUClast). The AUC extrapolated to 
infinity (AUCinf), the elimination rate constant (λz), volume of distribution (Vz), volume of 
distribution at steady state (Vss), plasma clearance (Cl), maximum plasma concentration 
(Cmax), and time to maximum plasma concentration (tmax) were also determined. The 
terminal plasma half-life (t1/2λz) was expressed using harmonic mean values. The absolute 
bioavailability (F) was calculated from the following equation:  
 
F(%) =  
AUC0→∞SC
AUC0→∞IV
 x 100 
 
The data are presented as mean ± standard deviation (SD) and were statistically analysed 
by means of single-factor analysis of variance (ANOVA), using SPSS Version 20.0 software 
for Windows. The level of significance was α = 0.05. 
 
3. Results 
 
No adverse effects following IV or SC administration were observed during the 
course of the study. The PK properties of GAM (mean ± SD) based on noncompartmental 
analysis are summarized in Table 1. The mean plasma concentration-time curves following 
IV and SC administration are plotted on semi-logaritmic graphs in Figure 2.  
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Figure 2. Mean (± SD) plasma concentration-time profiles of gamithromycin (GAM) after IV 
(n = 6) and SC (n = 6) bolus administration of 6 mg/kg BW in pigs. 
 
 
Quantifiable concentrations of GAM in plasma were present for 48 h and 72 h after 
IV and SC administration, respectively. 
Following an IV bolus injection of 6 mg/kg BW GAM, the AUCinf was 3.67 ± 0.75 
µg.h/mL. The t1/2λz was 16.03 h. The Vz and Cl were 40.47 ± 8.73 L/kg and 1.69 ± 0.33 
L/h.kg, respectively. The Vss was 31.03 ± 6.68 L/kg.  
Following a SC bolus injection of 6 mg/kg BW gamithromycin, the AUCinf was 4.31 ± 
1.14 µg.h/mL. A Cmax of 0.41 ± 0.090 µg/mL was reached at 0.63 ± 0.21 h (tmax). The t1/2λz 
was 18.76 h. The Vz and Cl were 42.70 ± 16.16 L/kg and 1.47 ± 0.40 L/h.kg, respectively. The 
absolute bioavailability of GAM was 117.6 ± 39.4 %. 
None of the PK properties significantly differed between both administration 
routes. 
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Table 1. Pharmacokinetic properties of GAM in pigs after IV (n = 6) and SC (n = 6) bolus 
administration of 6 mg/kg BW (mean ± SD) 
Parameter Unit IV SC 
AUClast µg.h/mL 3.24 ± 0.56 3.48 ±1.90 
AUCinf µg.h/mL 3.67 ± 0.75 4.31 ± 1.14 
λz /h 0.043 ± 0.011 0.037 ± 0.009 
t1/2λz h 16.03
A  18.76A 
MRTinf h 18.84 ± 4.94 24.41 ± 9.17 
Vss L/kg 31.03 ± 6.68 - 
Cl L/h.kg 1.69 ± 0.33 1.47 ± 0.40 
tmax h - 0.63 ± 0.21 
Cmax µg/mL - 0.41 ± 0.090 
F % - 117.6 ± 39.4 
AUClast, area under the plasma concentration-time curve from time 0 to the last time point with a 
quantifiable concentration; AUCinf, AUC extrapolated to infinity; λz, elimination rate constant; t1/2λz, 
half-life of elimination; Vz, volume of distribution; Vss, volume of distribution at steady state; Cl, 
clearance; tmax, time to maximum plasma concentration; Cmax, maximum plasma concentration; F, 
absolute bioavailability 
A: harmonic mean  
 
4. Discussion 
 
GAM is a novel semi-synthetic azalide which has been approved for the treatment 
of BRD caused by M. haemolytica, P. multocida and H. somni in cattle. Following a SC bolus 
injection of 6 mg/kg BW to cattle, GAM was well absorbed, reaching a mean Cmax at 1 h p.a. 
A corresponding absolute bioavailability of 110 % was assessed. Furthermore, the antibiotic 
was extensively and rapidly distributed to lung tissue which was demonstrated by the high 
Vss of 24.9 L/kg (Huang et al., 2010). Similarly, in foals, a tmax of 1 h was observed after an 
intramuscular (IM) injection of 6 mg/kg BW GAM, after which the drug largely distributed 
to pulmonary epithelial lining fluid, brochoalveolar lavage cells and neutrophils (Berghaus 
et al., 2011). 
In the current study in pigs, a SC bolus injection of 6 mg/kg BW GAM resulted in a 
relatively fast absorption reaching a Cmax at 0.63 h. The absolute bioavailability was 118 %. 
Compared to cattle, a higher clearance of GAM was observed in pigs (1.69 and 0.71 L/h.kg 
in pigs and cattle, respectively), resulting in a shorter t1/2λz after IV as well as SC 
administration (16.03 and 18.76 h, respectively in pigs and 44.9 and 50.8 h, respectively in 
cattle). Notwithstanding a generally more pronounced metabolic rate in birds, similar 
values for clearance and t1/2λz (1.61 L/h.kg and 14.12 h, respectively) were recently 
observed in broiler chickens. In addition, the Vss was high in both animal species (31.03 L/kg 
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in pigs and 29.16 L/kg in broiler chickens, respectively), indicating a distinct tissue 
penetration and corresponding intracellular levels (Watteyn et al., 2013).  
Macrolide antibiotics are lipophilic molecules which are well absorbed and 
extensively distributed in body fluids and tissues (Zuckerman et al., 2011). Conversely, 
binding to plasma proteins can considerably restrict this extravascular distribution (Huang 
et al., 2010). In pigs, the mean plasma protein binding of GAM was only 23 % (EMA, 
2008b), which contributed to the large Vss of 31.03 L/kg.  
In comparison with other macrolide antibiotics, GAM showed a relatively short t1/2λz 
after IV and SC injection in pigs. The clearance of GAM was considerably higher than that of 
tulathromycin (0.58 L/h.kg, Benchaoui et al., 2004 and 0.18 L/h.kg, Wang et al., 2012). In 
this respect, tulathromycin, approved for treatment of bacterial porcine as well as bovine 
respiratory disease, showed a t1/2λz of 67.5-76.5, 75.6 and 78.7 h after an IV, IM and oral 
bolus of 2.5 mg/kg BW, respectively (Benchaoui et al., 2004; Wang et al., 2012). Likewise, 
tildipirosin, a semi-synthetic tylosin analogue also approved for swine respiratory disease, 
revealed a very slow elimination with a t1/2λz of 97 h following a single IM injection of 6 
mg/kg BW (Rose et al., 2013). On the other hand, tylosin, a first generation macrolide 
antibiotic mainly used to treat pneumonia and dysentery in pigs, has a t1/2λz of 4.52 and 
24.5 h after IV and IM administration of 10 mg/kg BW, respectively. GAM has a comparable 
total body clearance as tylosin (1.88 L/h.kg, Prats et al., 2002). While the short t1/2λz after IV 
administration can be attributed to the smaller Vss (9.7 L/kg), the extended t1/2λz after IM 
administration is a reflection of a continuous, but slow release from the injection site (Prats 
et al., 2002). Tilmicosin is a macrolide antibiotic synthesized from tylosin which has been 
recommended for the treatment and prevention of bacterial pneumonia in pigs as a feed 
formulation. It has a t1/2λz of 25.3 and 20.7 h after oral bolus administration of 20 mg/kg 
and 40 mg/kg, respectively (Shen et al., 2005). 
GAM shows a very high absolute bioavailability of 118 % after SC administration in 
pigs. Similarly, tylosin has a bioavailability of around 95 % after an IM injection (Prats et al., 
2002). The bioavailability of tulathromycin after IM administration was > 87 %, whereas the 
oral bioavailability was only 51 % (Benchaoui et al., 2004; Wang et al., 2012). Since 
parenteral administration of tilmicosin in pigs is associated with considerable adverse 
cardiovascular effects, the bioavailability has not yet been determined (Shen et al., 2005).  
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For GAM, minimum inhibitory concentration (MIC) values of 0.25 and 2 µg/mL were 
established in pigs for M. hyopneumoniae (J-strain) and A. pleuropneumoniae (ATCC 27090 
reference strain), respectively (unpublished data). Of each pathogen, only one isolate was 
included. Therefore, these values can only be regarded as a first indication of the 
susceptibility. For tulathromycin, a MIC90 of 0.06 and 16 µg/mL was described for M. 
hyopneumoniae and A. pleuropneumoniae, respectively, in pigs (Benchaoui et al., 2004; 
Godinho, 2008). For tildipirosin, on the other hand, a MIC90 value of 8 µg/mL was reported 
for A. pleuropneumoniae (EMA, 2011), yet recent research of Rose et al. (2013) indicated 
that a MIC90 value of 2 µg/mL would be more plausible. 
In general, time above the MIC (t > MIC) is the PK/PD index considered to be best 
correlated with clinical efficacy of conventional macrolides. However, for newer advanced 
generation macrolide antibiotics such as azithromycin, the plasma AUC/MIC ratio would 
also be an appropriate index (Nightingale, 1997; Van Bambeke and Tulkens, 2001). Taking 
the MIC of 0.25 µg/mL for M. hyopneumoniae into account, it can be suggested that 
plasma levels are indeed higher for a certain period of time. In contrast, but in accordance 
with other macrolide antibiotics, plasma concentrations of GAM never exceed the MIC 
value of 2 µg/mL of A. pleuropneumoniae in this study. 
Nevertheless, it is generally accepted that plasma PK and plasma concentrations of 
macrolides are poor predictors of the antimicrobial activity and clinical efficacy of these 
drugs. Tissue concentrations at the site of infection would rather be more significant to 
comprehend the PD properties for this class of antibiotics (Nightingale, 1997). In this 
respect, it can be stated that for tulathromycin, concentrations were 24.9 – 181 times 
higher in the lung than those measured in plasma of pigs (Benchaoui et al., 2004). In 
addition, it was observed that bovine lung concentrations of GAM were 247 – 410 times 
higher than in plasma over the time course from 1 to 15 days after treatment (Huang et al., 
2010). 
In accordance with other macrolide antibiotics, the Vss of GAM is also very high and 
consequently much higher concentrations can be expected in the pig’s lung compared to 
those in plasma. 
In conclusion, GAM administered subcutaneously to pigs demonstrated a fast and 
complete absorption. However, plasma pharmacokinetics of macrolides are poor 
predictors of antimicrobial activity and clinical efficacy of these drugs. Therefore, tissue 
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concentrations at the site of infection would be more significant to comprehend the 
pharmacodynamic properties (Nightingale, 1997). The high Vss indicates a distinct tissue 
penetration. Although no lung concentrations are available, we still would like to suggest 
that, in analogy to other second generation macrolides, GAM might be advantageous for 
the treatment of bacterial respiratory diseases in pigs. 
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1.2. Pharmacokinetics of dexamethasone after intravenous and intramuscular 
administration in pigs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from 
Wyns, H., Meyer, E., Watteyn, A., Plessers, E., De Baere, S., De Backer, P., Croubels, 
S. (2013) Pharmacokinetics of dexamethasone after intravenous and intramuscular 
administration in pigs. The Veterinary Journal 198, 286-288. 
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Abstract 
 
The pharmacokinetics of dexamethasone (DEX) were investigated after an 
intravenous (IV) or intramuscular (IM) bolus injection of 0.3 mg/kg body weight DEX 
sodium phosphate in pigs. The plasma concentrations of DEX were determined using a 
validated high-performance liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method, and the pharmacokinetics were determined by one-compartmental 
analysis. 
The mean area under the plasma concentration-time curve and the mean 
elimination half-life were 133.07 ± 39.59 ng.h/mL and 0.77 h, and 173.24 ± 53.59  ng.h/mL 
and 1.06 h following IV and IM administration, respectively. The volume of distribution and 
clearance recorded after IV administration were 2.78 ± 0.88 L/kg and 2.39 ± 0.57 L/h.kg, 
respectively. 
An IM bolus injection of DEX sodium phosphate in pigs resulted in a fast and 
complete absorption, with a mean maximal plasma concentration of 80.94 ± 21.29 ng/mL 
at 0.35 ± 0.21 h and a high absolute bioavailability of 131.06 ± 26.05 %.  
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1. Introduction 
 
Dexamethasone (DEX; Figure 1A) is a long-acting synthetic hydrocortisone analogue 
and is one of the most potent glucocorticoid drugs. It is extensively used in veterinary 
medicine to treat inflammatory, immunological and allergic disorders (Toutain et al., 1982; 
EMA, 2004; Ferguson et al., 2009). In livestock, the use of DEX is indicated in inflammation 
processes such as mastitis, aseptic laminitis, arthritis and primary ketosis. In contrast, DEX 
is also reported to be used as an illegal growth promoter (Courtheyn et al., 2002; Ferguson 
et al., 2009; Vincenti et al., 2009).  
In order to improve water solubility, glucocorticoids are often formulated as a 
phosphate ester prodrug (Figure 1B), which rapidly hydrolyses and releases free and active 
alcohols (Rohdewald et al., 1987; EMA, 2004). The pharmacokinetic (PK) properties of DEX 
have been previously described in humans and diverse animal species, but not in pigs. 
Nonetheless, DEX has been approved for treatment of inflammatory and allergic disorders 
in this species (EMA, 2004). 
 
 
Figure 1. Chemical structures of dexamethasone (DEX; A) and its ester, DEX-sodium 
phosphate (B) 
 
Therefore, the aim of this study was to determine the PK properties of DEX in pigs. 
These characteristics will be applied in ongoing research to study the immunomodulatory 
properties of DEX, either alone or in combination with several antibiotics in a porcine 
lipopolysaccharide (LPS) inflammation model (Wyns et al., 2013).  
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2. Materials and methods 
 
2.1. Experimental design 
 
Six clinically healthy male pigs (Landrace) with a mean body weight (BW) of 28.3 ± 
3.01 kg were randomly divided in two groups. The animals had free access to feed and 
drinking water.  
The experiment was performed as a two-way cross-over design with a wash-out 
period of 5 days. A bolus of 0.3 mg/kg BW DEX sodium phosphate (DEXA 0.2%®, Kela 
Laboratoria) was injected intravenously (IV) in the ear vein or intramuscularly (IM) in the 
gluteus muscle via a sterile winged infusion needle (25G; Micro-floTM, Novolab). Blood was 
collected by venipuncture of the jugular vein into EDTA-coated tubes (Vacutest Kima) 
before administration (time 0 h) and at 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12 and 24 h 
post-administration (p.a.). Blood samples were centrifuged at 2800 x g for 10 min at 4 °C 
and plasma was stored at ≤ -15 °C until analysis within 2 months. 
The animal experiment was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine of Ghent University (EC 2011/156).  
 
2.2. Chemicals and solutions 
 
High-performance liquid chromatography (HPLC) grade water, HPLC methanol 
(MEOH) and pro-analysis grade glacial acetic acid and diethylether were purchased from 
VWR. Trichloroacetic (TCA) was obtained from Sigma-Aldrich. A 20 % solution of TCA was 
prepared in HPLC water. Ultra-performance liquid chromatography (UPLC) grade water and 
acetonitrile (ACN) were obtained from Biosolve. 
The analytical standards of DEX and desoximetasone (internal standard, IS) were 
obtained from Sigma-Aldrich. Stock solutions of 1 mg/mL of DEX and IS were prepared in 
HPLC methanol and stored at 2 – 8 °C. These stock solutions were found to be stable for at 
least three months. Working solutions of 100 and 1 µg/mL (DEX) and 10 µg/mL (IS) were 
obtained by diluting the stock solutions with HPLC water and were stored at 2 – 8 °C for at 
least one month. 
 
 
60 
2.3. Analysis of dexamethasone 
 
Quantification of DEX in porcine plasma was performed using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method.  
Prior to LC-MS/MS analysis, the plasma sample was subjected to protein 
precipitation. More specifically, sample preparation was performed by adding 25 µL of the 
IS working solution to 250 µL of porcine plasma. After a vortex mixing (15 s), 25 µL of a 
20 % TCA solution were added, followed by a vortex mixing (15 s) and a centrifugation step 
(10 min, 7800 x g). The supernatant was transferred to a screw-capped extraction tube (15 
mL, polyethylene, SPL Life Science, Novolab) and 3 mL diethylether were added. A liquid–
liquid extraction was performed by gentle rolling (20 min). After centrifugation (10 min, 
1500 x g), the upper ether layer was transferred into a new tube and evaporated to 
dryness using a nitrogen stream (35 °C). The residue was re-dissolved into 200 µL of UPLC 
water by vortex mixing (15 s) and transferred to an autosampler vial. A 10 µL aliquot was 
injected onto the LC-MS/MS system.  
The LC system consisted of a quaternary, low-pressure mixing pump with vacuum 
degassing, type Surveyor MSpump Plus and an autosampler with temperature controlled 
tray and column oven, type Autosampler Plus, from Thermo Scientific. Chromatographic 
separation was achieved on a Hypersil Gold (internal diameter, 50 x 2.1 mm; particle size, 
dp, 1.9 µm) column in combination with a Hypersil Gold Drop-in guard cartridge (internal 
diameter, 10 x 2.1 mm), both from Thermo Scientific. Two mobile phases were used, the 
mobile phase A consisted of 0.01 % acetic acid in UPLC grade water, while mobile phase B 
was UPLC ACN. A gradient elution was performed (0-1 min: 60 % A, 1-2 min: linear gradient 
to 30 % A, 2-3 min: 30 % A, 3-3.2 min: linear gradient to 60 % A, 3.2-6 min: 60 % A) at a 
flow-rate of 300 µL/min. The temperatures of the column oven and autosampler tray were 
set at 45 °C and 5 °C, respectively. 
The LC column effluent was interfaced to a TSQ Quantum Ultra triple quadrupole 
mass spectrometer, equipped with a heated electrospray ionisation (h-ESI) probe operating 
in the positive ionisation mode (all from Thermo Scientific). Instrument parameters were 
optimised for both analytes (DEX and IS). For each compound, the two most intense 
product ions were selected and monitored in the selected reaction monitoring (SRM) 
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mode. For quantification, the most intense product ion was used (i.e. DEX: m/z 393.0 > 
355.3; IS: m/z 377.1 > 339.3). 
The method was validated by a set of parameters that were in compliance with the 
recommendations defined by EU standards (Commission Decision 2002/657/EC; Heitzman, 
1994; VICH GL 49) and by Knecht and Stork (1974). The following parameters were 
evaluated: linearity, within-run and between-run accuracy and precision, limit of 
quantification (LOQ), limit of detection (LOD), extraction recovery, matrix effect and 
specificity. Linear calibration curves were constructed using matrix-matched calibrator 
samples (concentration range: 2–10000 ng/mL) and the correlation coefficients (r = 0.9967 
± 0.001, n = 3) and goodness-of-fit coefficients (g = 7.57 ± 0.001 %, n = 3) fell within the 
accepted ranges, i.e. r ≥ 0.99 and g ≤ 20 %, respectively.  
Within-run and between-run precision and accuracy were evaluated by analysing six 
independently spiked blank plasma samples at three concentration levels, i.e. 10, 100 and 
1000 ng/mL, respectively. The following mean results were obtained: within-run accuracy 
and precision (n = 6) 11.0 ± 2.1 ng/mL, 108.0 ± 14.59 ng/mL and 1072.2 ± 20.524 ng/mL; 
between-run accuracy and precision (n = 6) 10.2 ± 0.78 ng/mL, 96.5 ± 10.9 ng/mL and 965.5 
± 139.7 ng/mL. The results fell within the accepted ranges for accuracy (−20 % to +10 % of 
the theoretical concentration) and precision (within-run precision: relative standard 
deviation (RSD) ≤ RSDmax with RSDmax = 2
(1–0.5log Conc) x 2/3, i.e. 21.3 %, 15.1 % and 10.7 % at 
10 ng/mL, 100 ng/mL and 1000 ng/mL, respectively; between-run precision: RSD ≤ RSDmax 
with RSDmax = 2
(1–0.5log Conc), i.e. 32.0 %, 22.6 % and 16.0 % at 10 ng/mL, 100 ng/mL and 1000 
ng/mL, respectively). 
The LOQ was defined as the lowest concentration for which the method was 
validated with a within-run accuracy and precision that fell within the specified ranges. The 
LOQ was also the lowest point of the calibration curve and was set at 2 ng/mL (n = 6, mean 
result: 2.0 ± 0.24 ng/mL). The LOD was defined as the concentration corresponding with a 
signal-to-noise ratio of 3 and was found to be 1.17 ng/mL. The specificity of the method 
was shown, since no peaks of endogenous interferences could be determined in blank 
plasma samples. Correction for extraction recovery was not necessary since the method of 
internal standardisation was applied for quantification.  
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2.4. Pharmacokinetic and statistical analysis 
 
The PK properties were determined by means of WinNonlin®, version 6.2.0 
software program (Pharsight Corporation) using a one-compartmental model. Values 
below the LOQ of 2 ng/mL were not included in the analysis.  
The mean area under the plasma concentration-time curve (AUC0→∞) was 
calculated using the linear trapezoidal method with extrapolation to infinity. The 
absorption and elimination rate constant (kabs and kel, respectively), half-life of absorption 
and elimination (t1/2abs and t1/2el, respectively) expressed as the harmonic mean, volume of 
distribution (Vd), clearance (Cl), maximum plasma concentration (Cmax), and time to 
maximum plasma concentration (tmax) were also determined. The absolute bioavailability 
(F) was calculated from the following equation:  
 
F(%) =  
AUC0→∞IM
AUC0→∞IV
 x 100 
 
Data are presented as mean ± standard deviation (SD) and were statistically 
analysed by single-factor analysis of variance (ANOVA), using SPSS Version 20.0 software 
for Windows. The level of significance was α = 0.05. 
 
3. Results 
 
No adverse effects following IV or IM administration were observed during the 
course of the study. Quantifiable concentrations of DEX were measured in plasma until 4 h 
after both IV and IM administration. The PK properties of DEX (mean ± SD) are summarised 
in Table 1. Semi-logarithmic plots of the mean plasma concentration-time curves following 
IV and IM administration are presented in Figure 2. 
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Figure 2. Mean (± SD) plasma concentration-time profiles of dexamethasone (DEX) after IV 
and IM bolus injection of 0.3 mg/kg BW DEX sodium phosphate in pigs (n = 6). Quantifiable 
concentrations of DEX were measured in plasma for 4 h after IV and IM administration 
(LOQ = 2 ng/mL). 
 
 
Following an IV bolus injection of 0.3 mg/kg BW DEX sodium phosphate, the 
AUC0→∞ was 133.07 ± 39.59 ng.h/mL. The t1/2el was 0.77 h and the Vd and Cl were 2.78 ± 
0.88 L/kg and 2.39 ± 0.57 L/h.kg, respectively. 
Following an IM bolus injection of 0.3 mg/kg BW DEX sodium phosphate, the 
AUC0→∞ was 173.24 ± 53.59 ng.h/mL. A Cmax of 80.94 ± 21.29 ng/mL was reached at 0.35 ± 
0.21 h (tmax). The t1/2el was 1.06 h and the absolute bioavailability of DEX after IM injection 
was 131.06 ± 26.05%.  
None of the PK properties significantly differed between both administration 
routes. 
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Table 1. Pharmacokinetic parameters (mean ± SD) of dexamethasone in pigs after IV and 
IM bolus administration of 0.3 mg/kg BW DEX-sodium phosphate (n = 6) 
Parameter  Units  IV  IM  
AUC0∞  h.ng/mL  133.07 ± 39.59  173.24 ± 53.59  
kabs  /h  -  12.90 ± 10.57  
kel  /h  0.90 ± 0.28  0.65 ± 0.30  
t1/2abs  h  -  0.05
A  
t1/2el  h  0.77
A  1.06A  
Vd  L/kg  2.78 ± 0.88  - 
Cl  L/h.kg  2.39 ± 0.57  - 
tmax  h  -  0.35 ± 0.21  
C0  ng/mL  114.89 ± 26.56  -  
Cmax  ng/mL  -  80.94 ± 21.29  
F  %  -  131.06 ± 26.05  
AUC, area under the curve; kabs, absorption rate constant; kel, elimination rate constant; t1/2abs, half-
life of absorption; t1/2el, half-life of elimination; Vd, volume of distribution; Cl, clearance; tmax, time to 
maximum plasma concentration; C0, maximum plasma concentration at 0 h; Cmax, maximum plasma 
concentration; F, absolute bioavailability. 
A: harmonic mean 
 
4. Discussion 
 
The present study is the first to describe the pharmacokinetics and bioavailability of 
DEX after IV and IM administration in pigs.  
Sibila et al. (2008) demonstrated that the concomitant administration of a 
glucocorticoid with an antibiotic possesses beneficial effects in an experimental model of 
severe pneumonia in pigs. Particularly, in bronchial tissue a reduced local inflammatory 
response, and in the bronchoalveolar lavage and lung a reduced bacterial load could be 
observed.  
In this study, DEX was supplied as a water-soluble and stable sodium phosphate 
ester to pigs. As previously established by Rohdewald et al. (1987), DEX sodium phosphate 
is rapidly converted to the free and active alcohol form of DEX. Therefore, DEX alcohol, and 
not the esterified prodrug, was currently measured in plasma using the validated LC-
MS/MS method. 
An IM bolus injection of 0.3 mg/kg BW DEX sodium phosphate in pigs resulted in a 
relatively fast absorption and a Cmax of DEX at 0.35 h (tmax). However, in horses a faster tmax 
of 0.16 h was recently observed (Soma et al., 2013). After an IM injection, DEX sodium 
phosphate is fully bioavailable in pigs (F = 131 %), horses (F = 100 %; Soma et al., 2013) and 
broiler chickens (F = 123%; Watteyn et al., 2013).  
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In dogs, an IM administration of DEX alcohol resulted in a relatively early Cmax at 
0.63 h and a complete absorption, while in cattle a delayed Cmax at 4.27 h and an absolute 
bioavailability of only 67 % was observed. Likewise, after an IM bolus injection of DEX 21-
isonicotinate, an early Cmax at 0.50 h and a delayed Cmax at 3.57 h was observed in dogs and 
cattle, respectively. However, the absolute bioavailability was barely 40 % in dogs 
compared to 72 % in cattle (Toutain et al. 1982; 1983). 
In comparison with other mammalian species, a remarkably high clearance of DEX 
was observed in pigs (2.39 L/h.kg). Conversely, in dogs, cattle, horses and humans, a 
clearance of < 0.6 L/h.kg was reported (Toutain et al., 1982, 1983; Rohdewald et al., 1987; 
Greco et al., 1993; Hochhaus et al., 2001; Soma et al., 2013). In most species, the Vd of DEX 
is less than 2 L/kg (Toutain et al., 1982, 1983; Hochhaus et al., 2001; Soma et al., 2013). 
Interestingly, the Vd of DEX in pigs was 2.78 L/kg which suggests a good tissue penetration 
of this glucocorticoïd drug. However, a relatively short t1/2el (0.77 h) was observed in pigs. 
In other species, DEX is considered to be a long-acting (> 48 h) glucocorticoid in comparison 
to hydrocortisone and prednisolone. Notwithstanding the PK results observed in this study, 
DEX could have a longer action in pigs from a pharmacodynamical point of view. 
In conclusion, an IM bolus injection of DEX sodium phosphate in pigs resulted in a 
fast and complete absorption, followed by a fast elimination of the active DEX alcohol. The 
Vd and particularly the clearance of DEX are much higher in pigs in comparison with other 
mammalian species. 
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CHAPTER 2.  
Immunomodulatory properties of veterinary drugs 
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2.1. In vitro effect of gamithromycin, ketoprofen and dexamethasone on pro-
inflammatory cytokine and prostaglandin E2 production in LPS-stimulated porcine 
peripheral blood mononuclear cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from 
Wyns, H., Meyer, E., Plessers, E., Watteyn, A., van Bergen, T., Schauvliege, S., De 
Baere, S., Devreese, M., De Backer, P., Croubels, S. (2014) Modulation of gamithromycin 
and ketoprofen on in vitro and in vivo porcine lipopolysaccharide-induced inflammation 
(Submitted to PLoS ONE). 
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Abstract 
 
Immunomodulation is predominantly studied at the level of cytokine production, 
inflammatory mediators and cell functions. In this respect, isolated peripheral blood 
mononuclear cells (PBMCs) have been frequently used as an in vitro model to study the 
lipopolysaccharide (LPS)-induced immune response in different animal species. The aim of 
the present study was to investigate the effects of gamithromycin (GAM), ketoprofen 
(KETO), dexamethasone (DEX) and their combinations on the production of prostaglandin 
(PG) E2, tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in LPS-stimulated porcine 
PBMCs.  
Following an 18 h-incubation period with 1.25 µg/mL LPS, significantly increased 
levels of TNF-α, IL-1β and IL-6 (p < 0.05) were measured in the PBMC cell supernatants. 
Whereas DEX was successfully included as a positive control for cytokine inhibition (p < 
0.05), KETO had no inhibiting effect on cytokine production. Remarkably, KETO showed a 
trend to enhance TNF-α levels. Combinations of GAM and KETO, on the other hand, 
significantly reduced levels of LPS-induced IL-1β (p < 0.05) and IL-6 (p < 0.01). KETO, DEX 
and their respective combinations with GAM, significantly reduced PGE2 production (p < 
0.001). 
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1. Introduction 
 
Modulation of the immune response by drugs is of major interest. Research on this 
subject is predominantly performed at the level of cytokine production, inflammatory 
mediators and cell functions (Blecha, 1988; Kanoh and Rubin, 2010). In vitro research can 
offer a first indication of the expected in vivo outcome. Since blood monocytes and tissue 
macrophages are responsible for the onset of inflammation, isolated peripheral blood 
mononuclear cells (PBMCs) have been frequently used as a model of in vitro immune 
response stimulation (Bailly et al., 1991a; Baumann and Gauldie, 1994; Morikawa et al., 
1996, Ianaro et al., 2000; Cao et al., 2006). As a major part of the Gram-negative bacterial 
outer membrane, lipopolysaccharide (LPS) is a key molecule in several porcine diseases. 
Binding of LPS to Toll-like receptor 4 (TLR4) ultimately leads to the activation of nuclear 
factor-κB (NF-κB), subsequent gene transcription and production of pro-inflammatory 
cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6, and other 
mediators (Pålsson-McDermott and O’Neill, 2004). Additionally, NF-κB-mediated 
cyclooxygenase (COX)-2 expression is induced, resulting in prostaglandin (PG) E2 and 
thromboxane (TX) A2 production (Yamamoto et al., 1995). On the other hand, COX-1 is 
constitutively expressed in most cells and is mainly involved in the maintenance of 
physiological processes (Vane, 1971; Tegeder et al., 2001). The de novo formation of PGE2 
comprises a three-step cascade reaction catalyzed by phospholipase A2 (PLA2), which 
liberates arachidonic acid from membrane phospholipids; cyclooxygenase (COX), which 
converts arachidonic acid to PGH2; and PGE synthase, which finally isomerizes PGH2 to 
PGE2. Subsequently, PGE2 is rapidly converted to its major inactive metabolite 13,14-
dihydro-15-keto PGE2, and can be subject to further metabolism to 13,14-dihydro-15-keto 
PGA2 and finally bicyclic PGE2 (Fitzpatrick et al., 1980; Granström et al., 1980; Ivanov and 
Romanovsky, 2004). 
Non-steroidal anti-inflammatory drugs (NSAIDs) exert both their therapeutic and 
side effects by binding and blocking COX. However, it is hypothesized that some NSAIDs 
might also possess COX-independent properties, involving inhibition of NF-κB-related gene 
transcription (Tegeder et al., 2001). Ketoprofen (KETO) is an NSAID which has been 
commonly used in veterinary medicine because of its anti-inflammatory, antipyretic and 
analgesic properties (Mustonen et al., 2012a; Salichs et al., 2012). It was previously 
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suggested that KETO has not the ability to inhibit NF-κB activation (Matasić et al., 2000), 
yet Donalisio et al. (2013) recently described an inhibiting effect of KETO on the ex vivo LPS-
induced TNF-α production in dairy cows.  
Glucocorticoids induce lipocortin which inhibits PLA2. Dexamethasone (DEX) is a 
potent synthetic glucocorticoid and inhibition of LPS-induced cytokine production by DEX 
has been well-documented (Morikawa et al., 1996; Bessler et al., 1999).  
Numerous review articles have been dedicated to the diversity of clinically 
important in vitro and in vivo immunomodulatory effects of macrolide antibiotics (Labro, 
1998; Čulić et al., 2001; Tamaoki et al., 2004; Kanoh and Rubin, 2010). In this respect, these 
drugs are reported to influence monocyte-mediated cytokine release and PG production, 
as well as neutrophil adhesion, migration and accumulation (Čulić et al., 2001). In addition, 
it is suggested that macrolides prevent NF-κB activation and the following protein 
expression and production (Ianaro et al., 2000; Healy, 2007). Gamithromycin (GAM) is a 
macrolide antibiotic recently approved for the treatment of bovine respiratory disease. 
Furthermore, the influence of GAM on the porcine immune response has not yet been 
studied. Recently, Salichs et al. (2013) demonstrated that the combination of an NSAID and 
an antibiotic was advantageous in the treatment of swine respiratory disease compared to 
treatment with the antibiotic alone. 
The aim of the present study was therefore to investigate the effects of GAM, KETO 
and their combinations on the production of pro-inflammatory cytokines and PGE2 in LPS-
stimulated porcine PBMCs. DEX was included as a positive control inhibiting pro-
inflammatory cytokines.  
 
2. Materials and methods 
 
2.1. Standards and reagents 
 
Analytical standards of ketoprofen (KETO), dexamethasone (DEX) and indomethacin 
(IND) were purchased from Sigma-Aldrich. The standard of gamithromycin (GAM) was 
kindly donated by Merial. High-performance liquid chromatography (HPLC) grade methanol 
(MeOH) and ethanol absolute for analysis (EtOH) were obtained by VWR. Stock solutions of 
1 mg/mL of the analytical standards of GAM, KETO and DEX were prepared in HPLC MeOH 
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and were stored at 2-8°C (DEX) or at ≤ -15°C (GAM and KETO). Working solutions were 
prepared in RPMI 1640 medium (Invitrogen) supplemented with 10 % heat-inactivated 
fetal bovine serum (FBS), 1 % L-glutamine, 1 % sodium pyruvate and 1 % non-essential 
amino acids (complete RPMI). Ultrapure LPS from E. coli serotype O111:B4 was obtained by 
InvivoGen. A stock solution of 100 µg/mL of IND was prepared in EtOH. Subsequently, 100 
µL of the stock solution was dispensed in microcentrifuge tubes and evaporated to dryness. 
Tubes were kept closed and stored at 2-8°C until the start of the experiment.  
Standards of PGE2 and 13,14-dihydro-15-keto PGE2 (PGE2-met); as well as the 
internal standards (IS), deuterated PGE2 (PGE2-d4) and PGB2 (PGB2-d4) were all obtained by 
Cayman Chemical. Ultra-performance liquid chromatography (UPLC) grade MeOH, 
acetonitrile (ACN) and water were obtained by Biosolve. Stock solutions of 1 mg/mL of 
PGE2, PGE2-met, PGE2-d4 and PGB2-d4 were prepared in UPLC MeOH and stored at < -70°C. 
Mixed working solutions of PGE2 and PGE2-met of 0.1, 1.0 and 10 ng/mL; and a mixed IS 
working solution of PGE2-d4 and PGB2-d4 of 10 ng/mL were prepared in UPLC MeOH and 
stored at < -70°C. 
 
2.2. Isolation and stimulation of porcine peripheral blood mononuclear cells 
 
Jugular venipuncture was performed in six clinically healthy donor pigs, weighing on 
average 30 kg (Biocentrum Agri-Vet, Ghent University), and 10 mL blood was collected in 
lithium heparinized tubes and diluted 1:1 with 0.9% NaCl. Peripheral blood mononuclear 
cells (PBMCs) were subsequently isolated by density gradient centrifugation (800 x g for 25 
min at 18 °C) using LymphoprepTM (Lucron). Remaining erythrocytes were lysed in an ice-
cold isotonic ammonium chloride (NH4Cl) solution (138 mM NH4Cl and 21 mM Tris, pH 7.4). 
PBMCs were washed twice with RPMI 1640 containing 10 % heat-inactivated FBS and 
pelleted at 350 x g for 10 min at 4°C. Cells were counted using BD TruCOUNTTM tubes by 
means of a FACSArray BioanalyzerTM, following the manufacturer’s instructions (BD 
Biosciences). PBMCs were finally resuspended at a concentration of 2.5 x 106 cells/mL in 
complete RPMI.  
The cells were cultured in 15 mL polypropylene tubes at a density of 2 x 106 
cells/tube (800 µL) in the presence of LPS (1.25 µg/mL) with or without GAM, KETO and 
DEX or a combination of drugs (a total volume of 1 mL in each tube; Table 1) for 18 h on a 
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horizontal shaker (IKA® HS 260, Sigma-Aldrich) in a 37 °C humidified incubator containing 
5 % CO2. Subsequently, the cells were pelleted at 350 x g for 10 min at 4 °C and the 
supernatant was harvested in uncoated or IND-coated (10 µg/mL) microcentrifuge tubes 
for analysis of TNF-α, IL-1β and IL-6; and PGE2, respectively, and immediately stored at ≤ -
70 °C until analysis. 
Blood sampling was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of Ghent University (EC2013/23).  
 
Table 1. Overview of the drugs and their combination tested  
Groups GAM (µg/mL) KETO (µg/mL) DEX (µg/mL) % MeOH 
CONTR - - - 0 
LPS - - - 0 
GAM 10 10 - - 1 
GAM 20 20 - - 2 
KETO 10 - 10 - 1 
KETO 20 - 20 - 2 
DEX 1 - - 1 0.1 
DEX 10 - - 10 1 
GAM 10 – KETO 10  10 10 - 2 
GAM 20 – KETO 20 20 20 - 4 
GAM 10 – KETO 20 10 20 - 3 
GAM 20 – KETO 10 20 10 - 3 
GAM 10 – DEX 1  10 - 1 1.1 
GAM 20 – DEX 1 20 - 1 2.1 
GAM: gamithromycin; KETO: ketoprofen; DEX: dexamethasone; MeOH: methanol 
 
2.3. Cell viability 
 
Prior to LPS stimulation, cell viability was assessed after incubation of 2.5 x 105 cells 
for 10 min with 1 µg/mL propidium iodide (PI; Sigma-Aldrich). Five thousand events were 
evaluated by means of a FACSArray BioanalyzerTM and analysed using FACSDiva software 
(BD Biosciences). The influence of MeOH, GAM, KETO, DEX and the combination of drugs 
on cell viability was investigated in a similar manner after incubation of PBMCs for 18 h at 
37 °C with 5 % CO2.  
To exclude bacterial contamination of the cell culture after the 18 h-incubation 
period, the cell suspension was plated onto a trypticase soy agar (TSA) plate and incubated 
for 48 h at 37 °C. The TSA plate was visually inspected for the presence of bacterial growth. 
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2.4. Sample analysis 
 
The concentration of PGE2 and its inactive metabolite PGE2-met in cell supernatant 
was measured using an in-house validated UPLC-tandem mass spectrometry method 
(UPLC-MS/MS), which was initially developed for plasma samples (De Baere et al., 
unpublished data). In brief, sample preparation was performed by adding 25 µL of the IS 
working solution to 100 µL of cell supernatant. After a vortex mixing step (10s), 525 µL of 
UPLC ACN were added, followed by a vortex mixing (20s) and a centrifugation step (7800 x 
g for 10 min at 4 °C). The supernatant was transferred to a glass extraction tube and 
evaporated to dryness using a nitrogen stream (35 °C). The residue was re-dissolved in 200 
µL of UPLC water/ACN (80/20, v/v), filtered through a Millex®-GV PVDF filter unit (0.22 µm 
- Millipore) and transferred to an autosampler vial. A 10 µL-aliquot was injected onto the 
UPLC-MS/MS instrument. 
The LC system consisted of an Acquity UPLC H-Class Quaternary Solvent Manager 
and Flow-Through-Needle Sample Manager with temperature controlled tray and column 
oven from Waters. Chromatographic separation was achieved on an Acquity UPLC BEH C18 
column (50 mm x 2.1 mm i.d., dp: 1.7 µm) in combination with an Acquity BEH C18 1.7 µm 
Vanguard pre-column (Waters). The mobile phase A consisted of 0.01 % formic acid in 
water, while the mobile phase B was 0.01 % formic acid in ACN. 
The UPLC column effluent was interfaced to a XEVO TQ-S® MS/MS system, 
equipped with an electrospray ionization (ESI) probe operating in the negative mode (all 
from Waters). A divert valve was used and the UPLC effluent was directed to the mass 
spectrometer from 2.0 to 4.9 min. 
MS/MS acquisition was performed in the multiple reaction monitoring (MRM) 
mode. The MRM transitions monitored as quantification and identification ion, 
respectively, were m/z = 351.22 > 271.26 and 351.22 > 315.21 for PGE2; m/z = 355.16 > 
319.28 and 355.16 > 275.27 for PGE2-d4 (IS); m/z = 333.20 > 175.00 and 333.20 > 235.00 
for PGE2-met; m/z = 337.20 > 179.00 and 337.20 > 319.20 for PGB2-d4 (IS). 
The method was validated by a set of parameters that were in compliance with the 
recommendations defined by EU standards (Commission Decision 2002/657/EC, VICH GL 
49, Heitzman, 1994) and by Knecht and Stork (1974). In this respect, linearity, within- and 
between-run accuracy and precision, limit of quantification (LOQ), limit of detection (LOD) 
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and specificity were evaluated. Linear calibration curves (r > 0.99) were constructed in a 
concentration range of 50 and 5000 pg/mL. Within- and between-run accuracy and 
precision were evaluated by analysing independently spiked samples (n = 6) at four 
concentration levels i.e. 50, 125, 500 and 5000 pg/mL, respectively. The results fell within 
the accepted ranges for accuracy and precision (2002/657/EC; VICH GL49). The LOQ was 
defined as the lowest concentration for which the method was validated with a within-run 
accuracy and precision that fell within the specified ranges and was established at 50 
pg/mL for both PGE2 and PGE2-met. The LOD was defined as the concentration 
corresponding with a signal-to-noise ratio of 3 and was found to be 14.0 and 10.0 pg/mL 
for PGE2 and PGE2-met, respectively. The specificity of the method was proven, since no 
peaks of endogenous interferences could be determined in blank samples. 
All samples were analysed for detection of TNF-α, IL-1β and IL-6 using commercially 
available porcine DuoSet® ELISA Development Systems according to the manufacturer’s 
instructions (R&D Systems). Optical densities were determined using a plate reader 
(Multiskan MS Labsystems, Thermo Scientific). Data were analysed by means of DeltaSoft 
JV (BioMetallics Incorporated). 
 
2.5. Statistical analysis 
 
Data were statistically analyzed by single factor analysis of variance (ANOVA), using 
SPSS Statistics 22.0 software for Windows. Pairwise comparisons of means of the different 
groups were performed using the Tukey test. For those parameters that were not normally 
distributed, the Kruskal-Wallis ANOVA on ranks was used. A p-value of < 0.05 was 
considered statistically significant. 
 
3. Results 
 
3.1. Cell viability  
 
Before incubation with LPS and/or drugs, the mean viability of the cells was 99.7 ± 
0.06%. Neither MeOH (up to a concentration of 4%, Table 1), nor GAM, KETO, DEX or their 
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combination displayed harmful effects for porcine PBMCs, since the viability of the cells of 
all groups was still ≥ 96.3% after the 18 h-incubation period.  
No bacterial contamination was observed on the TSA plate after a 48 h-incubation 
at 37°C. 
 
3.2. Prostaglandin E2 production 
 
Incubation of porcine PBMCs with LPS significantly increased PGE2 in the 
supernatant of the LPS, GAM 10 and GAM 20 groups in comparison with unstimulated 
PBMCs (CONTR) after 18 h (p < 0.001). In the supernatant of the other groups, PGE2 could 
not be quantified (< LOQ). Incubation of the cells in the presence of KETO, DEX and their 
respective combinations with GAM, significantly reduced PGE2 production compared to the 
LPS group (p < 0.001) (Figure 1). 
No concentrations of PGE2-met could be quantified (< LOQ) (data not shown). 
 
 
 
Figure 1. Effect of gamithromycin (GAM), ketoprofen (KETO), dexamethasone (DEX) and 
their combination on lipopolysaccharide (LPS)-induced (1.25 µg/mL) PGE2 production by 
PBMCs. Data are presented as means + SD. Statistically significant differences compared to 
the LPS group are visualized as *** p < 0.001. 
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3.3. Cytokine production 
 
 Following incubation with LPS, the LPS, GAM 10, GAM 20, KETO 10, KETO 20, GAM 
10 – KETO 10, GAM 10 – KETO 20 and GAM 20 – KETO 10 groups showed a marked increase 
in supernatant levels of TNF-α (p < 0.001) and IL-1β (p < 0.01) in comparison with 
unstimulated PBMCs (CONTR) after 18 h (Figure 2A-B). As unstimulated PBMCs (CONTR) 
also produced considerable amounts of IL-6 (Figure 2C), only the LPS group showed a 
significant higher IL-6 level compared to the CONTR group (p < 0.05). Combinations of GAM 
and KETO significantly reduced levels of LPS-induced IL-1β (GAM 20 – KETO 20; p < 0.05) 
and IL-6 (GAM 20 – KETO 20, GAM 10 – KETO 20 and GAM 20 – KETO 10; p < 0.01) in 
comparison with the LPS group. 
As expected, the presence of the positive control DEX significantly suppressed the 
production of TNF-α (p < 0.05), IL-1β (p < 0.01) and IL-6 (p < 0.01) compared to the LPS 
group. 
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Figure 2. Effect of gamithromycin (GAM), ketoprofen (KETO), dexamethasone (DEX) and 
their combination on lipopolysaccharide (LPS)-induced (1.25 µg/mL) TNF-α (A), IL-1β (B) 
and IL-6 production by PBMCs (C). Data are presented as means + SD. Statistically 
significant differences compared to the LPS group are visualized as * p < 0.05; ** p < 0.01 
and *** p < 0.001. 
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4. Discussion 
 
The present study reports the influence of GAM, KETO and DEX on the production 
of TNF-α, IL-1β and IL-6; and PGE2 using an in vitro model of LPS-induced (1.25 µg/mL) 
inflammation in pigs. The experimental design concerning LPS dose, incubation period and 
doses of GAM tested was largely based on similar research (Ianaro et al., 2000; Cao et al., 
2006). Moreover, an in-house pilot study demonstrated that an incubation period of 18 h 
was more suitable in comparison with 6 h and 24 h (data not shown). In a previous 
pharmacokinetic study by our group, maximal plasma concentrations of 0.27-0.49 µg/mL 
were established for GAM in pigs after a single subcutaneous injection of 6 mg/kg (Wyns et 
al., 2014). Taking into account the total blood volume and estimated number of monocytes 
in the peripheral circulation of pigs, ± 6% of the total leukocyte count (Friendship et al., 
1984; Clark and Coffer, 2008; Williams et al., 2009), GAM doses of 10 and 20 µg/mL were 
considered appropriate for evaluating the possible immunomodulatory capacities of this 
macrolide antibiotic after incubation with 2 x 106 PBMCs. 
Due to instability and following rapid metabolism of PGs, the simultaneous 
detection of multiple PG metabolites is desirable for a more comprehensive understanding 
of the PG biosynthesis. Therefore, a highly specific LC-MS/MS method was in-house 
developed for the simultaneous determination of PGE2 and its inactive metabolite, PGE2-
met (De Baere et al., unpublished data). The presence of albumin and alkaline conditions 
(pH ≥ 9) promotes further degradation of 13,14-dihydro-15-keto PGE2 to PGE2-met and 
other inactive metabolites (Fitzpatrick et al., 1980; Granström et al., 1980; Kelly et al., 
1992). In this study, however, none of the groups showed detectable concentrations of 
PGE2-met (data not shown). This might be explained by the fact that the complete RPMI 
medium used was protein-free and showed a physiological pH. Furthermore, the in vitro 
incubation set-up might lack essential physiological circumstances, such as enzymes, as 
compared to the in vivo-situation.  
Both SAIDs and NSAIDs exert their main anti-inflammatory effects by inhibition of 
the PG biosynthesis. As expected, the administration of DEX as well as KETO to LPS-
stimulated PBMCs efficiently inhibited the production of PGE2. Conversely, high levels of 
PGE2 were detected in the supernatant of the LPS, GAM 10 and GAM 20 groups (Figure 1).  
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Macrolide antibiotics have been previously reported to reduce the COX-mediated 
eicosanoid production in LPS-stimulated murine mononuclear cells. In contrast to NSAIDs, 
it is suggested that macrolides do not interact directly with LPS-induced COX-2, but rather 
suppress its expression through inhibition of NF-κB (Ianaro et al., 2000; Cao et al., 2006; 
Leiva et al., 2008). Nevertheless, GAM did not show any (indirect) effect on the production 
of PGE2 by porcine PBMCs compared to the LPS group. 
In vivo, the cytokine-mediated activation of the hypothalamic-pituitary-adrenal axis 
and following endogenous glucocorticoid synthesis suppress further cytokine production, 
in order to protect the host from an excessive and possibly harmful immune response 
(Fantuzzi and Ghezzi, 1993; Coelho et al., 1995; Tuchscherer et al., 2010). DEX has been 
repeatedly reported to inhibit LPS-induced TNF-α, IL-1β and IL-6 levels both in vitro and in 
vivo in different animal species (Morikawa et al., 1996, Bessler et al., 1999; Teeling et al., 
2010; Myers et al., 2003). As expected, DEX also significantly suppressed the LPS-induced 
production of TNF-α, IL-1β and IL-6 in the current study. 
Administration of KETO neither inhibited LPS-induced TNF-α, IL-1β nor IL-6 
production by porcine PBMCs. In contrast, PBMCs of the KETO 10, KETO 20 as well as the 
combination group GAM 10 – KETO 10, showed a trend, yet not significant, to produce 
even higher levels of TNF-α compared to the LPS group. In this respect, our results are in 
agreement with previous studies, reporting that NSAIDs increase rather than inhibit TNF-α 
production both in vitro and in vivo (Pettipher and Wimberly, 1994; Ghezzi et al., 1998; 
Roth et al., 2002). Since PGE2 has been established as a feedback inhibitor of TNF-α 
production, increased TNF-α levels can be expected following COX-inhibition (Kunkel et al., 
1988; Sironi et al., 1992). Indeed, no PGE2 was detected in the groups receiving KETO. 
In contrast to many previous reports concerning inhibition of cytokine production 
by macrolide antibiotics, GAM had no influence on LPS-induced cytokine levels in the 
present study. Macrolides, including azithromycin, clarithromycin, erythromycin, 
roxithromycin, telithromycin, tilmicosin and tylosin are all reported to decrease the in vitro 
and/or in vivo production of TNF-α, IL-1β and IL-6 in humans and rodent species (Morikawa 
et al., 1996; Ianaro et al., 2000; Cao et al., 2006; Sugiyama et al., 2007; Leiva et al., 2008). In 
this respect, GAM seems to differ from other macrolide antibiotics. On the other hand, 
Bailly et al. (1991a) also observed no effect of roxithromycin on cytokine production, and 
even a stimulating effect of spiramycin, and to a lesser extent erythromycin, on IL-6 
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production in LPS-stimulated human monocytes. An alternative explanation is that the 
concentrations of GAM used in the present study (i.e. 10 and 20 µg/mL) were not sufficient 
to influence the cytokine as well as PGE2 production as these effects are generally 
considered to be concentration-dependent (Morikawa et al., 1996; Ianaro et al., 2000; Cao 
et al., 2006). Nevertheless, Cao et al. (2006) reported significant effects with similar 
concentrations of tilmicosin and tylosin. Being weak basic (and lipophilic) molecules, 
macrolides can easily penetrate and accumulate in cells and tissues reaching substantial 
intracellular and therapeutic concentrations, despite inadequate plasma concentrations 
(Anadón and Reeve-Johnson, 1999). Lung concentrations of GAM in cattle were established 
247-410 times higher compared to plasma (Huang et al., 2010). However, experimental 
conditions, such as the incubation temperature and the presence of extracellular Ca2+, can 
also influence their uptake and thus their immunomodulatory capacities (Vazifeh, 1997; 
Čulić et al., 2001). Furthermore, it has been described that some macrolides become 
inactive in acidic intracellular conditions, i.e. in phagosomes (Van Bambeke and Tulkens, 
2001). These results indicate that the effects of macrolides on cytokine production are 
equivocal and require a case-specific approach. Additional research using a broader range 
of GAM concentrations can further elucidate this hiatus. 
Interestingly, the combination of a high concentration of GAM as well as KETO 
(GAM 20 – KETO 20) reduced TNF-α, yet not significantly, IL-1β and IL-6 levels. This effect is 
not due to enhanced toxicity of higher drug concentrations since more than 96% of the 
cells of the GAM 20 – KETO 20 group was still viable after the 18 h-incubation period. High 
concentrations of both GAM and KETO might act synergistically and possibly lower the 
threshold to observe immunomodulatory effects. While these in vitro results provide a 
first, promising indication of the possible advantageous effects of the combination of GAM 
and KETO, the efficacy of this combination will be further evaluated in LPS-challenged pigs. 
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2.2. In vivo influence of gamithromycin and ketoprofen on the acute phase response in 
lipopolysaccharide-challenged pigs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from 
Wyns, H., Meyer, E., Plessers, E., Watteyn, A., van Bergen, T., Schauvliege, S., De 
Baere, S., Devreese, M., De Backer, P., Croubels, S. (2014) Modulation of gamithromycin 
and ketoprofen on in vitro and in vivo porcine lipopolysaccharide-induced inflammation 
(Submitted to PLoS ONE). 
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Abstract 
The immunomodulatory properties of gamithromycin (GAM), ketoprofen (KETO) 
and their combination (GAM-KETO) were studied on the production of prostaglandin (PG) 
E2 and pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-
6 in lipopolysaccharide (LPS)-challenged pigs. Additionally, the effects on the production of 
the acute phase proteins (APPs) pig-major acute phase protein (pig-MAP) and C-reactive 
protein (CRP), as well as on the development of fever, pulmonary symptoms and sickness 
behaviour were investigated.  
Maximal plasma concentrations of TNF-α and IL-6 were observed at 1 h and 2.5 h 
following intravenous LPS challenge in pigs, respectively. Neither GAM, KETO nor the 
combination GAM-KETO was able to inhibit the in vivo LPS-induced cytokine production. 
Furthermore, none of the drugs influenced the APPs production.  
Pretreatment of the pigs with KETO significantly reduced PGE2 production (p < 
0.001) and prevented the development of fever and severe symptoms following LPS 
challenge, including dyspnea, anorexia, vomiting and lateral decubitus. A crucial role for 
cyclooxygenase (COX)-1 mediated products, including PGE2 and thromboxane A2 is 
suggested in the development of early LPS-associated symptoms in pigs. 
  
 
84 
1. Introduction 
 
Lipopolysaccharide (LPS), a structural part of the outer membrane of Gram-negative 
bacteria, is one of the most effective stimulators of the immune system and has been 
widely applied in pigs as an experimental model for bacterial infection and septic shock 
(Dinarello, 1997; Schrauwen et al., 1988; Wyns et al., manuscript submitted). Both 
neutrophils and monocytes are important cells in the innate immune response (Baumann 
and Gauldie, 1994; Cavaillon and Adib-Conquy, 2005; Sanz-Santos et al., 2011). Bacterial 
LPS is recognized by Toll-like receptor 4 (TLR4) which is constitutively expressed on the 
surface of innate immune cells, including monocytes and tissue macrophages. Extracellular 
binding of LPS to TLR4 and following intracellular signaling ultimately leads to the 
activation of nuclear factor-κB (NF-κB) and subsequent gene transcription of pro-
inflammatory cytokines and mediators (Baumann and Gauldie, 1994; Peri et al., 2010). This 
results in the further recruitment and migration of immune cells to target tissues and the 
induction of the hepatic acute phase proteins (APPs) production, including C-reactive 
protein (CRP), haptoglobin (Hp) and pig major acute phase protein (pig-MAP) (Baumann 
and Gauldie, 1994; Cavaillon and Adib-Conquy, 2005). 
  This acute phase response (APR) can be modulated by drugs. Immunomodulation is 
defined as a reorganization of the inflammatory response by modifying or regulating 
functions of the hosts’ immune system. The immunomodulatory capacities of (non)-
steroidal anti-inflammatory drugs (N)SAIDs and antibiotics have been studied after both in 
vitro and in vivo LPS challenges in various animal species. In contrast to the rather 
restricted in vitro research, in vivo research includes the APPs and febrile response and 
thus offers a more complete evaluation of the APR.  
The Escherichia (E.) coli LPS-induced fever model has been accepted for the 
evaluation of the antipyretic effect of NSAIDs (EMA, 2001). These drugs exert both their 
therapeutic and their side effects by (non-)selective central and peripheral cyclooxygenase 
(COX)-inhibition, consequently blocking prostaglandin (PG) biosynthesis (Curry et al., 2005; 
Ferguson et al., 2009). Ketoprofen (KETO) is an NSAID which has been commonly used in 
veterinary medicine because of its anti-inflammatory, antipyretic and analgesic properties. 
It has been repeatedly established as a major antipyretic drug in pigs (Swinkels et al., 1994; 
Mustonen et al., 2012a; Salichs et al., 2012).  
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Compared to NSAIDs, antimicrobial drugs are even more frequently used in 
veterinary medicine. In pigs, bacterial respiratory infections are responsible for 
considerable economic losses and reduced animal welfare. Bacteria, including 
Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and 
Mycoplasma hyopneumoniae are major pathogens involved in swine respiratory disease 
(SRD). In addition to their anti-infectious properties, especially macrolide antibiotics are 
recurrently reported to possess clinically important immunomodulatory effects by 
influencing a variety of inflammatory processes varying from the release of cytokines and 
mediators, neutrophil function, migration, infiltration and accumulation to mucus 
(hyper)secretion (Čulić et al., 2001; Tamaoki et al., 2004; Kanoh and Rubin, 2010). 
Macrolides, including azithromycin, clarithromycin, erythromycin, roxithromycin, 
telithromycin, tilmicosin and tylosin are reported to decrease the in vitro and/or in vivo 
LPS-induced production of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 as well 
as PGE2 (Morikawa et al., 1996; Ianaro et al., 2000; Cao et al., 2006; Sugiyama et al., 2007; 
Leiva et al., 2008). To date, tulathromycin (Draxxin®) and tildipirosin (Zuprevo®) have been 
approved for treatment of SRD (EMA, 2008a; 2011). Gamithromycin (GAM), on the other 
hand, is a 15-membered semi-synthetic macrolide antibiotic of the azalide subclass, which 
has been recently developed for the treatment and prevention of bovine RD (Huang et al., 
2010). However, GAM has not yet been applied in porcine research, which makes it 
interesting to evaluate its therapeutic applicability in pigs. Recently, Salichs et al. (2013) 
demonstrated a significant improvement of the clinical condition of pigs with symptoms of 
SRD, including dyspnea, coughing, depression and fever when a combination of the 
antibiotic doxycycline and KETO was administered compared to the treatment with 
doxycycline solely. 
The aim of the present study was therefore to investigate the immunomodulatory 
activities of KETO, GAM and the combination of both drugs in LPS-challenged pigs. 
Immunomodulation was studied at the level of cytokine production (TNF-α, IL-1β and IL-6), 
APPs (pig-MAP and CRP), PGE2; and of the behavioural and febrile responses. It is 
hypothesized that administration of the combination of KETO and GAM, would be more 
beneficial compared to the exclusive administration of KETO or GAM due to possible 
synergistic and/or additive effects. 
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2. Materials and methods 
 
2.1. Animals 
 
Twenty-six clinically healthy 10-week-old male pigs of a stress resistant breed 
(Seghers Hybrid) with a mean (± SD) body weight (BW) of 28.5 ± 3.04 kg were housed in 
group. The animals had free access to feed and drinking water. After a one-week 
acclimatization period, a double-lumen jugular catheter was inserted for accurate 
intravenous (IV) LPS administration and blood sampling facilitation. 
In brief, after intramuscular (IM) premedication with midazolam, morphine and 
ketamine, anaesthesia was IV induced with propofol. Following endotracheal intubation, 
anaesthesia was maintained with isoflurane in a mixture of oxygen and air. Subsequently, 
the pigs were randomly assigned to receive either a constant rate infusion (CRI) of 
alfaxalone (n = 13) or a CRI of saline (n = 13) (Cerasoli et al., 2014). A central venous 
catheter (two-lumen central venous catheterization set, 7 Fr, 60 cm; Arrow® International) 
was surgically implanted in the left external jugular vein using a slightly adapted technique 
from Gasthuys et al. (1999). Briefly, the external jugular vein was surgically exposed after 
which the catheter was introduced with the Seldinger technique (Seldinger, 1953; 1984) 
and tunnelled subcutaneously to its dorsal exit point on the dorsal part of the neck. Finally, 
the catheter was fixed with a suture on the caudal part of the neck and a suture in the 
midline of the back. The surgical incision at the level of the jugular groove was closed in a 
two-layer continuous pattern.  
In order to reduce the risk of bacterial infections after anaesthesia and surgery, 24 h 
before and immediately after anaesthesia, the pigs received an IM injection of 3 mg/kg BW 
sodium ceftiofur (Excenel®, Zoetis).  
After surgery, the pigs were housed individually, the catheters were flushed at least 
once daily with heparinized NaCl 0.9 % (100 IU/mL) and the bandages were changed daily. 
 
2.2. Experimental design 
 
After a three-day recovery period, the pigs were randomly divided into four groups 
of six animals and an additional control group of two animals, considering that 50% of the 
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pigs of each group had been assigned to the alfaxalone anaesthesia protocol. All groups 
received either a single bolus of respectively 12 mg/kg BW GAM (Zactran®; Merial) 
subcutaneously (SC) in the flank region (n = 6), 6 mg/kg BW KETO (Ketofen® 10%; Merial) 
intramuscularly in the gluteus muscle (n = 6), the combination of both drugs (GAM-KETO at 
again 12 mg/kg and 6 mg/kg, respectively; n = 6) or no drugs (LPS, n = 6). Following a 1-
hour-interval, all these 24 pigs were intravenously challenged with 15 µg/kg BW (15 x 103 
EU/kg BW) ultrapure LPS from E. coli serotype O111:B4 through the proximal lumen of the 
catheter. The two additional control animals only received an equivalent volume of 0.9% 
NaCl IV (CONTR, n = 2).  
Since the SC administration of Zactran® to pigs turned out to be particularly painful, 
a local anaesthetic, lidocaine hydrochloride (Xylocaine® 2 %; AstraZeneca), was applied 
simultaneously to GAM injection in both the GAM and GAM-KETO group. 
The animals’ clinical condition was scored continuously by a qualified veterinarian 
observing the clinical symptoms and behaviour during the first 8 h after LPS challenge. 
More specifically, the occurrence of anorexia, nausea, vomiting, tachypnea, dyspnea, 
shivering and lateral decubitus were registered. 
Rectal body temperature (RT) was measured and blood samples were collected 
from the distal lumen of the catheter into lithium heparinized tubes before (0 h) and at 0.5, 
1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 18, 24, 30, 36, 48 and 72 h post administration (p.a.) of 
LPS. Additionally, 1 mL of blood was collected in a heparin- and indomethacin-coated (10 
µg/mL) microcentrifuge tube for PGE2 analysis, as previously described. Prior to the in vivo 
blood collection, heparin (10 IU; Leo Pharma) was added to the tubes. Indomethacin was 
added in order to prevent ex vivo artefactual eicosanoid generation (Pelligand et al., 2012). 
Samples were immediately placed on ice and centrifuged (at 2800 x g and 1000 x g, 
respectively, for 10 min at 4 °C) within 2 h. Plasma was isolated, aliquoted and stored at ≤ -
70 °C until analysis.  
All procedures were approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of Ghent University (EC2013/128). 
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2.3. Analysis of cytokines, APPs and PGE2 in porcine plasma 
 
All plasma samples were analysed for detection of the cytokines TNF-α, IL-1β and IL-
6; and the APPs CRP and pig-MAP using commercially available enzyme-linked 
immunosorbent assays (ELISAs). The concentrations of TNF-α, IL-1β and IL-6 as well as CRP, 
were determined using porcine DuoSet® ELISA Development Systems (R&D Systems) 
according to the manufacturer’s instructions. The suitability of these assays for porcine 
plasma samples was approved by a preceding in-house validation procedure. In this 
respect, imprecision (mean intra- and inter-assay coefficients of variation (CV)) and 
linearity were calculated for each parameter (Maddens et al., 2010). Intra- and inter-assay 
CV values of < 10 % and < 15 %, respectively, were considered to be acceptable. For the 
evaluation of linearity, a recovery range of 80 – 120 % for the linear dilutions was 
postulated. With the exception of IL-1β, all ELISAs were successfully validated and 
considered suitable for use on porcine plasma samples. For IL-1β, in which an inter-assay 
CV of 33 % was established, a higher dilution factor was required to obtain more reliable 
and reproducible results. Yet, the plasma concentration of this cytokine appeared to be 
relatively low, allowing no further dilution. Plasma levels of pig-MAP were evaluated using 
a ready-to-use ELISA kit according to the manufacturer’s instructions (PigCHAMP Pro 
Europa S.L.). Optical densities were determined using a plate reader (Multiskan MS 
Labsystems, Thermo Scientific). Data were analysed by means of DeltaSoft JV (BioMetallics 
Incorporated). 
The plasma concentrations of PGE2 and its inactive metabolite 13,14-dihydro-15-
keto PGA2 (PGE2-met) were measured using an in-house validated ultra-performance liquid 
chromatography-tandem mass spectrometry method (UPLC-MS/MS), as previously 
described. The limit of quantification (LOQ) in plasma was established at 50 pg/mL for both 
PGE2 and PGE2-met. The limit of detection (LOD) in plasma was found to be 28.2 and 9.0 
pg/mL for PGE2 and PGE2-met, respectively.  
 
2.4. Statistical analysis 
 
Data were statistically analyzed by single factor analysis of variance (ANOVA), using 
SPSS Statistics 22.0 software for Windows. Pairwise comparisons of means of the different 
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groups were performed using the Tukey test. For those parameters that were not normally 
distributed, the Kruskal-Wallis ANOVA on ranks was used. A p-value of <0.05 was 
considered statistically significant. 
 
3. Results 
 
3.1. Rectal body temperature 
 
At the start of the experiment (time 0 h), the mean RT of all pigs was 39.1 ± 0.55 °C. 
Following LPS challenge, the mean RT of the LPS and GAM group gradually increased to 
reach a maximum of 41.1 ± 0.56 °C and 41.0 ± 0.24 °C, respectively, as early as 2.5 h after 
LPS administration (p < 0.001) (Figure 1). The mean RT then steadily decreased to regain a 
normal RT by 8 h after LPS administration. Conversely, the pigs receiving KETO (both the 
KETO and GAM-KETO groups) showed no increase in RT. The CONTR group, which received 
neither LPS nor drugs, also showed no significant changes in RT (Figure 1). 
 
 
 
Figure 1. Rectal body temperature after intravenous administration of saline (CONTR; n = 
2) or LPS (15 µg/kg BW) and pretreatment with gamithromycin (GAM; n = 6), ketoprofen 
(KETO; n = 6), the combination of both drugs (GAM-KETO; n = 6) or no drugs (LPS; n = 6). 
Data are presented as means + SD.  
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3.2. Clinical scoring 
 
Table 1 provides an overview of the clinical symptoms occurring after LPS challenge. 
The severity of these symptoms was comparable between the animals. 
At the start of the experiment, all pigs were in good health and displayed no 
adverse signs. Within 15 min after LPS administration, all pigs of the LPS and GAM groups 
demonstrated a marked tachypnea (at 11.6 ± 3.51 min and 11.1 ± 3.12 min p.a., 
respectively) which was followed by a severe dyspnea in most animals of both these groups 
(at 21.8 ± 1.25 min and 25.8 ± 9.08 min p.a., respectively). All pigs of the LPS and GAM 
group showed anorexia, as demonstrated by a complete loss of interest in feed and 
drinking water. Vomiting was preceded by clear signs of nausea, including salivation, 
chewing movements and retching. With the exception of one pig, vomiting was observed in 
all animals of the LPS group at 20.9 ± 7.54 min after LPS administration, while in the GAM 
group, only two pigs vomited. Shivering was observed in all pigs of both groups from 42.0 ± 
10.1 min and 29.7 ± 8.82 min, respectively, p.a. of LPS.  
Following this first phase of general sickness and the onset of respiratory 
symptoms, all pigs of the LPS and GAM group experienced a depression phase, which was 
manifested by lateral decubitus with persistent respiratory distress. However, the start of 
this depression varied among both groups. Within 1h p.a. of LPS, the majority of the pigs of 
the GAM group already showed lateral decubitus (at 26.2 ± 19.4 min), while all the pigs of 
the LPS group showed this depression remarkably later (135 ± 42.3 min) (Table 1). 
The recovery phase, which is recognized by regaining alertness, vitality and 
appetite, already occurred at 335 ± 30.8 min after LPS administration in the LPS group, 
while the pigs of the GAM group recovered noticeably later (at 416 ± 23.3 min). 
After the SC injection of GAM (Zactran®), the pigs of the GAM (n = 6) and the GAM-
KETO groups (n = 6), all showed a local inflammation reaction, which was characterized by 
an immediate marked and painful swelling at the site of injection. During the first hours of 
the experiment, this swelling was experienced as extremely uncomfortable. 
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Apart from two pigs of both the KETO and GAM-KETO group showing tachypnea 
(Table 1), and the inconvenience related to the Zactran® injection by the GAM-KETO group, 
the animals of the KETO as well as the GAM-KETO group displayed no adverse effects 
following LPS challenge. These pigs showed normal behaviour throughout the experiment, 
as demonstrated by exploring the environment, social interaction, playing, sleeping and 
eating. 
As expected, neither clinical symptoms nor behavioural changes were observed by 
the two pigs of the CONTR group during the experiment. 
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Table 1. Overview of the onset of clinical symptoms p.a. of LPS (LPS, GAM, KETO and GAM-KETO groups) or saline (CONTR group) 
Data are presented as mean ± SD; p.a.: post administration; min.: minutes; N/A: not applicable  
 
 
 
Clinical symptoms LPS (n = 6) GAM (n = 6) KETO (n = 6) GAM-KETO (n = 6) CONTR (n = 2) 
Pigs 
(%) 
Time p.a. 
(min.) 
Pigs 
(%) 
Time p.a. 
(min.) 
Pigs 
(%) 
Time p.a. 
(min.) 
Pigs 
(%) 
Time p.a. 
(min.) 
Pigs 
(%) 
Time p.a. 
(min.) 
Tachypnea 100 11.6 ± 3.51 100 11.1 ± 3.12 33 75.5 ± 6.36 33 27.3 ± 25.1 0 - 
Dyspnea 83 21.8 ± 1.25 100 25.8 ± 9.08 0 - 0 - 0 - 
Nausea 100 20.5 ± 6.84 67 14.8 ± 5.74 0 - 0 - 0 - 
Vomiting 83 20.9 ± 7.54 33 16.5 ± 3.54 0 - 0 - 0 - 
Shivering 100 42.0 ± 10.1 100 29.7 ± 8.82 0 - 0 - 0 - 
Lateral decubitus ≤ 1h 
p.a. 
0 - 83 26.2 ± 19.4 0 - 0 - 0 - 
Lateral decubitus > 1h 
p.a. 
100 135 ± 42.3 17 247 0 - 0 - 0 - 
Recovery ≤ 6h p.a. 83 335 ± 30.8 17 310 N/A - N/A - N/A - 
Recovery > 6h p.a. 17 440 83 416 ± 23.3 N/A - N/A - N/A - 
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3.3. Cytokine plasma concentrations 
 
A time-dependent increase of TNF-α and IL-6 was observed in all pigs of the LPS, 
GAM, KETO and GAM-KETO groups following LPS challenge, whereas the CONTR group 
presented no detectable or basal levels of both cytokines (Figure 2A and 2B). Significant 
higher TNF-α levels were observed in the former groups compared to the CONTR group 
from 0.5 h to 5 h p.a. of LPS (p < 0.05). Levels of TNF-α dramatically increased in all groups 
reaching major mean peak concentrations as soon as 1 h p.a. of LPS (Figure 2A).  
While significant higher IL-6 levels were observed in all groups at 2 h p.a. of LPS (p ≤ 
0.01), the KETO group showed significantly increased levels of IL-6 compared to the CONTR 
group from 1.5 h to 3 h p.a. of LPS (p < 0.05). Maximal mean concentrations of IL-6 were 
recorded after a more gradual increase in these groups at 2.5 h p.a. of LPS (Figure 2B).  
Both TNF-α and IL-6 returned to pre-challenge concentrations within 6 h p.a. of LPS.  
No significant differences were observed between the GAM, KETO and GAM-KETO groups 
compared to the LPS group for both cytokines.  
 Although increased, overall low IL-1β plasma concentrations were measured in 
most pigs of the LPS, GAM, KETO and GAM-KETO groups (data not shown).  
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Figure 2. Plasma concentrations of TNF-α (A) and IL-6 (B) after intravenous administration 
of saline (CONTR; n = 2) or LPS (15 µg/kg BW) and pretreatment with gamithromycin (GAM; 
n = 6), ketoprofen (KETO; n = 6), the combination of both drugs (GAM-KETO; n = 6) or no 
drugs (LPS; n = 6). Data are presented as means + SD. Statistically significant differences 
compared to the LPS group are visualized as * p < 0.05; ** p < 0.01 and *** p < 0.001. 
 
 
 
 
 
 
 
95 
3.4. Acute phase protein plasma concentrations 
 
 At the start of the experiment (time 0 h), all pigs showed basal levels of both pig-
MAP and CRP. Increased plasma concentrations of both APPs could be observed in all 
groups following LPS challenge, whereas the CONTR group presented basal levels during 
the complete course of the experiment (Figure 3A and 3B).  
From 18 h until 30 h p.a. of LPS, significant increased pig-MAP levels were observed 
in all groups receiving LPS compared to the CONTR group (p ≤ 0.01). Maximal 
concentrations of pig-MAP were attained around 24 h p.a. of LPS (Figure 3A). At 36 h and 
48 h p.a., plasma concentrations of CRP were significantly increased in all groups receiving 
LPS compared to the CONTR group (p < 0.01). For CRP, a marked biphasic profile could be 
recognized in all groups (Figure 3B). With the exception of the GAM and GAM-KETO 
groups, showing significant higher concentrations of CRP at 36 h p.a. of LPS (p < 0.05), 
neither GAM nor KETO nor their combination had a significant influence on the production 
of pig-MAP and CRP compared to the LPS group. 
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Figure 3. Plasma concentrations of pig-MAP (A) and CRP (B) after intravenous 
administration of saline (CONTR; n = 2) or LPS (15 µg/kg BW) and pretreatment with 
gamithromycin (GAM; n = 6), ketoprofen (KETO; n = 6), the combination of both drugs 
(GAM-KETO; n = 6) or no drugs (LPS; n = 6). Data are presented as means + SD. Statistically 
significant differences compared to the LPS group are visualized as * p < 0.05 and ** p < 
0.01. 
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3.5. Prostaglandin E2 (-met) plasma concentrations 
 
 In the LPS and GAM groups, both PGE2 (data not shown) and PGE2-met increased to 
reach a peak concentration already at 1 h p.a. of LPS, whereas the CONTR group presented 
no detectable levels of PGE2 (data not shown) or PGE2-met (Figure 4).  
Administration of KETO significantly reduced PGE2 production compared to the LPS 
groups at 1, 1.5 and 2 h p.a. of LPS (p < 0.05). Pigs of the KETO and the GAM-KETO groups 
showed no quantifiable levels of both PGE2 (data not shown) and PGE2-met (Figure 4).  
 
 
Figure 4. Plasma concentrations of PGE2-met after intravenous administration of saline 
(CONTR; n = 2) or LPS (15 µg/kg BW) and pretreatment with gamithromycin (GAM; n = 6), 
ketoprofen (KETO; n = 6), the combination of both drugs (GAM-KETO; n = 6) or no drugs 
(LPS; n = 6). Data are presented as means + SD. Statistically significant differences 
compared to the LPS group are visualized as * p < 0.05 and ** p < 0.01. 
 
4. Discussion 
 
The present study is the first to report the possible immunomodulatory properties 
of GAM and KETO as well as their combination in LPS-challenged pigs. Therefore the 
influence of both drugs on the production of pro-inflammatory cytokines, APP and PGE2, as 
well as the development of fever, pulmonary symptoms and sickness behaviour was 
investigated.  
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All 26 pigs experienced an acclimatization period in which the animals were 
habituated to human presence, contact and experimental manipulations, including 
measurement of the RT. The pigs of the CONTR group were included in the experiment to 
exclude possible interfering influences related to handling stress (Straw et al., 1999; Clark 
and Coffer, 2008). These pigs showed neither clinical symptoms nor an increase in RT, 
systemic cytokines or APP during the experiment.  
E. coli LPS has been widely applied in porcine research to study the APR (Frank et 
al., 2003; Llamas Moya et al., 2006; Williams et al., 2009; Wyns et al., manuscript 
submitted). Pigs are very sensitive to the administration of LPS since relatively low doses 
induce pronounced cardiovascular and pulmonary effects. In this respect, the LD100 for E. 
coli LPS has been established to be 500 µg/kg BW for pigs (Schrauwen and Houvenaghel, 
1985; Olson et al., 1995). The dose of 15 µg/kg BW (15 x 103 EU/kg BW) LPS used in this 
study, which can be considered as moderate, was selected to provoke an apparent 
inflammation reaction, without causing mortality. E. coli serotype O111:B4 is the most 
frequently used one in porcine research (Williams et al., 2009; Wyns et al., manuscript 
submitted). In contrast to most commercial LPS preparations, the ultrapure LPS variant 
used in this study selectively activates TLR4 signaling, providing a more univocal immune 
response. 
LPS was supplied 1 h after IM and/or SC administration of KETO and/or GAM, 
respectively, when nearby maximal concentrations of both drugs were expected to be 
present in plasma. Indeed, the maximal plasma concentration (Cmax) of KETO has been 
reported to occur between 0.68 and 1.27 h after a single IM administration in pigs 
(Raekallio et al., 2008, Fosse et al., 2011; Mustonen et al., 2012b), while the Cmax of GAM 
was established at 0.63 h following a single SC administration in pigs (Wyns et al., 2014).  
Clear symptoms of acute lung failure were induced in the LPS and GAM groups. As 
fast as within 15 min after LPS administration, all pigs of both the LPS and GAM group 
displayed a marked tachypnea followed by a severe dyspnea. The occurrence of these early 
symptoms and the increased sensitivity of pigs to LPS in general, might be explained by the 
abundant presence and activation of mononuclear phagocytic cells within the porcine and 
bovine pulmonary capillaries. These pulmonary intravascular macrophages (PIMs) comprise 
a major resident population of differentiated lung macrophages junctionally anchored to 
the lung endothelium (Winkler and Cheville, 1985). In humans and laboratory animal 
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species, such as rats and mice, clearance of particles from the circulation predominantly 
occurs by hepatic Kupffer cells and splenic macrophages. In pigs and ruminants, on the 
other hand, PIMs are responsible for the rapid and efficient removal of blood-borne 
particles, including LPS, even before their hepatic passage (Winkler, 1988; Brain et al., 
1999). However, besides these excellent clearance capacities for blood LPS, PIMs also 
considerably contribute to the inflammatory response and the development of acute lung 
failure by the excessive release of inflammatory mediators, including vasoactive 
eicosanoids, after pathogen phagocytosis (Bertram, 1986; Winkler, 1988). It is therefore 
hypothesized that PIMs respond to LPS with a rapid and massive release of thromboxane 
A2 (TXA2), resulting in a severe pulmonary hypertension and possibly right heart 
dysfunction in pigs and calves (Ball et al., 1986; Klosterhalfen et al., 1992; Plessers et al., 
manuscript submitted). In pigs, peak plasma concentrations of TXB2, a stable metabolite of 
TXA2, are reported to appear as soon as 30 to 45 min after LPS challenge (Klosterhalfen et 
al., 1992; Mustonen et al., 2012a). Furthermore, the cytoplasmic presence of LPS in PIMs 
was confirmed as soon as 8-10 min after the IV administration of E. coli LPS in sheep, 
simultaneously with the development of pulmonary interstitial oedema (Singh and Atwal, 
1997). Also in pigs, LPS was found in lung macrophages (Nakajima et al., 1995). In the 
present study, pigs of the LPS and GAM groups showed marked respiratory symptoms 
before 15 min after LPS challenge, which is largely in accordance with the above-
mentioned findings. Administration of the COX-inhibitor KETO successfully prevented the 
development of severe pulmonary symptoms after LPS challenge in pigs of both the KETO 
and GAM-KETO groups, suggesting the involvement of eicosanoids. Only two pigs of both 
the KETO and GAM-KETO group showed a moderate and delayed tachypnea, while their 
clinical condition was not compromised. This might be attributed to the presence of high 
circulating TNF-α levels in both animals, since the latter cytokine has been reported to be, 
along with TXA2, involved in the pathogenesis of hypoxia, pulmonary oedema and 
hypertension (Li et al., 1995; Petrache et al., 2003). 
It is generally accepted that the prostaglandin PGE2 is responsible for the 
development of fever in mammals. It exerts its pyrogenic action by elevating the body 
temperature set point at the thermoregulatory center in the preoptic area of the anterior 
hypothalamus. Subsequently, fever is developed by an increased heat production and 
decreased heat loss (Baumann and Gauldie, 1994; Netea et al., 2000; Blatteis et al., 2005). 
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The half-life of PGE2 is estimated to be only a few seconds in plasma (Hamberg and 
Samuelsson, 1971; Bygdeman, 2003; Ivanov and Romanovsky, 2004). Due to this very rapid 
metabolism and the instability of its main metabolite 13,14-dihydro-15-keto PGE2, it is 
often preferred to quantify a more stable metabolite which in turn reflects the PGE2 
concentration (Granström et al., 1980). In the current study, the concentrations of both 
PGE2 and its inactive dehydration product PGE2-met were measured. Maximal plasma 
concentrations of PGE2 (data not shown) and PGE2-met were observed already at 1 h after 
LPS administration in the LPS and GAM groups. Accordingly, the RT of the pigs of both 
groups started to increase as soon as 0.5 h after LPS administration, reaching a maximum 
already at 2.5 h p.a. and normalizing by 8 h p.a. Earlier reports in pigs demonstrated a 
maximal febrile response at 4 h following LPS challenge (Johnson and von Borell, 1994; 
Warren et al., 1997; Leininger et al., 2000; Wright et al., 2000; Mustonen et al., 2012a). The 
occurrence of shivering in all pigs of the LPS and GAM groups was an external reflection of 
this enhanced heat production. In the present study GAM showed no inhibiting effect on 
the production of PGE2, which is inconsistent with some previous in vitro and in vivo studies 
on macrolide antibiotics (Ianaro et al., 2000; Cao et al., 2006). Since pigs of the KETO and 
GAM-KETO groups, on the other hand, showed no increase in either RT or PGE2 levels, a 
crucial role of PGE2 in the porcine febrile response was suggested. These in vivo results also 
confirmed our earlier in vitro data, as no PGE2 levels could be measured in the supernatant 
of LPS-stimulated porcine peripheral blood mononuclear cells (PBMCs) in both the KETO 
and GAM-KETO group. While PGE2-met, on the other hand, could not be measured in vitro 
in a buffer with similar pH and temperature, in vivo plasma levels of PGE2-met were formed 
considerably faster (Granström et al., 1980). 
As expected, increased levels of pro-inflammatory cytokines were observed 
following IV LPS administration. Plasma concentrations of TNF-α reached a major and sharp 
peak at 1 h p.a. of LPS in all groups, while IL-6 showed a more gradual increase and 
attained maximal levels at 2.5 h after LPS challenge in all groups. These findings in relation 
to these pro-inflammatory cytokines were largely in accordance to previous reports in pigs 
(Frank et al., 2003; Carroll et al., 2005; Williams et al., 2009). In contrast to TNF-α and IL-6, 
plasma concentrations of IL-1β could not be measured reproducibly. The latter results were 
in accordance with previous studies in which IL-1β has been reported either not detectable 
or not increasing in plasma after LPS challenge in pigs (Myers et al., 2003; Tuchscherer et 
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al., 2004; Llamas Moya et al., 2006; Ruud et al., 2007). In contrast, a significant increase of 
IL-1β following LPS administration has yet been formerly described in pigs (Frank et al., 
2003; John et al., 2008; Williams et al., 2009). In previous research from our group, a ready-
to-use ELISA (Quantikine®, R&D Systems), approved for use in porcine plasma, was applied 
and yielded a significant, albeit low maximal concentration of IL-1β at 3 h after LPS 
administration (Wyns et al., 2013). Since the less expensive ELISA (DuoSet®, R&D Systems) 
used in the present study was considered not suitable for measurement of IL-1β in porcine 
plasma and the IL-1β concentrations are again indicated to be relatively low, multiplex 
analysis of TNF-α, IL-1β and IL-6 might be a valuable and more sensitive alternative, as 
previously demonstrated (Wyns et al., 2013). The administration of neither GAM, KETO nor 
the combination of both drugs before LPS challenge, had a significant influence on the 
amplitude of the TNF-α and IL-6 concentrations after LPS challenge compared to the 
untreated LPS group. Although Donalisio et al. (2013) recently described an inhibiting effect 
of KETO on the ex vivo LPS-induced TNF-α production in dairy cows, it has previously been 
put forward that KETO has not the ability to inhibit NF-κB activation (Matasić et al., 2000). 
In our experiments, on the contrary, we have noticed that pigs of the KETO group even 
tended to show slightly enhanced plasma concentrations, yet not significant, of TNF-α and 
IL-6 after LPS challenge. Similar results were obtained in vitro, since LPS-stimulated porcine 
PBMCs of the KETO groups showed a trend to produce higher levels of TNF-α. Therefore, 
the current results in vivo confirm that NSAIDs, including KETO rather increase than 
decrease TNF-α production which has been associated with a significant increased 
mortality in animal models of endotoxic shock (Pettipher and Wimberly, 1994; Ghezzi et al., 
1998; Roth et al., 2002). It has been suggested that PGE2 is a feedback inhibitor of TNF-α 
production (Kunkel et al., 1988; Sironi et al., 1992). As mentioned before, no PGE2 levels 
could be quantified in the KETO group. Thus, and in marked contrast to most macrolide 
antibiotics studied so far, including azithromycin, clarithromycin, erythromycin, 
roxithromycin, telithromycin, tilmicosin and tylosin, GAM had no inhibiting effect on the 
LPS-induced production of cytokines in pigs. However, some macrolides have been 
occasionally reported to have no significant effect on cytokine production (Bailly et al., 
1991b; Er and Yazar, 2012).  
General sickness behaviour, including loss of appetite, nausea, vomiting and 
depression, is, along with the febrile response, regarded as a strategy of the host to 
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counter infection. These physiological changes are centrally mediated and pro-
inflammatory cytokines are assumed to have a major role in this process. Indeed, 
intracerebroventricular injection of TNF-α to pigs induces anorexia and depression (Warren 
et al., 1997). Two major pathways have been postulated to explain how peripherally 
released, hydrophilic cytokines can transfer immune signals to the central nerve system as 
they cannot passively pass the blood-brain barrier. These include a fast neural transmission 
via afferent vagal nerves from the site of inflammation and a slower humoral transmission 
to induce local cytokine production in the choroid plexus and circumventricular organs, 
where the blood-brain barrier is deficient. Additionally, local production of mediators, 
including PGE2 occurs in endothelial cells of brain vessels in animal and man (Konsman et 
al., 1999; Conti et al., 2004; Dantzer, 2009). IL-1β has been put forward to be a key cytokine 
for induction of behavioural changes following LPS challenge (Bluthé et al., 1991; 2000; 
Dantzer, 2009). Neuronal IL-1 receptors have been established in the circumventricular 
organ of the brainstem, where the area postrema is located. This could possibly explain the 
anorexia, nausea and vomiting observed following LPS challenge (Ericsson et al., 1995). 
Interestingly, the early clinical symptoms observed following LPS administration in pigs of 
the LPS and GAM group preceded the increasing levels of peripheral pro-inflammatory 
cytokines. Already at 15 and 20 min after LPS challenge, clear signs of nausea and 
subsequently vomiting were observed, respectively, whereas increasing plasma levels of 
TNF-α and IL-6 were recorded not earlier than 0.5 and 1.5h after LPS administration, 
respectively. Additionally, similar to the pigs of the LPS and GAM groups, pigs of the KETO 
and GAM-KETO groups displayed high cytokine levels in plasma, while showing no sickness 
behaviour at all. It has already been demonstrated that LPS-induced behavioural changes in 
pigs can be reversed by pretreatment with a COX-inhibitor (Johnson and von Borell, 1994; 
Friton et al., 2006; Mustonen et al., 2012a; Peters et al., 2012). The results of the present 
study therefore question the fundamental role for pro-inflammatory cytokines in the LPS-
mediated early sickness behaviour and rather suggest a pivotal role for arachidonic acid 
metabolites, more specifically PGE2. While COX-1 is mainly constitutively expressed in most 
cell types and is responsible for the production of PGs involved in a number of physiological 
functions, COX-2 is induced by diverse inflammatory stimuli and is responsible for the 
production of PGs in several inflammatory processes (Vane, 1971; Curry et al., 2005). 
Indeed, in contrast to the pigs of the LPS and GAM groups, those of the KETO and GAM-
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KETO groups, which were all pretreated with the COX-inhibitor KETO, demonstrated no 
quantifiable levels of PGE2 (data not shown) or PGE2-met, nor sickness behaviour. 
Paradoxically, the NF-κB-regulated transcription and de novo synthesis of cytokines and 
subsequently COX-2 requires considerable time, about 90 min, and hence the role of COX-2 
in generating early clinical symptoms or fever is controversial (Conti et al., 2004; Teeling et 
al., 2010). Of relevance, it has been ultimately hypothesized that COX-1-mediated PGE2 is 
induced by the immediate complement cascade activation by LPS and binding of the 
anaphylatoxic complement component C5a to hepatic Kupffer cells as soon as minutes 
after LPS administration (Blatteis et al., 2005). The PGE2 immune signal is then transferred 
to the brain via hepatic afferent nerves and possibly by passing the blood-brain barrier or 
diffusion in the brain parenchyma (Blatteis et al., 2005; Blatteis, 2007). Since it has been 
demonstrated that PIMs and not the Kupffer cells are the principal LPS-clearing 
mononuclear phagocytes in pigs, it is likely that the latter cells considerably contribute to 
the instant peripheral PGE2 synthesis after LPS challenge. Indeed, KETO is a non-selective 
COX-inhibitor, but is repeatedly reported to be relatively COX-1 selective in different 
animal species (Streppa et al., 2002; Curry et al., 2005; Donalisio et al., 2013). This might to 
some extent explain the often superior anti-inflammatory and antipyretic capacities of 
KETO compared to other, recently developed mainly COX-2 selective NSAIDs, including 
firocoxib (Jackman et al., 1994; Swinkels et al., 1994; Mustonen et al., 2012a; Salichs et al., 
2012). Interestingly, pigs of the GAM group showed a remarkable early and long-lasting 
depression phase following LPS challenge. Within one half h p.a. of LPS, most of the 
animals were already in lateral decubitus, which persisted until 7 h p.a. of LPS. It is 
generally accepted that macrolides accumulate within inflammatory cells, including 
monocytes and neutrophils, and thus can be accurately delivered in high concentrations to 
the bacterial infection site (Gladue et al., 1989; Čulić et al., 2001). Azalides, such as 
azythromcin and GAM have been reported to concentrate preferably within lung 
macrophages (Mattoes and Nightingale, 2002; Huang et al., 2010). Since the lung is a major 
target for both circulating LPS and GAM, it is not unthinkable that porcine PIMs and PIM-
related inflammatory mediators, including TXA2, contribute to the more severe symptoms 
of pigs of the GAM group in comparison to those of the LPS group. TXA2 has indeed been 
associated with more severe clinical symptoms (Ball et al., 1986; Mustonen et al., 2012a). 
Additionally, excipients included in the Zactran® formulation might also contribute to those 
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symptoms. Remarkably, only one pig of the GAM group showed lateral decubitus at a far 
later stage p.a. of LPS. However, this particular pig experienced a notable long-lasting 
irritation after its SC Zactran® injection, which appeared to prevent lateral decubitus 
despite severe LPS-related symptoms. 
Low basal concentrations of both APPs were detectable prior to LPS administration 
in all pigs and were in accordance with previous reports (Heegaard et al., 1998; Llamas 
Moya et al., 2006; Williams et al., 2009). Consequently, a major, negative impact of the 
previous surgery on APP levels could be excluded. Following LPS challenge, increased levels 
of pig-MAP and CRP were observed in all groups. The administration of GAM, KETO or the 
combination of both drugs (GAM-KETO) before LPS challenge revealed no major influences 
on APP production after LPS challenge. Similarly, it has been reported that meloxicam had 
no effect on the production of CRP and haptoglobin in LPS-challenged pigs (Friton et al., 
2006). Er and Yazar (2012), on the other hand, reported a decrease in LPS-induced CRP 
levels in bronchoalveolar lavage fluid of rats by tylosin, tulathromycin, and to a lesser 
extent by tilmicosin. However, at 36 h p.a. of LPS, the GAM and GAM-KETO groups 
demonstrated significantly higher concentrations of CRP compared to the LPS group. This 
might be explained and looks to be linked to the marked local inflammation reaction 
observed in pigs of the GAM and GAM-KETO group following the SC injection of the used 
GAM formulation. Local irritation has also been quoted after administration of macrolides 
(Zhanel et al., 2001). In some reports, local inflammation induced by a SC turpentine 
injection has been reported to elicit also considerable systemic CRP concentrations in pigs 
(Lampreave et al., 1994; Eckersall et al., 1996).  
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In conclusion, KETO was demonstrated to have a clear inhibiting effect on PGE2 
production and the development of fever, pulmonary symptoms and general sickness 
behaviour. Therefore, it can be hypothesized that the combination of GAM and KETO, 
would be beneficial compared to the administration of exclusively GAM. Preliminary in 
vitro research indeed confirmed the inhibition of TNF-α, yet not significant, IL-1β and IL-6 
production by LPS-stimulated PBMC when adding both GAM and KETO to the cells. Apart 
from the inconvenience and local inflammation reaction related to the Zactran® injection, 
no differences were observed between KETO and GAM-KETO concerning clinical 
symptoms, RT, cytokines and APP in this study. However, beneficial effects of GAM could 
be demonstrated in an appropriate bacterial infection model. 
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CHAPTER 3.  
Comparative study of immuno-assays for cytokine detection:  
ELISA vs flow cytometry 
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3.1. Development of a cytometric bead array screening tool for the simultaneous 
detection of pro-inflammatory cytokines in porcine plasma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from  
Wyns, H., Croubels, S., Demeyere, K., Watteyn, A., De Backer, P., Meyer, E. (2013) 
Development of a cytometric bead array screening tool for the simultaneous detection of 
pro-inflammatory cytokines in porcine plasma. Veterinary Immunology and 
Immunopathology 151, 28-36. 
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Abstract 
 
Lipopolysaccharide (LPS) has been widely used as a model of immune challenge in 
pigs as it induces the immediate synthesis of pro-inflammatory cytokines such as tumor 
necrosis factor (TNF)- α, interleukin (IL)-1β and IL-6, which trigger the production of the 
acute phase proteins (APPs) C-reactive protein (CRP), haptoglobin (Hp) and pig-major acute 
phase protein (pig-MAP). To measure secreted proteins in porcine plasma, specific and 
sensitive enzyme-linked immuno sorbent assays (ELISAs) are well-suited to perform single 
parameter analysis, yet this approach is time-consuming and expensive for multi-
parameter analyses. During the last decade, multiplex bead-based flow cytometry has been 
increasingly applied as it offers the opportunity to estimate protein ratios in a small sample 
volume.  
Cytometric bead array (CBA) is a flow cytometric application using a diversity of 
beads with unique fluorescence intensities, covalently coupled to a capture antibody for 
each protein of interest. Detection antibodies, either directly or indirectly conjugated to a 
fluorochrome, are added to accomplish the desired sandwich format. The aim of the 
present study was to develop a CBA 3-plex assay for the major pro-inflammatory cytokines 
TNF-α, IL-1β and IL-6, and an additional CBA 2-plex assay for the major APPs, CRP and pig-
MAP, in porcine plasma. Results were compared to commercial ELISA kits. For the CBA 3-
plex assay, the limits of detection (LODs) varied between 0.005 and 0.363 ng/mL, the intra- 
and inter-assay coefficients of variation were < 10 % and < 16 %, respectively. For TNF-α, IL-
1β, IL-6 and pig-MAP, CBA time-concentration profiles similar to those obtained with 
commercial ELISAs were observed. In conclusion, the novel validated CBA 3-plex assay 
provides a fast and economical screening tool for determination of pro-inflammatory 
cytokine profiles in limited porcine plasma volumes. This tool will be applied to study the 
immunomodulatory properties of drugs in a porcine LPS inflammation model. This study 
also demonstrated the applicability of CBA for measurement of APPs in pigs, although a 
different combination than pig-MAP with CRP is recommended. 
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1. Introduction 
 
Lipopolysaccharide (LPS), an intrinsic component of the outer membrane of Gram-
negative bacteria such as the ubiquitous Escherichia coli (E. coli), is a potent stimulator of 
the immune system. When released from bacteria during cellular division or lysis, it elicits 
the synthesis and release of pro-inflammatory cytokines such as tumor necrosis factor 
(TNF)-α, interleukin (IL)-1β and IL-6, which orchestrate the acute phase response by 
inducing fever and stimulating hepatocyte production of acute phase proteins (APPs) 
(Baumann and Gauldie, 1994; Feghali and Wright, 1997). The immune response following 
challenge with a diversity of LPS doses and serotypes has been widely studied in pigs 
(Webel et al., 1997; Frank et al., 2003; Myers et al., 2003; Carroll et al., 2005; Llamas Moya 
et al., 2006; Williams et al., 2009). Important APPs in this species are C-reactive protein 
(CRP) and haptoglobin (Hp) (Lampreave et al., 1994; Eckersall et al., 1996; Alava et al., 
1997). Less studied, is a 120-kDa glycoprotein, named pig-major acute phase protein (pig-
MAP), though the latter has been described as particularly relevant in pigs (Lampreave et 
al., 1994) and as an excellent biomarker of different porcine pathologies (Alava et al., 
1997). 
To measure secreted proteins in porcine plasma or serum, researchers commonly 
rely on enzyme-linked immuno sorbent assays (ELISAs) (Frank et al., 2003; Llamas Moya et 
al., 2006; Williams et al., 2009). Indeed, ELISAs are highly specific and sensitive and are still 
considered as the gold standard (Elshal and McCoy, 2006). However, they are restricted to 
the quantitation of only one parameter at a time and are consequently time-consuming 
and expensive for multi-parameter screening analyses. Moreover, since the procedure has 
to be repeated for every analyte of interest it requires multiple sample aliquots. 
Additionally, dilution steps are often indispensable to fit the generally narrow calibration 
range. Therefore, porcine research would benefit from a more elegant immuno-assay 
strategy allowing the fast simultaneous profiling of a number of selected parameters in a 
limited sample volume. In line with this need, an increasing number of multiplex bead-
based flow cytometric protocols were reported which capture the secreted analytes of 
interest on target particles (Carson and Vignali, 1999; Jiménez et al., 2005; Heijmans-
Antonissen et al., 2006). Both the Luminex xMAP and the cytometric bead array (CBA) 
technologies use a diversity of beads with unique fluorescence intensities, covalently 
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coupled to a capture antibody for each protein of interest. Subsequently, detection 
antibodies, either directly or indirectly conjugated to a fluorochrome, are added to 
accomplish the desired sandwich format. Compared to ELISA, multiplex bead-based assays 
minimize the sample volume and analysis time while maximizing the number of proteins 
that can be simultaneously analyzed (Morgan et al., 2004). The latter approach also 
provides a wider dynamic range limiting the required number of dilutions. Furthermore, 
particles in suspension are assumed to be more efficient in capturing soluble antigens than 
the immobilized antibodies on the surface of ELISA wells (Tarnók et al., 2003). While ELISAs 
typically use enzyme amplification of a colorimetric substrate, multiplex bead-based assays 
use a fluorescence reporter system. In addition, multiplexing allows to estimate the protein 
ratio in a sample, which might be even more biologically relevant than absolute 
concentrations since interacting proteins can significantly alter each other’s functions 
(Kelso, 1998). Another advantage of multiplex bead-based assays is their flexibility, 
enabling addition and withdrawal of proteins (Tarnók et al., 2003). Nevertheless, a 
powerful CBA tool is currently lacking in porcine research.  
Generally, multiplex bead-based assays for human and murine cytokines are well-
documented in marked contrast to the scarce reports for their porcine homologues. In 
2006, Johannisson et al. multiplexed 3 porcine pro-inflammatory mediators, i.e. TNF-α, IL-
1β and IL-8, in pig serum and plasma by means of the Luminex xMAP technology. More 
recently, Bjerre et al. (2009) developed both a 4-plex Luminex assay for TNF-α, IL-6, IL-8 
and IL-10, and a 2-plex assay for IL-1β and heat shock protein (Hsp) 32 in pig plasma. In 
2010, Lawson et al. created an 8-plex Luminex assay to simultaneously detect the swine 
cytokines TNF-α, IL-1β, IL-4, IL-8, IL-10, IL-12, IFN-α and IFN-γ. These Luminex assays 
require a specialized Luminex instrument. CBA, on the other hand, can be performed on a 
common dual-laser flow cytometer, which is an attractive feature of CBA (Elshal and 
McCoy, 2006). 
The aim of this study was to develop a CBA 3-plex assay combining for the first time 
the major pro-inflammatory cytokines TNF-α, IL-1β and IL-6, and an additional CBA 2-plex 
assay for the major APPs CRP and pig-MAP in porcine plasma after LPS-challenge. Using 
commercial ELISAs for each of these mediators, a critical comparison between both 
immuno-assays was made. 
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2. Materials and methods 
 
2.1. Experimental design 
 
Ultrapure LPS from E. coli serotype O111:B4 was purchased from Cayla-InvivoGen. 
Four male pigs (Seghers Hybrid), with a mean (± SD) body weight (BW) of 24.9 ± 3.17 kg 
were intravenously challenged with 15 µg LPS/kg BW through the proximal lumen of a 
double-lumen jugular catheter (13 G, 60 cm, Arrow) (Gasthuys et al., 2009). Rectal body 
temperature was measured and blood samples were collected from the distal lumen of the 
catheter at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 12, 24, 36 and 48 h after LPS administration. 
The samples were collected in EDTA-coated tubes, immediately placed on ice and 
centrifuged (500 x g for 10 min at 4 °C) within 2 h. Subsequently, plasma was isolated, 
aliquoted into polypropylene microcentrifuge tubes and stored at ≤ -70 °C until analysis. 
All procedures were approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of Ghent University (EC 2009/099 and 2010/072). 
 
2.2. Covalent coupling of capture antibodies to functional beads 
 
A CBA Functional Bead Conjugation Buffer Set was purchased from Becton 
Dickinson Biosciences (BD). Capture antibodies were covalently coupled to the surface of 
different color-coded 7.5 µm polystyrene functional beads according to the manufacturer’s 
instructions (Table 1). All functional beads have distinct fluorescence intensities and an 
alphanumeric label (A4 to E9) is assigned to each bead population, indicating its position 
relative to the other beads. As a result, beads with different positions can be combined to 
create a multiplex assay. DL-Dithiothreitol (DTT) and N-ethylmaleimide (NEM) (Sigma-
Aldrich), sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) 
(Thermo Scientific) and  Bio-Spin® 30 Tris Columns (Bio-Rad Laboratories) were used. The 
integral procedure was carried out at room temperature efficiently protecting functional 
beads and antibodies from light. Washing step centrifugations were performed at 900 x g 
for 3 min and incubation was performed on a shaker (BioSan Mini-Rocker).  
Briefly, the selected beads (at positions A7, B4, B8, D5 and D9) were vortexed 
thoroughly for 30 s after which 75 µL of bead suspension was transferred into a 
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polypropylene microcentrifuge tube and sonicated during 1 min. After addition of 1.9 µL 
1M DTT the tube was vortexed for 5 s and incubated for 1 h. Subsequently, the beads were 
washed 4 times with 1 mL of coupling buffer and the bead pellet was finally resuspended in 
20 µL of coupling buffer. Next, 2 µL of sulfo-SMCC was added to 90 µg of capture antibody 
at a stock concentration of 1 mg/mL in a polypropylene microcentrifuge tube to accomplish 
the protein modification. The tube was again vortexed for 5 s and incubated for 1 h. A Bio-
Rad Spin Column was inverted vigorously several times, placed into a 12 x 75 mm 
polystyrene test tube (BD) and centrifuged at 1000 x g for 2 min to remove the packing-
buffer. The Spin Column was then completely filled 3 times with coupling buffer, placed 
into a clean test tube and centrifuged at 1000 x g for 1 min. In order to remove unreacted 
components, the antibody/sulfo-SMCC solution was completely transferred to the Spin 
Column and centrifuged at 1000 x g for 2 min and 15 s. The modified antibody was then 
transferred to the tube with beads, again vortexed for 5 s and incubated for 1 h. After 
addition of 2 µL of NEM, the tube was vortexed for 5 s and incubated for 15 min. 
Subsequently, the beads were washed 4 times with 1 mL of storage buffer. Finally, the 
bead pellet was resuspended in 500 µL of storage buffer at a final concentration of 
approximately 6 x 106 beads/mL and stored in the dark at 2 - 8°C. 
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Table 1. Antibodies, beads and standards used in the CBA 3-plex assay 
*The pig-MAP antibodies and standard were kindly donated by Dr. M. Piñeiro (PigCHAMP Pro 
Europe S.A.); **The standards were used from the respective ELISA kits 
 
 
 
 
Analyte Reagent Catalog # 
Description / 
Beadposition 
Source 
TNF-α capture Ab 
detection Ab 
standard 
functional bead 
MP390 
MP391 
RPTNFAI 
558657 
mAb Mouse IgG1 
mAb Mouse IgG1 
recombinant protein 
D9 
Thermo Scientific 
Thermo Scientific 
Thermo Scientific 
BD 
IL-1β capture Ab 
detection Ab 
standard 
functional bead 
MAB6811 
BAF681 
681-PI 
560035 
mAb Mouse IgG1 
Biotinylated  pAb Goat IgG 
recombinant protein 
B4 
R&D Systems 
R&D Systems 
R&D Systems 
BD 
IL-6 capture Ab 
detection Ab 
standard 
functional bead 
AF686 
BAF686 
686-PI-025 
560033 
pAb  Goat IgG 
Biotinylated pAb Goat IgG 
recombinant protein 
A7 
R&D Systems 
R&D Systems 
R&D Systems 
BD 
Pig-MAP capture Ab 
detection Ab 
standard 
functional bead 
AbM1* 
AbM3* 
ELISA** 
558583 
mAb Mouse IgG2A 
mAb Mouse IgG1 
diluted serum fraction 
D5 
PigCHAMP Pro Europa S.A. 
PigCHAMP Pro Europa S.A. 
PigCHAMP Pro Europa S.A. 
BD 
CRP capture Ab 
detection Ab 
standard 
functional bead 
18-374-130062 
MAB1707 
ELISA** 
558581 
pAb Chicken IgY 
mAb Mouse IgG2A 
- 
B8 
GenWay Biotech 
R&D Systems 
ALPCO Diagnostics 
BD 
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Coupling of antibodies to the beads was confirmed by appropriate fluorochrome-
conjugated secondary antibodies. Depending on the used fluorochrome, analyses were 
performed either on a BD FACSCantoTM flow cytometer, equipped with a 488 and 633 nm 
laser or on a BD FACSArrayTM Bioanalyzer, equipped with a 532 and 635 nm laser. When 
the signal of the test sample was at least a median fluorescence intensity (MFI) of 500 
higher than the MFI signal of the negative control sample, the coupling was considered 
successful. 
 
2.3. Conjugation of detection antibodies to R-Phycoerythrin 
 
A Lightning-LinkTM (LL) R-Phycoerythrin (R-PE) conjugation kit was used for the R-PE 
conjugation of the TNF-α, CRP and pig-MAP detection antibodies according to the 
manufacturer’s instructions (Innova Biosciences).  
 
2.4. CBA multiplex assays 
 
2.4.1. CBA 3-plex assay for TNF-α, IL-1β and IL-6 
 
Antibodies, beads and standards used in the CBA 3-plex assay are listed in Table 1. 
The CBA Human Enhanced Sensitivity Master Buffer Kit was also obtained from BD. Indeed, 
because of the inclusion of the more sensitive commercial biotinylated detection 
antibodies in this porcine CBA, a two-step detection system was required. Bead-coupled 
capture antibodies (A7, B4 and D9) were sonicated and vortexed. For the assay, 1 µL/test 
of each capture bead was mixed and diluted in capture bead diluent to a total volume of 50 
µL/test. Recombinant porcine TNF-α, IL-1β and IL-6 were carefully mixed and diluted in 
assay diluent to generate appropriate standard curves (0.0, 0.5, 1.0, 2.5, 5.0, 7.5, 10, 20, 50 
ng/mL). EDTA-plasma samples were vortexed thoroughly and diluted 1/4 with assay 
diluent. A new aliquot of recombinant cytokines and plasma samples was used for each 
assay to avoid repeated freeze-thaw cycles. A mixture of detection antibodies (200, 100 
and 50 ng/test for TNF-α, IL-1β and IL-6, respectively) was prepared and diluted in 
detection reagent diluent. The assay was carried out in a polypropylene 96-well plate with 
V-bottom (BD). First, 100 µL of wash buffer was added to the wells and completely 
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removed, then 50 µL of each standard concentration or diluted plasma samples were 
applied to the plate. Subsequently, 50 µL of the bead mixture was added to each well. The 
plate was covered with a plate sealer, gently vortexed and incubated for 30 min in the dark 
at room temperature. Next, 50 µL of the detection antibody mixture was added to each 
well and the plate was covered, vortexed and incubated for 2 h as mentioned above. After 
incubation, the plate was centrifuged at 200 x g for 5 min and the supernatant was gently 
discarded. Next, 150 µL of wash buffer was added to the wells, the plate was centrifuged 
once more at 200 x g for 5 min and the supernatant was gently discarded. Enhanced 
sensitivity detection reagent was prepared following the manufacturer’s instructions and 
100 µL was added to each well. The plate was covered, vortexed and incubated for 1 h. 
After incubation, the plate was centrifuged at 200 x g for 5 min and the supernatant was 
gently discarded. Next, 150 µL of wash buffer was added to the wells, the plate was 
vortexed and immediately analyzed on a validated BD FACSArrayTM Bioanalyzer. The flow 
cytometer was calibrated with set-up beads and 1500 events were acquired for each well. 
After forward versus side scatter gating of the 7.5 µm beads, the different bead 
populations were displayed in a 2-color dot plot (Near-infrared vs. Red). For each bead, the 
PE-signal was measured as a parameter for the analyte concentration. Subsequently, data 
were analyzed by means of the FCAPArrayTM software (BD). A 4-parameter logistic 
regression model was used to fit the curve. 
 
2.4.2. CBA 2-plex assay for pig-MAP and CRP 
 
Antibodies, beads and standards used in the CBA 2-plex assay are listed in Table 1. 
For this purpose, a CBA Human Soluble Protein Master Buffer Kit was used (BD). With the 
exception of the following variations, the 2-plex assay was performed similar to the 3-plex 
assay. The capture beads for standard samples were mixed and diluted in regular capture 
bead diluent, yet, the capture beads for plasma samples were mixed and diluted in capture 
bead diluent for serum/plasma. Standard curves for CRP (0.0, 15.6, 31.3, 62.5, 125, 250, 
500, 750, 1000 ng/mL) and pig-MAP (0.0, 156, 312, 625, 1250, 2500, 5000, 7500, 10000 
ng/mL) were prepared in assay diluent. EDTA-plasma samples were vortexed thoroughly 
and diluted 1/1000 with assay diluent. Unlike the 3-plex assay, 50 µL of the bead mixture 
was first added to the wells. After adding the detection antibody mixture to the wells (200 
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ng/test for both CRP and pig-MAP), the plate was incubated for 2.5 h before flow 
cytometric analysis.  
 
2.5. Validation of the CBA 3-plex assay for TNF-α, IL-1β and IL-6 
 
The limit of detection (LOD) was determined for each cytokine and defined as the 
lowest detectable cytokine concentration within the linear range of the individual cytokine 
standard curve in the multiplex assay. The LOD was calculated by evaluation of 7 standard 
curves for each of the three cytokines. 
Intra-assay variation was evaluated for each cytokine by analyzing multiple 
replicates (n = 6) of a sample with a known concentration of recombinant protein (5000 
pg/mL) spiked in a 1/4 diluted plasma pool prepared from 5 healthy pigs. 
Inter-assay variation was determined for each cytokine by evaluating the MFI-values 
of 2 different plasma samples of an LPS-challenged pig in duplicate, which were each 
analysed on 3 different days. Intra- and inter-assay coefficients of variation (CVs) were 
subsequently calculated for each cytokine. 
 
2.6. ELISAs 
 
Porcine cytokines and APPs were also analyzed using 6 ready-to-use porcine ELISA 
kits. TNF-α, IL-1β and IL-6 kits were all purchased from R&D Systems (Quantikine® ELISA 
PTA00, PLB00B and P6000B, respectively). The dynamic ranges of these assays were 0.023 
to 1.500 ng/mL, 0.039 to 2.500 ng/mL and 0.010 to 1.200 ng/mL, respectively. Table 2 
summarizes the LODs, intra- and inter-assay variations of the ELISAs as provided by the 
manufacturer. The pig-MAP ELISA was obtained from PigCHAMP Pro Europe S.A., while 
concentrations of CRP were determined using porcine-specific immuno-assays from both 
Tridelta Development Ltd and ALPCO Diagnostics. The dynamic ranges of these assays were 
440 to 3500 ng/mL, 46.9 to 1500 ng/mL and 6.25 to 200 ng/mL, respectively. All ELISAs 
contained precoated 96-well plates and were performed as described by the 
manufacturers. Optical densities were determined using a plate reader (Multiskan MS 
Labsystems, Thermo Scientific). Data were analyzed by means of DeltaSoft JV (BioMetallics 
Incorporated). 
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Table 2. Limits of detection (LOD), mean intra- and inter-assay variations (CV %) and 
dynamic ranges of each cytokine in the in-house validated CBA 3-plex assay and 
commercially available ELISAs (R&D Systems) 
Cytokine LOD (ng/mL) Intra-assay (CV %) Inter-assay (CV %) Dynamic range (ng/mL) 
CBA ELISA CBA ELISA CBA ELISA CBA ELISA 
TNF-α 0.363 0.004 8.45 4.86 15.71 8.90 0.50 - 50 
 
0.023 - 1.50 
 
IL-1β 0.109 0.007 2.26 5.77 15.48 6.27 0.50 - 50 0.039 - 2.50 
IL-6 0.005 0.002 2.33 4.00 11.41 5.97 0.50 - 50 0.010 - 1.20 
LOD: limit of detection; CV: coefficient of variation 
 
2.7. Statistical analysis 
 
A linear mixed model with pig as random effect was fitted for the 3 different 
cytokines. The fixed categorical effect was time after administration. Comparisons to time 
0 were adjusted according to the Bonferroni technique and the corresponding adjusted p-
values are reported for CBA.  
A Pearson’s correlation coefficient (r) was determined for the single plex vs. 
multiplex comparisons of TNF-α, IL-1β and IL-6. The level of significance was α = 0.05. All 
values represent mean + standard deviation (SD). Statistical analysis was performed using 
SPSS Version 20.0 for Windows. 
 
3. Results 
 
3.1. Selection of the capture-detection antibody pairs 
 
To establish appropriate antibody pairs for the 3-plex assay, diverse combinations 
of commercially available antibodies were tested. The selected compatible antibody pairs 
are shown in Table 1. For IL-1β and IL-6, respectively 5 and 3 combinations of antibodies 
evaluated as capture and/or as detection antibody were considered unsuitable and 
therefore excluded for use in our CBA assay for porcine plasma samples (Table 3).  
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For CRP, the 18-374-130062 (GenWay Biotech) / PP169 (Tridelta Development Ltd) 
antibody pair was considered unsuitable for use in our CBA assay for porcine plasma 
samples. 
 
Table 3. Incompatible pairs of antibodies 
Analyte Capture Ab Source Detection Ab Source 
IL-1β PP425 
 
MAB6811 
 
MAB6811 
 
MAB681 
 
PP425 
Thermo Scientific 
 
R&D Systems 
 
R&D Systems 
 
R&D Systems 
 
Thermo Scientific 
PP425 
 
MAB681 
 
PP425 
 
MAB6811 
 
MAB681 
Thermo Scientific 
 
R&D Systems 
 
Thermo Scientific 
 
R&D Systems 
 
R&D Systems 
IL-6 PP690 
 
MAB6861 
 
MAB6861 
Thermo Scientific 
 
R&D Systems 
 
R&D Systems 
PP690 
 
PP690 
 
MAB686 
Thermo Scientific 
 
Thermo Scientific 
 
R&D Systems 
CRP 18-374-130062 GenWay Biotech PP169* Tridelta 
*The CRP detection antibody was kindly donated by M. Gallagher (Tridelta Development Ltd) 
 
3.2. Confirmation of adequate bead conjugation for selected capture antibodies 
 
As a first step in the development of the 3-plex and 2-plex assays, the successful 
coupling of the 5 selected capture antibodies to their beads had to be confirmed. For this 
purpose, the MFI of each test sample was compared to the MFI of a negative control 
sample. The following MFI values of test vs. control samples were obtained for the 5 
parameters included in our CBA set-up: TNF-α (235325 vs. 93), IL-1β (199834 vs. 109), IL-6 
(261294 vs. 171), pig-MAP (229180 vs. 61) and CRP (262143 vs. 192). These data clearly 
indicated that all 5 bead conjugations were adequately performed, as the manufacturer 
considers a capture antibody-bead coupling step successful when the MFI signal of the test 
sample exceeds that of the negative control sample at least 500 times. 
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3.3. Validation of the CBA 3-plex assay for TNF-α, IL-1β and IL-6 
 
Representative standard curves of the CBA 3-plex cytokine assay are shown in 
Figure 1, while Table 2 reports its corresponding LODs, intra- and inter-assay CVs and 
dynamic ranges. The LODs were found to be acceptable, varying between 0.005 and 0.363 
ng/mL. The intra-assay CVs were also satisfactory and ranged from 2.26 to 8.45%. As 
expected, the inter-assay CVs were found to be higher than those obtained within-day and 
ranged from 11.41 to 15.71%. The dynamic ranges of the standard curves for TNF-α, IL-1β 
and IL-6 ranged from 0.50 to 50 ng/mL. The comparison between both immuno-assays is 
described in the next paragraph. 
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Figure 1. Representative standard curves of TNF-α, IL-1β and IL-6 from the CBA 3-plex 
assay. Each standard curve shows median fluorescence intensities (MFIs) presented as 
mean ± SD obtained from 5 independent assays. 
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3.4. Analysis of porcine plasma samples after LPS-challenge 
 
3.4.1. CBA 3-plex assay for TNF-α, IL-1β and IL-6 
 
Plasma samples from LPS-challenged pigs were analysed using the developed CBA 
3-plex cytokine assay and levels were compared to the results obtained by commercially 
available ELISAs. A single 1/4 dilution was found to be sufficient for all time points to fit the 
dynamic range of the standard curves, while for the ELISAs dilutions ranging from 1/2 to 
1/100 were required. As expected, the intravenous administration of 15 µg/kg BW LPS 
induced a time-dependent increase of cytokines in all pigs (n = 4). For the three cytokines 
measured, a similar trend was observed with both immuno-assay techniques as shown in 
Figure 2. Prior to LPS administration, systemic concentrations of TNF-α were very low. 
However, plasma levels of TNF-α rapidly increased after LPS administration, reaching peak 
concentrations at 1 h post administration (p.a.) (p < 0.0005 for CBA and ELISA). Plasma TNF-
α already resumed levels comparable to basal levels at 6 h p.a. Similar to TNF-α, IL-6 
concentrations prior to LPS administration were negligible. Following LPS administration, 
IL-6 increased to maximal concentrations at 2.5 h (p = 0.019 for CBA), whereas basal 
concentrations were not yet resumed at 6 h p.a. Remarkably, CBA, and to a lesser degree 
also ELISA, demonstrated elevated IL-1β plasma levels already prior to LPS administration. 
After a gradual increase, maximal concentrations of IL-1β were attained at 3 h p.a. (p = 
0.005 for CBA) and similar to IL-6, these systemic levels remained elevated at 6 h p.a. In 
contrast to CBA, the results obtained for IL-1β and IL-6 by ELISA were not significantly 
different compared to time 0. 
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Figure 2. Mean (+ SD) plasma concentration-time curves of TNF-α, IL-1β and IL-6 obtained 
from LPS-challenged pigs (n = 4). Adjusted p-values are reported as a (p < 0.0005), b (p = 
0.033), c (p = 0.004), d (p = 0.005), e (p = 0.039), f (p = 0.019) and g (p = 0.026). 
Concentrations were measured using both ELISA (left panel) and CBA (right panel). Note 
that the detection sensitivities, mentioned in Table 2 allowed the reliable quantification of 
all 3 parameters for both ELISA and CBA. Remarkable differences between both techniques 
were however observed for IL-1β and IL-6. 
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Before the CBA 3-plex assay, it was attempted to develop a CBA 4-plex assay for the 
simultaneous detection of TNF-α, IL-1β, IL-6 and pig-MAP. This 4-plex analysis of LPS-
challenged porcine plasma generated comparable results as with the CBA 3-plex assay 
(data not shown). Furthermore, the CBA 4-plex assay was successfully compared to the 
single plex assays for all three cytokines as illustrated in Figure 3. Nevertheless, finally a 
CBA 3-plex and an additional CBA 2-plex format was preferred since the peak 
concentrations of cytokines and APPs severely differ in order of magnitude and time points 
after LPS administration. 
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Figure 3. Comparison of median fluorescence intensities (MFIs) between the CBA 4-plex 
assay (solid rhomb) and the single plex assays (open rhomb) of TNF-α, IL-1β and IL-6. 
Pearson’s correlation coefficients were 0.999, 0.995 and 0.999, respectively (p < 0.05). 
Note different scales on the y-axes for TNF-α, IL-1β and IL-6. 
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3.4.2. CBA 2-plex assay for pig-MAP and CRP 
 
Representative standard curves of the CBA 2-plex APP assay are shown in Figure 4. 
Considerable plasma levels of pig-MAP were detected prior to LPS administration, which 
gradually increased to maximal concentrations at 24 h p.a. Systemic pig-MAP levels 
remained elevated at 36 p.a. A similar trend was observed with ELISA as shown in Figure 5. 
 
   
Figure 4. Representative standard curves of pig-MAP and CRP from the CBA 2-plex assay. 
Each standard curve shows median fluorescence intensities (MFIs) presented as means and 
standard deviations obtained from 3 independent assays. 
 
 
It should be remarked that inclusion of CRP in a CBA 2-plex format with pig-MAP 
severely decreased the measured plasma concentrations of pig-MAP in comparison to the 
CBA single plex and 4-plex analysis (Figure 5). Moreover, for CRP, no plasma levels were 
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detectable with this CBA 2-plex assay. Results for CRP obtained using the Tridelta ELISA 
were too dubious and consequently could not be taken into account (data not shown). It 
should be remarked that in line with our observations, Slagman et al. (2011) also 
considered the results generated by the latter immuno-assay as controversial. Conversely, 
the ALPCO ELISA demonstrated low plasma concentrations of CRP prior to LPS-challenge, 
reaching maximal concentrations at 24 h p.a. Systemic CRP levels also remained elevated at 
36 h p.a. (data not shown). 
 
 
 
Figure 5. Mean (+ SD) plasma concentration-time curves of pig-MAP obtained from LPS- 
challenged pigs (n = 4). Concentrations were measured using ELISA (A), CBA single plex (B), 
CBA 2-plex (C) and CBA 4-plex (D) assays. Note different scales on the y-axes. 
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4. Discussion 
 
This is the first CBA study describing a validated multiplex protocol for the 
simultaneous measurement of the major porcine pro-inflammatory cytokines TNF-α, IL-1β 
and IL-6. Additionally, a concept for porcine APPs is provided. This technology was used to 
analyze porcine plasma samples obtained in an LPS inflammation model and the results 
were compared to those obtained with commercial ELISA kits.  
Similar concentration-time profiles were observed for all three cytokines and for 
pig-MAP with CBA and ELISA in plasma from LPS-challenged pigs. However, the absolute 
concentrations of the systemic cytokines and APP were found to differ considerably.  
The acceptance by the scientific community of multiplex bead-based assays largely 
depends on achieving similar results as with ELISA, which is still generally considered as the 
gold standard. However, comparisons between multiplex assays and ELISA kits are only 
straightforward when the same antibodies and cytokine standards are used in both 
immuno-assay formats (Chen et al., 1999; Khan et al., 2004). Several divergent absolute 
concentrations between both types of immuno-assays have been reported and attributed 
to the use of reagents from different manufacturers (Prabhakar et al., 2002; Ray et al., 
2005; Maier et al., 2006). To develop our CBA 3-plex assay, we also used different 
antibodies and standards than those used in the commercial porcine ELISA kits. 
Furthermore, the CBA concept with capture beads in suspension versus surface-coated in 
ELISA, as well as the execution of both procedures and the final analysis method, imply 
major dissimilarities between the two immuno-assays. 
As the primary focus of our developed methodology lays on the time- and cost-
efficient study of relative changes in the systemic levels of TNF-α, IL-1β and IL-6 after LPS-
challenge in pigs, the results currently obtained with the novel CBA 3-plex assay serve our 
purpose. Moreover, multiplex flow cytometry additionally allows the estimation of the 
cytokine ratio in a biological sample, which might be more relevant than absolute 
concentrations. Since cytokines interact in a complex immunological network, multiplexing 
carried out on analytes in suspension may even provide a more accurate view of the 
immune response than the single parameter and surface-immobilized ELISA strategy. 
Furthermore, results obtained with multiplex bead-based assays are generally more 
accurate since these are calculated from the mean of at least 300 beads, each functioning 
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as an individual replicate. In contrast, ELISA data are derived from a single reading of an 
individual well (Carson and Vignali, 1999). Consequently, CBA provides a suitable screening 
tool for large sample numbers. Our CBA 3-plex data corroborate those from Williams et al. 
(2009) who reported similar cytokine profiles with ELISA after an intravenous LPS-challenge 
in pigs except for a second peak of IL-6 at 3.5 h p.a. Although the presence of plasma IL-1β 
prior to LPS-challenge in the current study was rather unexpected, Myers et al. (2003) also 
detected constitutive plasma levels of this cytokine with ELISA. According to Dernfalk et al. 
(2007), comparisons of the (absolute) concentrations obtained with multiplex bead-based 
assays and ELISA kits are rather redundant, since a standard curve of recombinant protein 
is included in each immuno-assay providing an adequate internal control. 
Notwithstanding the fact that generally ELISA kits are specific, sensitive and well-
suited to perform single parameter analysis, some limitations have to be taken into 
account. For our porcine cytokine ELISAs, 50 µL of plasma and a total incubation time of 4.5 
h were required per cytokine, while the CBA 3-plex assay for simultaneous quantitation of 
TNF-α, IL-1β and IL-6 required 50 µL of plasma and a total incubation time of 3.5 h.  In our 
CBA 3-plex assay, LODs were higher than in the respective ELISAs (Table 2). On the other 
hand, the dynamic range of ELISAs only covered 2 to 3 logs, as mentioned above, whereas 
CBA substantially expanded this range to 4 logs, which is particularly attractive for the 
measurement of samples from an LPS inflammation model as few sample dilutions will 
suffice.  
Although this implies that the CBA 3-plex assay presented here does not allows the 
detection of equally low concentrations, it is certainly a valuable tool to screen a panel of 
porcine biomarkers of which high systemic levels are typically expected during severe 
inflammation.  When we consider the reported LODs either in comparable porcine or in 
bovine 3-plex Luminex assays, i.e. those developed by Johannisson et al. (2006) (range 0.92 
- 12 ng/mL) and Dernfalk et al. (2007) (range 2.0 - 6.5 ng/mL), respectively, our LODs 
certainly are acceptable. On the other hand, for TNF-α and IL-1β, Bjerre et al. (2009) 
achieved lower LODs in their multiplex assays, respectively 0.010 and 0.020 ng/mL, but for 
optimal sensitivity the assays had to be performed as a 4-plex and 2-plex assay. 
The intra-assay CVs of the CBA 3-plex assay were < 10 %, which is considered acceptable. 
As a result, the use of duplicate samples becomes redundant, again saving both time and 
sample volume. Although we recognize that the inter-assay CVs were higher, a low inter-
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assay variation is only important to compare analysis results in studies where repeated 
analyses are performed over a longer period of time. We therefore recommend to perform 
analyses preferably within one day which should reduce analytical variation to a minimum.  
Both the CBA and Luminex xMAP techniques, are increasingly applied in human 
(clinical) and mouse (preclinical) research. Indeed, to date commercial CBA kits are offered 
for a wide variety of analytes for these species. In marked contrast, only a limited number 
of studies report the simultaneous detection of biomarkers by multiplex flow cytometry in 
veterinary science. For veterinary species, the lack of specific antibody pairs suitable for 
detecting secreted proteins has been defined as a major limitation (Wagner and Freer, 
2009). Moreover, it is hard to obtain the commercial antibodies as single reagents from 
either the ELISA companies or their suppliers. On the other hand, commercial antibody 
pairs that were found to be optimal for ELISA format, may not be suitable for multiplex 
bead-based immuno-assays. Therefore, antibodies should be carefully screened to select 
the suited antibody pairs (Kellar and Iannone, 2002). In the current study, several 
combinations of commercial antibodies were preliminary evaluated, which was a very 
labor- and cost-intensive process that often did not provide satisfactory results (Table 3). It 
should be remarked that we were able to generate accurate standard curves for IL-6 with 
the monoclonal antibody pair MAB6861/MAB686 (Table 3) as capture and detection 
antibody, respectively (data not shown). Unfortunately, no IL-6 signal was observed even 
not with a CBA single plex in porcine plasma samples obtained after LPS-challenge and 
analyzed as positive for this cytokine with ELISA. Likewise, Lawson et al. (2010) also 
experienced major problems finding a suitable antibody pair for the determination of 
porcine IL-6 in their Luminex assay.  
As described, pig-MAP was originally included in a CBA 4-plex assay together with 
TNF-α, IL-1β and IL-6. This initial 4-plex analysis of LPS plasma samples yielded satisfactory 
results for all 4 parameters (data not shown). Nevertheless, the simultaneous 
measurement of pro-inflammatory cytokines and APPs proved to be rather redundant 
within an acute LPS inflammation model as their peak concentrations differ in order of 
magnitude and time points after LPS administration. Consequently, pig-MAP was 
withdrawn from this original 4-plex format and we decided to develop a separate 3-plex 
cytokine and a separate 2-plex APP assay. Regardless the presence of pig-MAP, comparable 
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absolute concentrations were obtained with the original CBA 4-plex and final CBA 3-plex 
assay, demonstrating the flexibility of the CBA technique.  
As demonstrated, for CRP, adequate standard curves were created with the 18-374-
130062/MAB1707 antibody pair (Table 1). Unfortunately, in porcine plasma, no 
reproducible nor sensitive signals were obtained with neither the CBA single plex nor the 
CBA 2-plex assay for this APP. Furthermore, the inclusion of CRP negatively influenced 
concentration levels of pig-MAP compared to the CBA single plex and the original CBA 4-
plex assay format (data not shown).  
To the best of our knowledge, this is the first study attempting to detect porcine 
APPs by means of (multiplex) bead-based flow cytometry. As the first antibody pair failed 
on the plasma level, the use of an alternative second antibody pair is indicated. However, 
currently no alternative porcine CRP antibodies are available to further optimize our CBA 2-
plex APP assay. An alternative strategy might be the use of bead-coupled phosphocholine 
as a catching agent, since CRP possesses a Ca2+-dependent binding affinity for 
phosphocholine (Deegan et al. 2003). The substitution of CRP by the third important APP in 
pigs, haptoglobin, is also conceived as an option.  
Finally, it can be remarked that CBA assays should not be restricted to the detection 
of cytokines or APPs, since other biomarkers of infection and inflammation can be 
included. The major restriction of the applicability of this technique probably remains the 
accessibility of suitable porcine-specific antibody pairs. Another challenge remains the 
requirement to balance the individual optimal dilution factors for the single analytes with 
an acceptable universal one for all analytes. 
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5. Conclusion 
 
Our optimized and validated CBA 3-plex cytokine protocol provides a fast, flexible 
and cost-effective screening tool for simultaneous determination of pro-inflammatory 
cytokine profiles in a limited porcine plasma volume. Similar cytokine profiles were 
obtained for TNF-α, IL-1β, IL-6 and pig-MAP compared to conventional ELISAs, which are 
specific, sensitive and well-suited to perform single parameter analysis. Hence, this 
technique will be applied in future research to study the immunomodulating properties of 
drugs in a porcine LPS inflammation model. This study also demonstrated the applicability 
of CBA for measurement of APPs, although further optimization is required. 
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3.2. Multiplex analysis of pro-inflammatory cytokines in serum of Actinobacillus 
pleuropneumoniae-infected pigs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from 
Wyns, H., Croubels, S., Vandekerckhove, M., Demeyere, K., De Backer, P., 
Goddeeris, B.M., Meyer, E. (2014) Multiplex analysis of pro-inflammatory cytokines in 
serum of Actinobacillus pleuropneumoniae-infected pigs (manuscript in preparation).   
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Abstract 
 
Porcine pleuropneumonia is a severe respiratory disease caused by the Gram-
negative pathogen Actinobacillus (A.) pleuropneumoniae. Reports on systemic cytokine 
production following experimental infections with this pathogen in pigs are not 
straightforward. Nevertheless, IL-6 has been consistently detected in the majority of these 
infected pigs and has consequently been put forward as a valuable biomarker for 
monitoring bacterial infections.  
As multiplex bead-based flow cytometry is gaining popularity for the simultaneous 
detection of diverse inflammatory markers in veterinary research, the aim of the present 
study was to analyze serum samples of A. pleuropneumoniae-infected pigs at the onset of 
infection for TNF-α, IL-1β and IL-6 using our previously developed CBA 3-plex assay for 
porcine plasma (Chapter 3.1). Additionally, these samples were also analyzed for IL-6 by 
means of a commercial porcine-specific ELISA to compare the results of both immuno-
assays. 
The CBA 3-plex assay was successfully validated for its use in serum samples. The 
limits of detection (LODs) varied between 0.012 and 0.333 ng/mL, and the inter- and inter-
assay coefficients of variation were < 5 % and < 10%, respectively. 
Using the CBA 3-plex assay, increased levels were observed for all 3 cytokines 
following experimental infection with A. pleuropneumoniae. Mean serum peak 
concentrations of TNF-α and IL-6 were recorded at 12 h p.i. and at 10 h p.i., respectively. 
Serum concentrations of IL-1β also increased, albeit without reaching a maximum in the 0-
18 h period of analysis. A similar concentration-time profile as with CBA was observed for 
IL-6 when analyzing these serum samples in parallel with ELISA. 
In conclusion, the feasibility of the CBA 3-plex assay for pro-inflammatory cytokine 
detection in porcine serum beside plasma samples was confirmed. Moreover, we propose 
that this elegant immuno-assay can be applied for the screening of immunomodulatory 
properties of drugs and vaccine adjuvants in infection, inflammation and vaccination. 
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1. Introduction 
 
Multiplex bead-based flow cytometry is gaining popularity for the simultaneous 
detection of diverse inflammatory markers in veterinary research. Compared to other 
commonly used methods, including the gold standard i.e. enzyme-linked immunosorbent 
assay (ELISA), multiplex bead-based assays significantly minimize the sample volume and 
analysis time required, while maximizing the number of parameters that can be 
simultaneously analyzed. Christopher-Hennings et al. (2013) provided a comprehensive 
overview of current multiplex technologies with attention to veterinary diagnostic 
purposes. This highlighted that in contrast to humans and rodent species, multiplex assays 
for porcine research are scarce. During the past decade, several multiplex bead-based 
assays have been in-house developed to characterize the immune response in pigs 
(Johannisson et al., 2006; Bjerre et al., 2009; Lawson et al., 2010; Bongoni et al., 2013; 
Wyns et al., 2013). 
Porcine pleuropneumonia is a severe respiratory disease caused by the Gram-
negative pathogen Actinobacillus (A.) pleuropneumoniae, characterized by a 
fibrinohemorrhagic necrotizing bronchopneumonia and a fibrinous pleuritic. It is 
responsible for major economic losses and reduced animal welfare. A. pleuropneumoniae 
has a multifactorial pathogenicity, involving different secreted and non-secreted virulence 
factors, including lipopolysaccharide (LPS), cytotoxins (Apx toxins), hemolysin, proteases, 
host and environmental factors (Haesebrouck, 1997; Huang et al., 1998; Chiers et al., 
2010). Reports on systemic cytokine production following experimental infections with A. 
pleuropneumoniae in pigs are not equivocal (Fossum et al., 1998; Huang et al., 1999; Balaji 
et al., 2002; Myers et al., 2004). Only IL-6 has been consistently detected in the majority of 
infected pigs and has consequently been put forward as a valuable marker for bacterial 
infections (Fossum et al., 1998; Tambuyzer et al., 2014). 
The present study was designed to test out serum samples of A. pleuropneumoniae-
infected pigs at the onset of infection for pro-inflammatory cytokines using a novel 
developed cytometric bead array (CBA) 3-plex assay for a fast and simultaneous profiling of 
TNF-α, IL-1β and IL-6, as previously described for porcine plasma in an LPS-induced 
inflammation model by Wyns et al. (2013), with special attention to the IL-6 response. 
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2. Materials and methods 
 
2.1. Serum samples 
 
Serum samples were obtained from early weaned outbred pigs (n = 9) of 
approximately 20 kg body weight (BW) (Rattlerow Seghers Holding N.V.) in an experimental 
design with A. pleuropneumoniae as described by Tambuyzer et al. (2014). Five pigs were 
endobronchially infected with 1 x 107 CFU (biotype 1-serotype 9, strain no. 13261; Van 
Overbeke et al., 2001) A. pleuropneumoniae, whereas four other pigs received 
endobronchially sterile medium and served as negative controls. The pigs were 
catheterized three days before infection for repetitive blood sampling. Serum samples 
were collected immediately before (baseline value; 0 h) and at 2, 4, 6, 8, 10, 12, 14, 16 and 
18 h post infection (p.i.) and serum separated. Samples were stored aliquoted at -70 °C 
until analysis for presence of TNF-α, IL-1β and IL-6. 
 
2.2. CBA 3-plex assay for TNF-α, IL-1β and IL-6 
 
With the exception of the selected beads (A4, C7 and D9 for IL-6, IL-1β and TNF-α, 
respectively), antibodies, beads and standards were applied as previously described (Wyns 
et al., 2013). Standard curves of 0.0, 0.125, 0.25, 0.5, 1.0, 2.5, 5.0, 7.5, 10.0, 20.0 and 50.0 
ng/mL were generated. A single universal 4-fold dilution was used for all samples. Analyses 
were performed on a validated FACSCantoTM dual-laser (488 and 633 nm) flow cytometer 
(BD Biosciences). After forward vs side scatter gating of the single bead population, the 
distinct bead populations were displayed in a 2-color dot plot (FL-5 and FL-6). 
The applicability of the CBA 3-plex assay for serum samples was evaluated prior to 
use. The limit of detection (LOD) as well as intra- and inter-assay coefficients of variation 
(CVs) were assessed and compared to the values previously obtained in porcinplasma 
(Wyns et al., 2013).  
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2.3. ELISA for IL-6 
 
Serum samples were additionally analyzed for IL-6 by means of a commercial 
porcine ELISA (DuoSet® ELISA Development Systems; R&D Systems) to confirm the results 
obtained by CBA. The lowest quantifiable IL-6 concentration was approximately 0.125 
ng/mL (i.e. the lowest calibration point, the LOQ was not in-house determined for serum).  
 
2.4. Statistical analysis 
 
Data were statistically analyzed by a Student’s t-test comparing the mean area 
under the curve (AUC)-values of the negative control pigs (CONTR) and the A. 
pleuropneumoniae-infected pigs using SPSS Statistics 22.0 software for Windows. For those 
parameters that were not normally distributed, the Mann-Whitney U test was used. A p-
value of < 0.05 was considered statistically significant. 
 
3. Results 
 
3.1. Validation of the CBA 3-plex assay for porcine serum 
 
The LOD, defined as the lowest detectable cytokine concentration within the linear 
range of the standard curve, was established at 0.333, 0.054 and 0.012 ng/mL for serum 
TNF-α, IL-1β and IL-6, respectively. Intra- and inter-assay CVs of each cytokine were 
calculated by evaluating MFI-values of two different serum samples from infected pigs in 
duplicate within a day or at different analysis days, respectively. The intra- and inter-assay 
CV % were, 3.83 and 4.72 for TNF-α, 2.67 and 3.47 for IL-1β; and 2.83 and 6.31 for IL-6, 
respectively. 
 Validation parameters for serum samples are summarized in Table 1 and compared 
to those previously obtained in porcine plasma by our group (Wyns et al., 2013). 
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Table 1. Validation parameters of the CBA 3-plex assay of TNF-α, IL-1β and IL-6 for both 
serum and plasma samples 
 
LOD (ng/mL) Intra-assay (CV %) Inter-assay (CV %) 
 
serum plasma serum plasma serum plasma 
TNF-α 0.333 0.363 3.83 8.45 4.72 15.71 
IL-1β 0.054 0.109 2.67 2.26 3.47 15.48 
IL-6 0.012 0.005 2.83 2.33 6.31 11.41 
LOD: limit of detection; CV: coefficient of variation 
 
3.2. Analysis of TNF-α, IL-1β and IL-6 with CBA 3-plex assay 
  
Following experimental infection with A. pleuropneumoniae, increased levels were 
present for all 3 cytokines. In the CONTR group, levels of TNF-α and IL-6 remained 
undetectable, whereas basal levels were present for IL-1β (Figure 1A-C). As the inter-
animal (biological) variation of these cytokine responses was high.  
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Figure 1. Mean (+ SD) serum concentration-time profiles of TNF-α (A), IL-1β (B) and IL-6 (C) 
obtained from A. pleuropneumoniae-infected (n = 5) and negative control pigs (n = 4), using 
the CBA 3-plex porcine cytokine assay. 
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A mean maximal serum concentration of TNF-α was recorded at 12 h p.i. (range 0 - 
10.4 ng/mL), which transiently declined and increased again at 16 h p.i. (Figure 1A). In one 
infected pig, TNF-α was undetectable, whereas two other infected pigs demonstrated a 
delayed and only moderate TNF-α response (data not shown), which explains the gradual 
mean increase of this cytokine (Figure 1A). The mean serum concentration of IL-1β 
increased without reaching a maximum in the 0-18 h period of analysis (Figure 1B). The 
levels of IL-1β substantially increased in all infected pigs, yet again one pig showed both a 
slower and lower response compared to the other pigs of this group (range 0.40 - 2.99 
ng/mL). Due to the large biological variations, no significant differences were observed for 
TNF-α and IL-1β between the negative control group and the A. pleuropneumoniae-
infected pigs. 
For IL-6, on the other hand, a clear mean maximal serum concentration (p < 0.05) 
was observed at 10 h p.i. (range 1.35 - 6.04 ng/mL), which started to decline consistently at 
16 h p.i. (Figure 1C). Remarkably, one pig already had substantial IL-6 serum levels at the 
baseline (0 h) and showed no noticeable IL-6 response following infection. In one other pig, 
IL-6 increased considerably, without reaching a maximal concentration within the 18 h-
analysis-period (data not shown).  
For all three cytokines, basal levels were not reached within 18 h p.i. in the infected 
animals. 
 
3.3. Analysis of IL-6 with ELISA 
 
Compared to the results obtained by the CBA 3-plex assay, a similar concentration-
time profile was observed for IL-6 when analyzing the serum samples with ELISA. Again 
after a gradual increase, a mean maximal serum concentration was reached at 14 h p.i. and 
a marked decrease started at 16 h p.i. (Figure 2). The IL-6 levels in the pigs of the CONTR 
group remained below the concentration of the lowest standard (Figure 2). No significant 
differences were observed between CBA and ELISA for IL-6 analysis. 
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Figure 2. Mean (+ SD) serum concentration-time profiles of IL-6 obtained from A. 
pleuropneumoniae-infected (n = 5) and negative control pigs (n = 4), using a porcine ELISA. 
 
4. Discussion 
 
This study validated and subsequently demonstrated the applicability of the in-
house developed CBA 3-plex assay in porcine serum samples. The LOD and intra-assay 
parameters obtained for serum were comparable with those previously obtained for 
plasma and are considered to be again acceptable (Wyns et al., 2013). The inter-assay CVs 
for serum were even a bit lower, indicating an even better reproducibility of this immuno-
assay in serum compared to plasma samples. Its wide dynamic range and the single 4-fold 
dilution offer the opportunity of measuring both high (infected pigs) and low (negative 
control pigs) TNF-α, IL-1β and IL-6 levels in a standardized and reproducible manner. 
In the present study, increased levels of TNF-α, IL-1β and IL-6 were demonstrated in 
the serum of pigs infected with A. pleuropneumoniae, while the control animals did not 
show an increased cytokine production. The first 18 h p.i. were selected for analysis using 
the CBA 3-plex cytokine assay, as the induction of pro-inflammatory cytokines TNF-α, IL-1β 
and IL-6 can be expected immediately after infection (Baarsch et al., 1995; Fossum et al., 
1998; Huang et al., 1999; Myers et al., 2004). Indeed, TNF-α reached a maximal 
concentration at 12 h p.i., while IL-1β levels increased steadily p.i. of A. pleuropneumoniae. 
These results are inconsistent with some previous reports, in which no systemic changes in 
TNF-α and IL-1β could be detected in A. pleuropneumoniae-infected pigs (Fossum et al., 
1998; Balaji et al., 2002; Myers et al., 2004). Yet, Huang et al. (1999) described an increase 
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in TNF-α as well as IL-1β after both an in vitro and in vivo stimulation and infection with A. 
pleuropneumoniae, respectively. In contrast to the rather unpredictable TNF-α and IL-1β 
responses, IL-6 has been postulated as a valuable biomarker for monitoring (porcine) 
bacterial infections (Fossum et al., 1998; Tambuyzer et al., 2014) as well as for the 
evaluation of antibiotic treatment (Lauritzen et al., 2003). In the current study, 80 % of the 
pigs showed a marked IL-6 response following experimental infection with A. 
pleuropneumoniae and a maximal mean IL-6 concentration was recorded at 10 h p.i. Of 
relevance, these findings are largely in agreement with other reports including a very 
recent one from the Tambuyzer et al. (2014) (Fossum et al., 1998; Lauritzen et al., 2003; 
Myers et al., 2004). 
Still, the discrepancies between some of these studies can be partially explained by 
the fact that the outcome of an in vivo experimental bacterial infection model is far less 
predictable compared to a more standardized and reproducible LPS model (Olson et al., 
1995; Myers et al., 2003). The sequence of cytokine release following LPS administration is 
quite straightforward (Gerros et al., 1993). In contrast, the substantial biological variations 
observed between outbred animals in a bacterial infection model, which was also obvious 
in our experiments, remain of major concern (Fossum et al., 1998; Huang et al., 1999; 
Myers et al., 2004). Moreover, the mode of infection, bacterial dosage, strain and 
associated virulence factors might also contribute to a different outcome (Huang et al., 
1999; Balaji et al., 2002).  
Although the concentration-time profiles of IL-6 were similar between CBA and 
ELISA, different absolute mean concentrations were clearly registered between both 
immuno-assay. These dissimilarities can be ascribed to the use of different antibodies, 
standards and reagents in both immuno-assay formats, as also previously mentioned by 
our group and other authors (Prabhakar et al., 2002; Khan et al., 2004; Wyns et al., 2013). 
In addition, the simultaneous measurement of three parameters is more complex 
compared to the single-parameter-approach of the gold standard ELISA. Nevertheless, 
multiplexing offers the opportunity to characterize the relative changes in the systemic 
cytokine levels more completely in a time- and cost-efficient manner, avoiding freeze-thaw 
cycles and aliquot variations. 
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Additionally, our developed and validated CBA 3-plex assay was applied to re-
analyze the porcine plasma samples from LPS-challenged pigs as described in Chapter 2.2. 
As shown for plasma (Chapter 3.1) and here for serum of infected pigs, similar trend was 
demonstrated between ELISA and CBA, with peak concentrations of TNF-α and IL-6 
observed at 1 h and 2.5 h in these plasma samples from LPS-induced inflammation. 
Concentrations of IL-1β were confirmed to be low and inconsistent (data not shown). 
In summary, this acute infection model study has demonstrated at first the 
feasibility of the CBA 3-plex assay for pro-inflammatory cytokine simultaneous detection in 
porcine serum samples. Moreover, we suggest that this immuno-assay can now be applied 
for the evaluation of immunomodulatory properties of drugs and vaccine adjuvants in 
infection and vaccination. 
 
 
  
 
145 
GENERAL DISCUSSION 
 
Modulation of the host immune response is of growing interest in human and 
veterinary medicine. Innate immunity guarantees the first, non-specific line of defense 
against invading micro-organisms. It mainly comprises of peripheral blood monocytes 
(PBMCs) and resident tissue macrophages which are concentrated at locations exposed to 
pathogen infiltration (Ulevitch, 2004; Fairnbairn et al., 2011). Additionally, neutrophils, 
dendritic, endothelial and epithelial cells participate in this complex process. Pattern 
recognition comprises the basic concept of innate immunity, with lipopolysaccharide (LPS) 
as a major pathogen-associated molecular pattern (PAMP), that triggers innate immunity 
through stimulation of toll-like receptor (TLR) 4 (Heumann and Roger, 2002; Sanz-Santos et 
al., 2011).  
Administration of LPS has been widely applied to study the immunomodulatory 
properties of drugs in various animal species, including the pig. These studies were 
predominantly carried out at the levels of leukocyte function and cytokine production. 
Cytokines coordinate a wide variety of intercellular interactions after their secretion (Healy, 
2007). The ongoing quest for a multi-efficient drug has focused especially on antibiotics, as 
these may also possess marked beneficial immunomodulatory properties besides their 
main antimicrobial activities. The past decade, rising evidence concerning the 
immunomodulatory abilities of macrolide antibiotics has emerged.  
The main accomplishments of this thesis were summarized in Figure 1. 
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Figure 1. Overview of the main realizations achieved in this work. 
 
Pharmacokinetic studies on gamithromycin, ketoprofen and dexamethasone 
Pharmacokinetic (PK) studies provide essential information concerning maximal 
concentrations (Cmax) that can be expected in the pig’s plasma. Additionally, the time to 
this Cmax (Tmax) and thus the time at which a high efficacy is expected, can be estimated.  
Gamithromycin (GAM) is a 2nd generation macrolide antibiotic of the azalide 
subclass, which is registered for use as a single subcutaneous (SC) administration at 6 
mg/kg body weight (BW) in cattle (Zactran®; EMA, 2008b). Nevertheless, the PK properties 
of GAM have been previously described not only in cattle, but also in foals and recently by 
our group in broiler chickens (Huang et al., 2010; Berghaus et al., 2011; Giguère et al., 
2011; Watteyn et al., 2013). Our PK study in pigs at first demonstrates that GAM is rapidly 
absorbed and fully bioavailable (F = 117%) after a SC injection of 6 mg/kg BW. A mean Cmax 
of 0.41 µg/mL was attained at 0.63 h, which was highly comparable to the Cmax in calves 
(0.43 µg/mL; Giguère et al., 2011), yet plasma concentrations generally remained far below 
the estimated minimum inhibitory concentration (MIC) for Mycoplasma (M.) 
hyopneumoniae (0.25 µg/mL) and Actinobacillus (A.) pleuropneumoniae (2 µg/mL) in pigs 
(unpublished data). As GAM was eliminated 3 to 4 times faster in pigs compared to cattle, 
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it likely requires more frequent dosage in pigs (Huang et al., 2010; Giguère et al., 2011). 
However, plasma concentrations of macrolides are usually considerably lower than the MIC 
of the pathogens against which these drugs have been proven to be effective. Of more 
clinical relevance is the evaluation of the drug concentration at the site of bacterial 
infection (Van Bambeke and Tulkens, 2001). Indeed, the high volume of distribution (Vd) of 
31 L/kg indicates that much higher concentrations of GAM can be expected within porcine 
pulmonary epithelial lining fluid (PELF), bronchoalveolar lavage (BAL) fluid and cells and 
lung tissue, as is the case in cattle and foals. In addition, therapeutic concentrations 
persisted in these compartments for 7 to > 15 days after a single SC or intramuscular (IM) 
administration of 6 mg/kg BW in both the latter species (Huang et al., 2010; Berghaus et 
al., 2011; Giguère et al., 2011). Overall, the plasma PK properties of GAM in pigs are 
comparable to those obtained in other animal species. In future research, the disposition 
and efficacy of GAM can be evaluated in A. pleuropneumoniae or M. hyopneumoniae-
infected pigs, as these are major pathogens involved in swine respiratory disease (SRD). 
As clearly shown by the data obtained in this thesis, the current formulation of GAM 
for use in cattle might be of concern in its therapeutic applicability in pigs. Indeed, the SC 
administration of Zactran® to pigs was experienced as painful and was accompanied by a 
marked local inflammation reaction. An IM injection, which is a more appropriate route of 
drug administration in pig practice, was therefore not considered. On the other hand, after 
3-fold dilution, as applied in our PK study, no local or systemic adverse effects were noticed 
after SC injection. It can thus be stated that the Zactran® formulation as such is not yet pig-
proof, but can be adapted to become so. 
The NSAID ketoprofen (KETO) was selected in this research for its excellent 
antipyretic properties and promising effects regarding combination therapy for the 
treatment of SRD. KETO or 2-(phenyl 3-benzoyl) propionic acid is a chiral compound and 
consequently exists in two enantiomeric forms. All veterinary formulations, including 
Ketofen 10%®, are racemic mixtures, containing both enantiomers in equal amounts. The 
S(+) enantiomer has been generally accepted to be pharmacologically active, through 
inhibition of the cyclooxygenase (COX) pathway (Cabré et al., 1998). The PK characteristics 
of KETO have been well-established in pigs. In this respect, the maximal plasma 
concentration (Cmax) of KETO has been reported to occur between 0.68 and 1.27 h after a 
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single IM administration in pigs (Raekallio et al., 2008, Fosse et al., 2011; Mustonen et al., 
2012b). 
Glucocorticoids are among the most widely (mis)used drugs in veterinary medicine. 
Regardless their potent anti-inflammatory effect, this class of drugs is mainly 
immunosuppressive and therefore potentially harmful (Ferguson et al., 2009). Additionally, 
the use of glucocorticoids in both cattle and pigs remains highly controversial as they can 
be illegally used as growth promoters (Courtheyn et al., 2002; Vincenti et al., 2009). 
Dexamethasone (DEX) is expected to be a long-acting (> 48 h) synthetic glucocorticoid. Yet 
in our research its PK characteristics in pigs revealed a remarkably higher clearance (Cl; 
2.39 L/h) and a rather short half-life of elimination (t1/2el; 0.77 h) compared to those 
reported for dogs, cattle and horses (Toutain et al., 1982; Greco et al., 1993; Soma et al., 
2013). However, the Vd (2.78 L/kg) suggests a good tissue penetration in pigs. Although 
DEX is a well-known inhibitor of cytokine production both in vitro and in vivo, its influence 
on LPS-induced sickness behaviour was quite disappointing in mice and, as recently 
evaluated by our group, in cattle too (Morikawa et al., 1996; Myers et al., 2003; Teeling et 
al., 2010; Plessers et al., manuscript in preparation). Therefore, DEX was only included as a 
positive control in our in vitro research.  
 
Appropriate in vitro and in vivo porcine LPS inflammation models  
To evaluate the influence of GAM and KETO on the acute phase response (APR), as 
well as the animals’ clinical condition, we opted for in vitro and in vivo porcine LPS-induced 
inflammation models. In vitro research is expected to offer a first indication of the 
expected in vivo outcome (Ianaro et al., 2000; Leiva et al., 2008). Peripheral blood 
mononuclear cells have been frequently used as a model of in vitro immune response 
stimulation. In this study, incubation of porcine PBMCs with LPS induced a marked increase 
in the pro-inflammatory mediators PGE2, TNF-α, IL-1β and IL-6.   
The Escherichia coli LPS-induced fever model has been accepted and applied for the 
evaluation of the antipyretic effect of NSAIDs (EMA, 2001; Salichs et al., 2012). Compared 
to infection with live bacteria, this rather straightforward LPS model provides major 
advantages as the sequence of mediator release following LPS administration is well-
documented and quite standardized (Gerros et al., 1993).   
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The administration of LPS to pigs immediately initiates a cascade of events which 
can be approached from both an immunological and a clinical point of view. On the one 
hand, binding of LPS to its TLR4 leads to the activation of transcription factors initiating the 
expression, production and/or release of COX, prostaglandins (PGs), thromboxane (TX), 
cytokines and at a later stage also of acute phase proteins (APPs). On the other hand, 
severe clinical symptoms including anorexia, nausea, tachypnea, dyspnea, fever and a 
prolonged depression phase are simultaneously induced which considerably restrict the 
animals’ clinical condition and well-being. 
Nevertheless, it should be emphasized that the development of a suitable in vivo 
model in pigs is quite challenging and needs to be subjected to some critical 
considerations, as illustrated below.  
A first step in applying such an LPS model in pigs is the selection of an appropriate 
LPS serotype and of pig-related variables, including age, weight and breed. 
Different LPS serotypes and preparations are commercially available of which the 
O111:B4 preparation provided by Sigma is indisputably the most frequently used in porcine 
research (Frank et al., 2003; Carroll et al., 2005; Williams et al., 2009; Wyns et al., 
manuscript submitted). However, protein impurities in those LPS preparations may 
influence the transcriptional profile as both TLR2- and TLR4-mediated signaling can occur 
(Lorne et al., 2010; Rutledge et al., 2012). To date, our research group is the only one 
applying the ultrapure O111:B4 variant of InvivoGen, which is recognized to selectively 
activate TLR4 but not TLR2.  
The response to LPS significantly differs between animal species, with pigs and 
ruminants being very sensitive since relative low LPS doses induce marked effects on the 
cardiovascular system. This has been ascribed to the presence of pulmonary intravascular 
macrophages (PIMs) in the pulmonary circulation of both species. Cardiovascular effects of 
endotoxin in cats, rabbits, ponies and horses are less pronounced (Olson et al., 1995). In 
dogs, rodents and broiler chickens, extremely high endotoxin dosages (> 1 mg/kg) are 
administered (Olson et al., 1995; De Boever et al., 2010).  
In this respect, we had to find a compromise between eliciting a marked clinical and 
immunological inflammatory response with systemically measurable PGE2, TNF-α, IL-1β, IL-
6, pig-MAP and CRP concentrations, but without causing shock or mortality. Based on 
previous reports, a dose of 15 µg/kg BW (or 15 x 103 EU/kg BW) was selected and can be 
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considered as moderate for use in pigs. As pigs with a BW > 20 kg are considered 
immunologically mature animals with respect to their cellular functionality and cytokine 
production (Myers et al., 1999), in our LPS experiments they all had a BW of 20-30 kg. We 
also opted to work with a central venous catheter for accurate IV LPS administration and 
atraumatic repetitive blood sampling in sick animals.   
To perform this catheterization, a team of surgeons and anesthetists had to be 
mobilized and subsequently a careful individual follow-up of the catheterized animals was 
required. For the latter purpose, the surgical suture at the jugular groove was visually 
evaluated, the catheters were flushed at least once daily with heparinized saline, and the 
bandages protecting the catheter from trauma and contamination, were changed daily.  
In our study, the IV administration of 15 µg/kg BW ultrapure LPS induced systemic 
peak concentrations of PGE2 and TNF-α at 1 h p.a., and maximal concentrations of IL-6 at 
2.5 h p.a. As expected, levels of pig-MAP and CRP started to increase not earlier than 18 h 
after LPS administration. In contrast to previous reports, the mean maximal rectal body 
temperatures occurred as early as 2.5 h p.a. of LPS. Severe clinical symptoms of acute lung 
failure and general sickness, including tachypnea, dyspnea, anorexia, nausea, vomiting and 
depression were developed in all LPS-induced pigs. 
Compared to the standardized and reproducible LPS model, the APR of an in vivo 
experimental bacterial infection model, on the other hand, is far less predictable (Olson et 
al., 1995; Myers et al., 2003). In contrast to TNF-α and IL-1β, IL-6 has been consistently 
detected in the majority, if not all, of the infected pigs (Fossum et al., 1998; Myers et al., 
2004). Consequently, IL-6 has been postulated as a valuable biomarker for early disease 
detection in bacterial infections (Fossum et al., 1998; Tambuyzer et al., 2014), as well as for 
the evaluation of antibiotic treatment (Lauritzen et al., 2003). The appearance of TNF-α, IL-
1β and IL-6 in the serum of A. pleuropneumoniae-infected pigs occurred remarkably later 
compared to our LPS model, with mean maximal serum concentrations of TNF-α and IL-6 at 
12 h and 10 h after infection, respectively. 
In summary, we can conclude that both our in vitro and in vivo LPS models were 
appropriate for testing the immunomodulatory effect of GAM, KETO and their combination 
on the animal’s clinical condition and the inflammatory mediator release, using DEX as a 
positive control.  
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As a counterpart for IL-6 in porcine bacterial infections, PGE2 can be put forward as 
a candidate valuable early-disease-monitoring biomarker for LPS-induced fever and 
inflammation in pigs.   
 
Immunology orchestrates symptomatology 
“Can the deteriorating clinical condition following LPS administration be ascribed to the 
systemic appearance of PGE2 and/or of TNF-α, IL-1β, IL-6, pig-MAP, CRP?” 
 
Cytokines have long been regarded as responsible for the various and often severe 
clinical symptoms that occur after LPS administration, including the induction of fever and 
the species-specific expression of sickness behaviour (Bluthé et al., 1991; Konsman et al., 
2002; Dantzer, 2009). Indeed, the peripheral injection of TNF-α, IL-1 and IL-6 all mimic LPS-
induced symptoms, whereas the administration of anti-TNF antibodies, IL-1 receptor 
antagonists or the use of IL-1 receptor or IL-6-deficient animals to a larger or lesser extent 
reverse these symptoms (Fong et al., 1989; Bluthé et al., 1991; 2000a; 2000b; Teeling et al.; 
2007; Dantzer, 2009). Since cytokines act in a complex interacting network after their 
release, it is relatively difficult to address specific actions to a single cytokine (Dantzer, 
2009). On the one hand, similar to LPS, the intra-cerebroventricular injection of 
recombinant porcine TNF-α induced anorexia and depression in pigs (Warren et al., 1997). 
On the other hand, Johnson and von Borell (1994) suggested a crucial role for COX and PGs, 
as LPS-induced symptoms could be completely inhibited by pretreatment of pigs with the 
selective COX-1-inhibitor indomethacin. This COX-pathway of thinking was also suggested 
by other authors (Teeling et al., 2007 and 2010) and found to be plausible to explain our 
results as discussed below.  
Although pigs of the KETO and GAM-KETO groups demonstrated high systemic 
cytokine levels, which were sometimes even higher than those measured in pigs of the LPS 
group, these animals surprisingly showed no sickness behaviour and no febrile response 
following LPS administration. Furthermore, these pigs had no quantifiable levels of PGE2.  
On the other hand, DEX which is a known repressor of NF-κB-regulated gene 
transcription, including cytokines and COX-2, was reported to efficiently block TNF-α, IL-1β 
and IL-6, but had no effect on the LPS-induced behavioural changes in mice (Adcock et al., 
1999; Bezugla et al., 2006; Teeling et al., 2010).  Similarly, it has been shown by our group 
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that DEX only attenuated the depression phase of the APR in calves (Plessers et al., 
manuscript in preparation). In our in vitro study, DEX successfully and significantly 
suppressed the production of PGE2, TNF-α, IL-1β and IL-6. Additionally, and somehow 
surprisingly, selective COX-1 inhibitors, including indomethacin, were more potent 
inhibitors of LPS-induced behavioural changes (Botting, 2006; Teeling et al., 2010).  
These findings offer different perspectives on the functions of both COX enzymes 
and suggest that COX-1, besides its function as a housekeeping enzyme, plays a significant 
role in inflammation-related sickness behaviour and the development of fever. COX-1 is 
also considered responsible for the early and massive production of TXA2 in platelets 
following LPS administration (Botting, 2006). These findings might also partially explain 
why KETO, which is a COX-1-selective NSAID, has been proven to be a superior antipyretic 
drug in pigs (Swinkels et al., 1994; Salichs et al., 2012).  
 
Pharmacology encounters immunology 
“Can modulation of the innate immune response contribute to an improved 
pharmacodynamic activity?” 
 
It has become nearly generally accepted that macrolide antibiotics reduce the 
production of pro-inflammatory mediators. However, unlike the reports on azithromycin, 
erythromycin, clarithromycin, roxithromycin, telithromycin, tylosin and tilmicosin (Kanoh 
and Rubin, 2010), GAM did not affect the production of PGE2, TNF-α, IL-1β and IL-6 either 
in vitro or in vivo. Moreover, pretreatment with GAM did not improve the pigs’ welfare. In 
contrast, these pigs even showed a worse clinical condition as demonstrated by a 
remarkably early and longer-lasting depression phase compared to the pigs receiving only 
LPS.  
Azalides, including GAM, have been reported to concentrate preferably within lung 
macrophages (Mattoes and Nightingale, 2002; Huang et al., 2010). In this context, it is not 
unlikely that GAM stimulates porcine pulmonary intravascular macrophages (PIMs) to 
release more TXA2 which at least in part can explain the observed discrepancy between the 
LPS and GAM groups. However, it has to be taken into account that a likely cause would be 
the GAM formulation and related marked local inflammation reaction. 
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Pretreatment of the pigs with KETO nearly completely counteracted the deleterious 
effects of LPS. This was both surprising and expected. Indeed, the efficacy of KETO, and its 
superiority to other NSAIDs, has already been demonstrated after LPS administration, in A. 
pleuropneumoniae-infected pigs as well as in pigs with clear symptoms of SRD (Swinkels et 
al., 1994; Mustonen et al., 2012a; Salichs et al., 2012; 2013). Still, it was surprising that 
those pigs experienced no adverse clinical effects of LPS administration at all. Being a 
potent COX-inhibitor, KETO significantly reduced the concentration of PGE2, both in vitro 
and in vivo, whereas no influence on the production of TNF-α, IL-1β and IL-6 was observed. 
In this respect, KETO has certainly to be considered as a pharmacological agent to improve 
animal welfare. 
The concomitant use of an antibiotic and an (N)SAID has been recommended by 
some authors to decrease the severity of clinical symptoms, including anorexia and 
inflammation-induced lung failure. This therapeutic strategy can limit the impact of 
bacterial respiratory diseases on weight gain and animal welfare (Francoz et al., 2012). In 
this respect, it was hypothesized that the combination of GAM and KETO would be more 
beneficial in decreasing LPS-associated symptoms compared to the exclusive 
administration of each of the respective drugs. It should be nevertheless be stressed that in 
this study, we demonstrated that the administration of both GAM and KETO was not 
advantageous compared to administration of KETO alone. Although this was a 
disappointing observation, a positive finding of this research was that the combination 
KETO and GAM did not evoke any adverse effects in marked contrast to GAM alone. 
Overall, we can suggest that its combination with KETO might be beneficial in experimental 
porcine bacterial infection models, including A. pleuropneumoniae or M. hyopneumoniae 
and should subsequently be investigated under field conditions.  
Last but not least, macrolides indirectly facilitate their direct antimicrobial activity 
by stimulating innate immunity through enhanced leukocyte phagocytosis, degranulation, 
oxidative burst and chemotaxis (Parnham, 2005). As these drugs are potent weak bases 
they become ion-trapped within acidic intracellular compartments such as lysosomes and 
phagosomes. This mechanism potentially increases their antimicrobial activity against 
intracellular pathogens too (Labro, 1996). It was recently demonstrated that tulathromycin 
inhibits cytosolic phospholipase A2 and the production of PGE2 in bovine neutrophils and 
zymosan-challenged calves, respectively (Fischer et al., 2014). In A. pleuropneumoniae-
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infected pigs, tulathromycin significantly improved the clinical condition of the animals 
(Prof. dr. Buret; personal communication). 
In brief, while KETO can guarantee appetite, weight gain and animal welfare, GAM 
can efficiently battle the bacterial infection and limit persisting lung damage, supporting 
the combined use of both drugs. 
Both in vitro and in vivo, KETO showed a trend to enhance TNF-α levels, which is in 
agreement with previous reports (Pettipher and Wimberly, 1994; Ghezzi et al., 1998; Roth 
et al., 2002). Additionally, KETO and the combination of GAM and KETO significantly 
reduced the production of PGE2. In this respect, the results of our in vitro study were 
largely confirmed by our in vivo study. Remarkably, the combination of GAM and KETO 
significantly reduced the in vitro production of IL-1β and IL-6, and showed a trend to 
reduce TNF-α production. This latter effect was not confirmed in vivo. 
 
Analytical methodology profiles immunology  
“Towards an improved multi-screening method for cytokine profiling” 
 
From the three major pro-inflammatory cytokines, IL-1β remains a major source of 
concern from an analytical point of view. Indeed, several authors have vainly attempted to 
include this cytokine in the characterization of the porcine innate immune response, yet IL-
1β was reported recurrently as neither detectable, nor increasing following LPS 
administration (Myers et al., 2003; Tuchscherer et al., 2004; Llamas Moya et al., 2006; 
Ruud et al., 2007). Nevertheless, it is still widely assumed that IL-1β plays a pivotal role in 
the LPS-induced sickness behaviour in several species (Bluthé et al., 1991; 2000a; Dantzer, 
2009). During our research, we used two different porcine-specific commercial ELISA kits, 
both provided by R&D Systems: a less expensive one (DuoSet®), which needed in-house 
validation before its use for plasma samples and a more expensive ready-to-use kit 
(Quantikine®). Using the latter kit, a maximal yet low plasma concentration of IL-1β was 
demonstrated at 3 h after LPS administration. However the large standard deviations (SDs) 
measured indicated major biological variability between the individual animals. The 
economical more attractive ELISA was even considered not suitable for measurement of IL-
1β in porcine plasma, as a higher dilution factor was required to reduce matrix 
interferences and the IL-1β concentrations in these diluted samples were too low to remain 
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quantifiable. Overall, concentrations of porcine IL-1β are low and inconsistent, which is in 
marked contrast to the well-characterised sky-rocketing levels of TNF-α and substantial 
increase of IL-6 following LPS administration in our model. 
From this point of view, we intended to develop a cytometric bead array (CBA) 
screening tool for the simultaneous detection (multiplexing) of TNF-α, IL-1β and IL-6, and 
compared these data with our gold standard ELISA results. Our CBA screening tool has 
been proven to be a valuable time-saving multi-parameter screening alternative for the 
time-consuming single-parameter approach offered by ELISA. Similar to ELISA, a maximal 
plasma concentration of IL-1β was demonstrated at 3 h after LPS administration. CBA 
offers the opportunity to evaluate the cytokine profiles relative to each other in one 
sample analysis. Within the scope of the above-mentioned cytokine network, this strategy 
has been regarded to be potentially more biologically relevant than the measurement of 
absolute concentrations (Kelso, 1999). 
 
“Towards an improved efficient multi-method for eicosanoid profiling” 
 
PGE2 is generally measured by means of immuno-based assays such as ELISA, which 
is considered as the gold standard. As PGE2 is rapidly metabolized both in vitro and in vivo, 
we succeeded in developing and validating a specific and accurate ultra-performance liquid 
chromatography (UPLC)-tandem mass spectrometry (MS/MS) method for the simultaneous 
detection of PGE2 and its major inactive metabolite 13,14-dihydro-15-keto PGE2 in plasma. 
In order to determine the in vivo PG concentration, it is of major importance to block the 
ex vivo PG generation immediately after blood sampling, by adding a COX-inhibitor to the 
samples (Pelligand et al., 2012). This LC-MS/MS methodology offers the advantage of a 
very high specificity and sensitivity, especially needed when dealing with the analysis of 
hundreds of eicosanoid metabolites with very similar chemical structures and physico-
chemical properties, and present in small quantities of biological samples. Our data suggest 
that it may be useful e.g. to monitor eicosanoid biomarkers as readouts reflecting disease, 
or as tool in (veterinary) drug research for efficacy testing. 
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In conclusion, we succeeded in developing an appropriate LPS inflammation model 
with efficient multi-parameter methods for both pro-inflammatory cytokines and 
eicosanoids, allowing for the state-of-the-art evaluation of immunomodulatory properties 
of drugs in pigs. 
 
Future perspectives 
Our current research has provided an ideal basis to: 
- Evaluate the in vivo influence of glucocorticoids on the LPS-induced production 
of PGE2, TNF-α, IL-1β and IL-6 in pigs, and thus gain a more profound insight and 
confirmation of the additional rather than essential role of cytokines in the 
development of severe symptoms following LPS administration.  
- Evaluate the in vivo immunomodulatory properties of other antibiotics in 
porcine LPS and/or experimental bacterial infection models such as A. 
pleuropneumoniae or M. hyopneumoniae, either with or without the combined 
administration of KETO. 
- Measure the concentration of TXA2 in our developed porcine LPS inflammation 
model, as this mediator is considered to be responsible for the LPS-associated 
symptoms of acute lung failure and can be used as an early detection parameter 
of bacterial infections. It might be interesting to include this mediator in a multi-
eicosanoid ultra-performance LC-MS/MS method for the qualitative and 
quantitative detection of eicosanoids. 
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SUMMARY 
 
Lipopolysaccharide (LPS), a major part of the Gram-negative bacterial outer 
membrane, has been widely applied to study the acute phase response (APR). This APR is 
well-established in pigs. Modulation of the host immune response is of growing interest in 
both human and veterinary medicine, yet is beyond the frontiers of knowledge in porcine 
research. This immune response can be influenced by either (non)steroidal anti-
inflammatory drugs ((N)SAIDs) or antibiotics such as macrolides. It largely remains to be 
determined whether a combination therapy of antibiotics and (N)SAIDs would be beneficial 
in the treatment of pigs compared to single drug administration.  
 
Therefore, the General Aim of this thesis was to investigate immunomodulation by 
the macrolide antibiotic gamithromycin (GAM), the NSAID ketoprofen (KETO) and their 
combination in appropriate in vitro and in vivo porcine LPS inflammation models. 
Dexamethasone (DEX), a glucocorticoid and a well-known cytokine inhibitor, was included 
as a positive control. 
 
In the General Introduction, selected aspects of the molecular structure, 
extracellular recognition and intracellular signaling pathways of LPS are highlighted. The 
LPS-induced porcine APR with regard to the systemic release of (pro-)inflammatory 
mediators and clinical symptoms, including the febrile response is extensively described. 
Additionally, a comprehensive overview is provided about the use of LPS-induced 
inflammation models in pigs to characterize the host immune response and to study 
immunomodulation by antibiotics and (N)SAIDs.  
 
In Chapter 1, the pharmacokinetics of GAM and DEX were evaluated in pig to 
determine their disposition and to estimate the time to maximal plasma concentration 
(Tmax). Both GAM and DEX are rapidly absorbed and fully bioavailable after subcutaneous 
(SC) and intramuscular (IM) injection, respectively. Mean maximal plasma concentration of 
GAM was observed at 38 min, whereas the Tmax of DEX was established at 21 min. For both 
drugs, a remarkably higher clearance was observed in pigs in comparison with other animal 
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species. Additionally, GAM showed a similar volume of distribution compared to cattle and 
was therefore eliminated 3 to 4 times faster in pigs. In cattle, a withdrawal period of 64 
days is taken into account for meat. 
 
In Chapter 2, the immunomodulatory properties of GAM, KETO, DEX and their 
combinations were investigated in appropriate in vitro and in vivo porcine LPS-induced 
inflammation models. Peripheral blood mononuclear cells (PBMCs) were used as a model 
of in vitro immune response stimulation. Incubation of porcine PBMCs with LPS induced a 
marked increase in the pro-inflammatory mediators prostaglandin (PG) E2, tumor necrosis 
factor (TNF)-α, interleukin (IL)-1β and IL-6. A highly specific and sensitive ultra-performance 
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed 
and validated for the quantification of PGE2 and its metabolite in cell supernatant and 
plasma. 
In vivo, 15 µg/kg BW ultrapure LPS was intravenously administered to pigs 1 h after 
SC and/or IM administration of GAM and/or KETO, respectively, when nearby maximal 
concentrations of both drugs (Tmax) were expected in plasma. Lipopolysaccharide induced 
systemic plasma peak concentrations of PGE2 and TNF-α at 1 h post administration (p.a.), 
and maximal concentrations of IL-6 at 2.5 h p.a. A maximal febrile response was recorded 
at 2.5 h p.a. of LPS. Concomitantly, severe symptoms of acute lung failure and general 
sickness, including tachypnea, dyspnea, anorexia, nausea, vomiting and depression 
developed in the pigs. Levels of pig-major acute phase protein (pig-MAP) and C-reactive 
protein (CRP) increased not earlier than 18 h p.a. of LPS.  
The macrolide GAM had no significant effect on the production of PGE2, TNF-α, IL-
1β and IL-6 either in vitro or in vivo, which was in contrast to previous reports on other 
macrolides. The NSAID KETO had no significant effect on cytokine production, yet showed a 
trend to enhance TNF-α levels both in vitro and in vivo. On the other hand, KETO and its 
combination with GAM, significantly reduced PGE2 production both in vitro and in vivo. 
Additionally, pigs of both groups showed no increase in rectal body temperature and 
developed no severe symptoms following LPS challenge. In general, none of these drugs or 
their combination had a major influence on the production of acute phase proteins pig-
MAP and CRP. DEX, which was used as a positive control in the in vitro research, 
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significantly suppressed the production of PGE2, TNF-α, IL-1β and IL-6, also in combination 
with GAM. 
These results suggest a major role for both COX-1- and COX-2-mediated PGs in the APR, 
and a more additional role for pro-inflammatory cytokines. 
 
In Chapter 3, a comparative study of immuno-assays was performed for the 
detection of porcine cytokines. In porcine research, detection and quantification of IL-1β 
remains a major source of concern from an analytical point of view. In this respect, a 
cytometric bead array (CBA) screening tool was developed and validated for the 
simultaneous detection of TNF-α, IL-1β and IL-6 in porcine plasma and critically compared 
with the gold standard enzyme-linked immuno sorbent assay (ELISA). A similar trend was 
observed with both immuno-assays for the three cytokines. Overall, LPS-induced 
concentrations of IL-1β were low and inconsistent, yet a maximal plasma concentration of 
IL-1β was demonstrated at 3 h after LPS administration with both immuno-assays. This CBA 
screening tool has therefore been proven a valuable time-saving multi-parameter 
screening alternative for the time-consuming single-parameter approach offered by ELISA 
methods. 
Additionally, our CBA 3-plex assay was successfully tested and validated for use in 
serum samples of Actinobacillus (A.) pleuropneumoniae-infected pigs. The appearance of 
TNF-α, IL-1β and IL-6 in the serum of the A. pleuropneumoniae-infected pigs occurred 
remarkably later compared to our LPS model, with mean maximal serum concentrations of 
TNF-α and IL-6 observed only at 12 h and 10 h after infection, respectively. 
 
In Conclusion, we succeeded in developing appropriate in vitro and in vivo LPS 
inflammation models for the evaluation of immunomodulation of drugs in pigs. The NSAID 
KETO as well as its combination with the macrolide GAM was clearly demonstrated to have 
an inhibiting effect on PGE2 production as well as the development of fever, pulmonary 
symptoms and general sickness following LPS administration, while GAM alone did not.  
Additionally, a cost-effective CBA screening tool for pro-inflammatory cytokines 
TNF-α, IL-1β and IL-6, as well as a specific UPLC-MS/MS method for PGs quantification were 
developed and validated for use in cell media and porcine samples. 
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We developed appropriate porcine in vitro and in vivo LPS inflammation models for 
testing of different classes of drugs, as well as efficient multi-parameter methods for both 
pro-inflammatory cytokines and eicosanoids. 
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SAMENVATTING 
 
Lipopolysaccharide (LPS) is een belangrijke component van de buitenste membraan 
van Gram-negatieve bacteriën. Deze substantie werd reeds uitvoerig gebruikt voor het 
bestuderen van de acute fase reactie (AFR) bij verschillende diersoorten. Bij het varken 
werd de AFR reeds in detail beschreven. Zowel vanuit de humane- als de diergeneeskunde 
is er een groeiende belangstelling voor het moduleren van de immuunrespons, maar dit 
aspect is nog relatief weinig bestudeerd bij het varken. De immuunrespons zou vooral 
kunnen beïnvloed worden door zowel (niet-)steroïdale anti-inflammatoire geneesmiddelen 
((N)SAIDs), als door antibiotica waaronder de macroliden. Hierbij is ook belangrijk in welke 
mate het gecombineerd gebruik van een antibioticum en een (N)SAID voordeel kan hebben 
voor de behandeling van varkens in vergelijking met de toediening van beide klassen van 
geneesmiddelen afzonderlijk. 
 
De Algemene Doelstelling van dit onderzoek was daarom het bestuderen van de 
immunomodulerende eigenschappen van het macrolide antibioticum gamithromycine 
(GAM), het NSAID ketoprofen (KETO) en de combinatie van beide geneesmiddelen in 
reproduceerbare in vitro en in vivo LPS inflammatie modellen bij het varken. 
Dexamethasone (DEX), een glucocorticoïde en een gekende inhibitor van cytokines, werd 
hierbij gebruikt als positieve controle. 
 
In de Algemene Inleiding werden eerst specifieke aspecten van de moleculaire 
structuur, de extracellulaire herkenning en de intracellulaire signaaltransductie van LPS 
toegelicht. Vervolgens werd de LPS-geïnduceerde AFR bij het varken beschreven met 
bijzondere aandacht voor de systemische vrijstelling van (pro-)inflammatoire mediatoren 
en klinische symptomen, waaronder de koortsreactie. Aansluitend werd een uitgebreid 
overzicht gegeven over het gebruik van LPS-geïnduceerde inflammatie modellen voor het 
bestuderen van de immuunrespons bij het varken. 
 
In Hoofdstuk 1 werden de farmacokinetische eigenschappen van GAM en DEX 
bestudeerd bij het varken om zowel de dispositie als de tijd nodig om maximale plasma 
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concentraties (Tmax) te bereiken, te bepalen. Zowel GAM als DEX worden snel geabsorbeerd 
en zijn volledig biologisch beschikbaar na subcutane (SC) en intramusculaire (IM) injectie, 
respectievelijk. De gemiddelde maximale plasma concentratie van GAM werd vastgesteld 
op 38 minuten (min), de Tmax van DEX werd gemeten op 21 min. Voor beide 
geneesmiddelen werd een opvallend hogere klaring genoteerd bij het varken in vergelijking 
met andere diersoorten. Aangezien GAM een vergelijkbaar distributievolume vertoonde 
met het rund, kunnen we besluiten dat GAM bij het varken 3 tot 4 keer sneller 
geëlimineerd wordt. Bij het rund wordt voor GAM een wachttijd van 64 dagen voor vlees in 
acht genomen. 
 
In Hoofdstuk 2 worden de immunomodulerende eigenschappen van GAM, KETO, 
DEX en hun respectievelijke combinaties bestudeerd in reproduceerbare in vitro en in vivo 
LPS-geïnduceerde inflammatie modellen bij het varken. Perifere bloed mononucleaire 
cellen (PBMCs) van varkens werden gebruikt in een in vitro model voor de studie van de 
immuunrespons. Incubatie van deze PBMCs met LPS induceerde een duidelijke stijging van 
pro-inflammatoire mediatoren zoals tumor necrosis factor (TNF)-α, interleukine (IL)-1β, IL-6 
en prostaglandine (PG) E2. Een uiterst specifieke en gevoelige ultra-performantie 
vloeistofchromatografie-tandem massaspectrometrische (UPLC-MS/MS) methode werd 
ontwikkeld en gevalideerd voor de kwantitatieve bepaling van PGE2 en zijn metaboliet in 
celcultuur supernatans en plasma. 
Voor het in vivo onderzoek werd 15 µg/kg lichaamsgewicht (LG) (15 x 103 EU/kg LG) 
ultra-zuiver LPS intraveneus toegediend aan varkens op 1 u na de SC en/of IM toediening 
van GAM en/of KETO, respectievelijk. Op dit tijdstip worden namelijk hoge plasma 
concentraties van beide geneesmiddelen (Tmax) verwacht. LPS induceerde inderdaad 
systemische piekconcentraties van PGE2 en TNF-α in het plasma op het tijdstip 1 u, en 
maximale concentraties van IL-6 op 2,5 u na LPS toediening. De koortspiek werd reeds 
vastgesteld 2,5 u na LPS toediening. De varkens ontwikkelden simultaan ernstige 
symptomen van acuut longfalen zoals een versnelde en bemoeilijkte ademhaling en ook 
een algemeen ziektebeeld gekarakteriseerd door anorexie, misselijkheid, braken en 
algemene depressie. De concentraties van de acute fase eiwitten "pig major” acute fase 
proteïne (pig-MAP) en C-reactief proteïne (CRP) namen pas toe vanaf 18 u na LPS 
toediening. 
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Het macrolide antibioticum GAM had geen significant effect op de productie van 
PGE2, TNF-α, IL-1β en IL-6 in vitro noch in vivo. Het NSAID KETO had eveneens geen 
significant effect op de productie van cytokines, maar vertoonde wel een trend tot het 
verhogen van TNF-α (plasma)concentraties, zowel in vitro als in vivo. Zowel KETO als zijn 
combinatie met GAM, reduceerden significant de concentratie van PGE2 in vitro en in vivo. 
De varkens van beide groepen vertoonden geen stijging van de rectale 
lichaamstemperatuur en ontwikkelden geen ernstige symptomen na LPS toediening. Over 
het algemeen hadden de individueel geteste geneesmiddelen, noch hun combinatie een 
belangrijke invloed op de productie van pig-MAP en CRP. DEX daarentegen, dat werd 
ingesloten als een positieve controle in het in vitro onderzoek, onderdrukte wel significant 
de productie van PGE2, TNF-α, IL-1β en IL-6 en dit ook in combinatie met GAM.  
De resultaten van dit onderzoek suggereren een belangrijke rol voor zowel COX-1- 
als COX-2-gemedieerde PGs in de AFR en een minder ingrijpende rol voor pro-
inflammatoire cytokines. 
 
In Hoofdstuk 3 werd een vergelijkende studie uitgevoerd van twee immunologische 
methoden voor de bepaling van porciene cytokines. Vooral het bepalen en kwantificeren 
van IL-1β is een uitdaging. Daarom werd eerst een cytometric bead array (CBA) 
screeningsmethode ontwikkeld en gevalideerd voor de gelijktijdige bepaling van TNF-α, IL-
1β en IL-6 in varkensplasma. Vervolgens werd een kritische vergelijking gemaakt met de 
algemeen aanvaarde enzyme-linked immuno sorbent assay (ELISA). Eenzelfde trend was 
duidelijk waarneembaar tussen beide immunologische methoden voor alle cytokines. 
Ondanks het feit dat de LPS-geïnduceerde concentraties van IL-1β doorgaans laag en 
variabel waren tussen de varkens, kon met beide technieken toch een maximale 
concentratie 3 u na LPS toediening worden genoteerd. Deze multiplex CBA 
screeningsmethode kan daarom worden beschouwd als een waardevol en tijdbesparend 
alternatief voor de enkelvoudige-parameter benadering van ELISA. 
De CBA screeningsmethode werd vervolgens ook succesvol getest en gevalideerd 
voor gebruik in serumstalen van varkens geïnfecteerd met Actinobacillus 
pleuropneumoniae. De systemische vrijstelling van TNF-α, IL-1β en IL-6 in het serum van de 
varkens trad opmerkelijk later op in vergelijking met deze in het LPS-geïnduceerd 
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inflammatie model. Zo werden maximale serumconcentraties van TNF-α en IL-6 pas bereikt 
op 12 u en 10 u na infectie, respectievelijk. 
 
Samengevat kunnen we stellen dat we erin geslaagd om reproduceerbare in vitro en 
in vivo LPS inflammatie modellen te ontwikkelen bij het varken voor de studie van de 
immunomodulerende eigenschappen van geneesmiddelen. Zowel het NSAID KETO, als de 
combinatie met GAM, vertoonde een duidelijk inhiberend effect op de PGE2 productie, de 
koortsrespons, longsymptomen en het algemene ziektebeeld na LPS toediening. De 
toediening van GAM alleen vertoonde deze gunstige werking echter niet. 
Tijdens ons onderzoek werd tevens een CBA screeningsmethode voor de pro-
inflammatoire cytokines TNF-α, IL-1β en IL-6 en een specifieke UPLC-MS/MS methode voor 
PG kwantificatie ontwikkeld en gevalideerd voor gebruik in celcultuur media en biologische 
stalen van varkens. 
Er werden reproduceerbare porciene in vitro en in vivo LPS inflammatie modellen 
ontwikkeld voor het bestuderen van verschillende klassen van geneesmiddelen, alsook 
werden efficiënte multi-parameter methodes ontwikkeld voor het bepalen van zowel pro-
inflammatoire cytokines, als eicosanoiden. 
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DANKWOORD 
 
Beste lezer, na het doorworstelen van de lijvige brok wetenschap, bent u nu aanbeland bij 
het dankwoord. U mag het gerust beschouwen als een laatste, persoonlijke aim van dit 
proefschrift. Heel eenvoudig, maar tegelijkertijd zeer moeilijk... 
 
Eerst en vooral wil ik mijn drie promotoren bedanken voor de aangeboden kans mijn 
doctoraatsonderzoek op deze vakgroep aan te vatten. 
 
Prof. dr. Patrick De Backer, voor mij beantwoordt u perfect aan het beeld van de wijze (en 
een beetje grijze) professor. Op elke vraag, wetenschappelijk of niet, heeft u steeds snel 
een antwoord klaar - vaak nog vergezeld van een komische kwinkslag. Bedankt voor de 
kritische interpretaties, constructieve inbreng en wijze raad bij het schrijven van deze 
doctoraatsthesis! 
 
Prof. dr. Croubels, Siska, u verslindt manuscripten van allerhande pluimage - abstracts, 
artikels, posters, verslagen - bij de vleet. Toch maakt u steeds met een glimlach de nodige 
tijd vrij om uw standpunten toe te lichten. Het is dan ook bewonderenswaardig hoe u met 
uw legendarisch oog voor detail overbodige punten, spaties en komma’s geen schijn van 
kans gunt. Bedankt voor alles! 
 
Prof. dr. Meyer, Evelyne, hoe hopeloos en uitzichtloos een resultaat er op het eerste zicht 
ook mag uitzien, u probeert er steeds iets positief in terug te vinden. Dit weerspiegelt 
eveneens hoe u - ondanks enkele tegenslagen - in het leven staat. Bedankt voor alle 
suggesties en het aanbrengen van alternatieve denkpistes! 
 
Bijzondere dank gaat uit naar de leden van de lees- en examencommissie, prof. dr. 
Claerebout, prof. dr. Maes, prof. dr. Goddeeris, prof. dr. Pasmans en dr. Meyns, voor het 
kritisch nalezen van dit proefschrif, de rake opmerkingen en het aanreiken van waardevolle 
suggesties. Special thanks to prof. dr. Werling for the valuable suggestions and for 
attending my PhD defense. 
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Mijn oprechte dank aan prof. dr. Gasthuys, en het hele heelkunde-team, voor de 
chirurgische katheterisaties van de varkens. 
 
En dan de collega’s... 
Graag wil ik starten met het bedanken van twee personen die al lang geen gewone 
collega’s meer zijn, maar echte vriendinnen zijn geworden, Anneleen en Elke. Er is geen 
onderwerp dat ik niet met jullie kon bespreken. Jullie waren mijn twee rechterhanden 
wanneer nodig, een luisterend oor, partners-in-crime! We hebben heel wat afgezeverd en 
gelachen. En we zetten, samen met Eva, uiteraard onze hippe DDD-traditie verder!  
 
Anneleen, samen met jou heb ik meermaals de nacht doorgebracht op onze bureau voor 
de nachtelijke bloednames bij onze beestjes, en hebben we onze kinderen tijdens de 
weekends vaak ‘meegelokt’ voor het verzorgen van de kippen, kalkoenen en/of varkens. Ik 
wens je heel veel geluk met je - (hopelijk ondertussen) uitgebreide - gezinnetje, de verdere 
afwerking van jullie gezellige ‘nest’ en uiteraard het finaliseren van je doctoraat! 
 
Elke - tegenwoordig a.k.a. Elke P. - mijn koffiezuster. We waren een geoliede tandem voor 
het nemen van bloed en de toediening van geneesmiddelen bij de varkens. Ook voor jou is 
het einde van je doctoraat in zicht - je hebt de resultaten letterlijk en figuurlijk uit je 
ontelbare ELISA’s geklopt - maar eerst heb je nog enkele andere noten te kraken! Ik wens 
je veel sterkte, het beste en succes ;-) met de afwerking van je doctoraat, de bevalling en je 
ongetwijfeld prachtig gezinnetje! 
 
Jorien, ook jij bent ondertussen een echte vriendin geworden. Jij staat altijd klaar om te 
helpen waar en wanneer nodig. Ik kijk al uit naar onze toekomstige stapjes in de wereld, 
ook samen met Nele. Hopelijk bezorgt sloeber Yari je niet al te veel kopzorgen meer. Ik 
wens je nog heel veel succes met je verdere onderzoek! 
 
Sophie, het koffieverslaafde Mytox koekoeksjong in onze LPS-nest!  Met je droge humor 
weet je overal een komische noot aan toe te voegen. Ik wens je heel veel succes met je 
verdere onderzoek en het afwerken van jullie gezellige huisje, tuintje en wie weet ook 
kindje ;-)! 
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Elke G., je werkt nog niet zo heel lang bij ons, maar door jouw enthousiaste gezelligheid 
lijkt het alsof we elkaar al jaren kennen! Ik wens je nog heel veel succes met die kleine, 
schattige - en na enkele weken iets minder schattige - varkentjes! 
 
Kristel, de leading lady van het labo biochemie. Voor elk probleem bedenk jij een creatieve 
oplossing. Jij begeleidde mij in de mysterieuze en fascinerende wereld van de flow 
cytometrie. Bedankt voor alle hulp met de ELISA’s, CBA-analyses én de vele fijne babbels! 
 
Koen, jou zal ik mij herinneren als die toffe, gemotiveerde collega met een licht 
ochtendhumeur. Ik wil je alvast heel veel succes toewensen met de laatste loodjes van je 
doctoraat en het verder ‘uitdoctoren’ van  ingewikkelde inflammasoom-aangelegenheden 
in je postdoc-onderzoek! 
 
Donna, jouw eeuwige optimisme en bijhorende aanstekelijke lach zinderen nog na in mijn 
hoofd. Bij jou kon ik steeds terecht voor een luchtige babbel over onvermoeibare en 
slechtslapende kindjes. Bedankt voor alle PhD tips & tricks! 
 
En dan ben ik aanbeland bij de ‘mannen van het mycotoxine-team’. Eerst en vooral wil ik 
een collectief woordje van dank richten voor de hulp bij de dierproeven! 
 
Mathias, jou wens ik heel veel succes met je postdoc en je PROFessionele carrière ;-), 
alsook in je persoonlijke leven samen met Joke. 
 
Nathan, de nonchalante bon vivant van het gezelschap. Jouw gezangen weerklonken 
aandoenlijk vals door de gangen. Veel succes met het afronden van je doctoraat! 
 
Thomas, jou zal ik me steeds herinneren als de gemotiveerde doctoraatsstudent die in 
witte labojas door de gangen raast, maar stipt om 11u30 onze bureau binnenspringt om te 
vragen of er iemand mee gaat eten . 
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Gunther, je zou een toevallige passant in de gang kunnen geweest zijn, maar we kwamen 
elkaar meestal ook nog tegen in de stallen. Veel succes met je verdere onderzoek! 
 
Jelle, één van de weinige vaste waarden tijdens de middagpauze in de refter. Bedankt voor 
de hulp bij het oneindige aliquoteren tijdens de varkensproeven en de vele gezellige 
babbels. Veel geluk met de verbouwingen en de beestenboel. 
 
Siegrid, er bestaat geen HPLC-UV noch LC-MS/MS analysemethode die niet door jou 
ontwikkeld en gevalideerd kan worden! Bedankt voor alle goede raad en hulp met de 
analyses en validaties! 
 
Ann S., wij hebben nooit rechtstreeks samengewerkt - dit dankwoord is bijgevolg (nog) niet 
GLP-approved - maar toch zal ik me jou herinneren als die altijd goedlachse collega! 
 
An, meermaals heb je mij - terecht - op de vingers getikt, wanneer ik weer eens iets niet 
volgens het laboboekje had gedaan. Dankzij jou verloopt alles op rolletjes in het labo. 
Bedankt voor de fijne babbels - oa. over de fratsen van Nacho. 
 
Kris, jarenlang heb ik je gestalkt met de meest uiteenlopende en onmogelijke 
computerproblemen - aangezien ik verkeerdelijk dacht dat dit een ware hobby en pure 
ontspanning was voor jou - maar toch was je steeds bereid om deze met een glimlach 
meteen op te lossen.  
 
Marc, jouw vrolijke fluitdeuntjes en lachsalvo’s weerklinken dagdagelijks door het labo. Jij 
bent steeds je opgewekte zelve en altijd bereid raad te geven wanneer nodig. 
 
Veerle, aan jou wil ik nog een speciaal woordje van dank richten voor de hulp met de PGE2-
analyses. 
 
Nathalie, jij staat steeds met de glimlach klaar om te helpen met eender welke 
administratieve rompslomp. Bedankt hiervoor! 
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Toen ik hier 6 jaar geleden aan de vakgroep begon, behoorde ik bij de jongste 
doctoraatsstudenten en waren er nog met vitamientjes overgoten fruitpauzes. Intussen 
ben ik helaas langzaam, maar zeker geëvolueerd tot een ‘ancien’ en deden ook steeds 
decadenter wordende en uitdijende koekjespauzes hun intrede. Graag wil ik van de 
gelegenheid gebruik maken om enkele andere anciens te bedanken en even terug te 
denken aan ‘die tijd van toen’: 
 
Eva, toen ik als groentje bij jou in de bureau werd gedropt, heb je mij meteen moederlijk 
onder jouw vleugels genomen. Ik ben blij dat we elkaar na al die jaren nog steeds niet uit 
het oog verloren zijn en kijk alvast reikhalzend uit naar onze volgende decadente 
bijeenkomst! Ik wens je nog heel veel geluk samen met je grote en je kleine ventje! 
 
Joline en Anja, samen met jullie heb ik mijn eerste stapjes op deze vakgroep gezet. Ik 
herinner me nog levendig onze fotoshoots, wie-is-het? en pictionary spelletjes op dode 
momenten in de varkensstal. Een feestje was met jullie nooit ver af. Bedankt voor alle hulp 
met de dierproeven en de vele leuke momenten! 
 
Ann O., jij hebt ondertussen ook je (kippen)vleugels elders uitgeslaan. Ik wens je veel geluk 
in je verdere leven, zowel op persoonlijk als professioneel gebied. 
 
Jella, jij bent slechts twee verdiepingen naar beneden gemigreerd en we komen elkaar nog 
regelmatig tegen op de AAP-vergaderingen. Heel veel succes met je verdere carrière, je 
gezinnetje en al je beestjes thuis! 
 
Bert en Dieter, veel succes met jullie verdere professionele carrière.  
 
Sandra en Virginie, jullie waren een vaste waarde toen ik hier begon. Sandra, jij leerde me 
de LPS-kneepjes van het vak. Virginie, jij hebt mij op de meet geklopt door één dag voor mij 
te bevallen van Andreas. Ik wens jullie nog veel succes in jullie persoonlijke en 
professionele leven! 
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Ons aller Maggy, ik kijk steeds uit naar doctoraatsverdedigingen om jou nog eens terug te 
zien. Helaas kan je er vandaag niet bij zijn. Bedankt voor het prachtige kaartje en de mooie 
woorden! 
 
En uiteraard mag ik de jonge garde niet vergeten: 
 
Mijn huidige bureaugenootjes, Jonas en Nermin, ik duim alvast mee voor (super)goed 
nieuws van het IWT-front! 
Joske en Joren, de vluchtige schim die af en toe mijn bureau inpalmde, heel veel succes 
met jullie onderzoek! 
 
En, last but not least, een welgemeende dankjewel en tegelijkertijd oprechte sorry aan alle 
varkentjes die hebben bijgedragen aan dit proefschrift. 
 
En ja,... Nemo, ook al haal je met je kattenkwaad regelmatig het bloed vanonder mijn 
nagels, bedankt voor je rustgevend gespin en je attente en aanmoedigende 
schouderkopjes. 
 
Graag wens ik ook nog enkele mensen te bedanken die iets verder van mijn onderzoek 
staan, maar veel dichter bij mezelf. 
 
Elke S., Stephanie en Sieglinde, we moeten dringend nog eens werk maken van een 
reünieke!  
P.S. Stephanie, mocht je hier aanwezig zijn, gelieve plaats te nemen op een onopvallend 
plaatsje ;-). 
 
Tineke en Jelle, bedankt voor de steun tijdens de voorbije maanden. Ik wens jullie nog heel 
veel geluk, samen met de mooie Annabel. 
 
Meters, jullie zijn er vandaag helaas niet bij, maar ik weet dat jullie fier op mij zijn. 
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Mijn ‘kleine’ broertje, Steven, en Xandrine, ik wens jullie nog heel veel geluk met jullie 
twee prachtige kindjes, Lentl en Milo. Ik ben dan ook nog steeds zeer fier en blij dat ik 
meter mocht zijn van de kleine Milo! 
 
Vake en moeke, bedankt voor de onvoorwaardelijke steun de voorbije jaren, maar vooral 
de voorbije maanden. Jullie staan altijd paraat om de kindjes op te vangen, wanneer nodig. 
Zonder jullie had ik hier nu niet gestaan! Voor duizend en één dingen. BEDANKT! 
 
Noémi en Senne, het is met geen pen te beschrijven hoeveel jullie voor mij betekenen. 
Jullie zijn mijn twee zonnetjes - met af en toe een beetje bewolking - in huis. Ik besef dat ik 
de voorbije maanden niet zoveel tijd heb kunnen vrijmaken voor jullie, maar ik beloof dat 
ik dit zeker en vast zal goedmaken! Binnenkort verhuizen we naar ons ‘nieuwe’ huisje, waar 
jullie zo naar uitkijken. Met ons 3-tjes slaan we ons overal wel door! 
 
En om af te sluiten: een doctoraat maak je niet alleen... 
...maar vele handen maken licht(er) werk! 
 
 
 
 
